Ying Yuan, Ph.D.

Department of Biostatistics, Division of Discovery Science

About Dr. Ying Yuan

As a statistical expert in biomedical research, my primary focus is on developing innovative designs, methods, and tools for data analysis. I have a particular interest in applying Bayesian adaptive clinical trial design, statistical analysis of longitudinal data and missing data, and mediation analysis to biomedical studies. With extensive experience in collaborative medical research and clinical trials, I currently serve as the contact Principal Investigator for the Coordination and Data Management Center (CDMC) for the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer (U01) and for the Translational and Basic Science Research in Early Lesions (U24). Additionally, I am the Biostatistics and Bioinformatics Core Director for several Specialized Programs of Research Excellence (SPORE), including the Ovarian Cancer (P50CA217685), Brain Cancer (P50CA127001), and Gastrointestinal Cancer (P50CA221707). My research has resulted in over 200 peer-reviewed publications on the development of new statistical methodologies and collaborative medical research. The designs and software created by my team have been widely used in medical research institutes and pharmaceutical companies. Notably, the BOIN design, which my team developed, is an oncology dose-finding design that has been recognized by the FDA as a fit-for-purpose drug development tool. I am the Chair of the institutional Data and Safety Monitoring Board (DSMB) at The University of Texas MD Anderson Cancer Center, overseeing over 100 ongoing randomized clinical trials. Through my work, I aim to contribute to the development of effective biomedical research strategies and improve patient outcomes.

Primary Appointment

Chair, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas

Deputy Chair, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas

Bettyann Asche Murray Distinguished Professor, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas

Adjunct Professor, Department of Statistics, Rice University, Houston, TX

Chief, Section of Adaptive Clinical Trials, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas

Professor (tenured), Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX

Associate Faculty Member, The University of Texas Graduate School of Biomedical Science, Houston, TX

Research Interests

Bayesian clinical trial design
Statistical analysis of missing data and longitudinal data
Mediation analysis
Survey sampling

More about my research can be found at http://odin.mdacc.tmc.edu/~yyuan

Education & Training

Degree-Granting Education

2005	University of Michigan, Ann Arbor, Michigan, US, Biostatistics, Ph.D
2000	Brandeis University, Waltham, Massachusetts, US, Biochemistry, M.S
1998	Peking University, Beijing, CN, Biochemistry, M.S
1995	Huazhong University of Science and Technology, Wuhan, CN, Biomedical Engineering, BS

Experience & Service

Faculty Academic Appointments

Associate Professor (tenured), Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2010 - 2016

Assistant Professor, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2005 - 2010

Other Professional Positions

Graduate Research Assistant, University of Michigan, Ann Arbor, MI, 2001 - 2005

Summer Statistical Consultant, University of Michigan, Ann Arbor, MI, 2001 - 2003

Extramural Institutional Committee Activities

Member, American Association for Cancer Research (AACR) 2025 Annual Meeting, American Association for Cancer Research (AACR) 2025 Annual Meeting, 2024 - 2025

Member, Society of Clinical Trials,, The University of Texas MD Anderson Cancer Center, 2022 - 2024

Mentor, Society of Neuro-Oncology Clinical Trials Scholars Workshop, The University of Texas MD Anderson Cancer Center, 2020 - 2021

Chair, Data and Safety Monitoring Board (DSMB), The University of Texas MD Anderson Cancer Center, 2019 - Present

Member, Executive Institutional Review Board (IRB), The University of Texas MD Anderson Cancer Center, 2019 - 2021

Member, Multidisciplinary Research Advisory Committee, The University of Texas MD Anderson Cancer Center, 2016 - Present

Member, Data and Safety Monitoring Board (DSMB), The University of Texas MD Anderson Cancer Center, 2016 - Present

Group Leader, 2nd Annual Clinical Trial Methods & Design Workshop for Junior Faculty, The University of Texas MD Anderson Cancer Center, 2015

Member, Institutional Review Board (IRB), The University of Texas MD Anderson Cancer Center, 2014 - Present

Chair, Statistical Computing Committee, The University of Texas MD Anderson Cancer Center, 2014 - Present

Member, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2013 - 2016

Member, Psychosocial, Behavioral and Health Services Research Committee (PBHSRC), The University of Texas MD Anderson Cancer Center, 2010 - 2012

Editorial Activities

Editorial Board, Clinical Cancer Research, 2025 - Present

Guess Editor, Journal of the Royal Statistical Society Series C, Special issue on early-phase dose-finding methodology, 2016

Associate Editor, Biometrics, 2012 - 2015

Honors & Awards

2017	Elected Fellow, American Statistical Association
2015	Elected Fellow, International Statistical Institute
2004	Rackham Travel Grant Award, University of Michigan
2001	Outstanding Performance First Year MS Program, University of Michigan
1998	Brandeis Graduate Fellowship, University of Brandeis

Professional Memberships

Society for Clinical Trials (SCT)

2010 - Present

Society for Prevention Research (SPR)

2008 - Present

The Royal Statistical Society

2008 - Present

International Society for Bayesian Analysis

2007 - Present

Institute of Mathematical Statistics

2007 - Present

American Statistical Association

2005 - Present

Eastern North American Biometrics Society (ENAR)

2005 - Present

Selected Presentations & Talks

Local Presentations

2025. Using Backfill to Expedite Drug Development. Invited. Houston, Texas, US.
2025. Digital Controls: An Efficient, Robust, and Privacy-Preserving Bayesian Tool for Adaptive Information Borrowing from External Data. Invited. Woodlands, TX, US.
2025. BOIN designs – what does future hold on finding the right dose?. Invited. Houston, Texas, US.
2021. Novel Bayesian design for early phase clinical trials (II). Invited. Department of Investigational Cancer Therapy. Houston, US.
2021. Novel Bayesian design for early phase clinical trials (I). Invited. Department of Investigational Cancer Therapy. Houston, US.
2014. Bayesian Optimal Interval Designs for Phase I Clinical Trials. Invited. Houston Chapter of American Statistical Association. Houston, TX, US.
2014. BOIN: a novel Bayesian optimal design for phase I clinical trials. Invited. Center for Clinical and Translational Sciences University of Texas Health Science Center. Houston, TX, US.
2014. Bayesian Optimal Interval Designs for Phase I Clinical Trials. Invited. Dan L. Duncan Cancer, Baylor College of Medicine. Houston, TX, US.
2011. Bayesian Data Augmentation Approach to Continual Reassessment Method With Delayed Outcomes. Conference. 4th Annual Bayesian Biostatistics Conference. Houston, TX, US.
2007. Statistical Analysis with Missing Data. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.

Regional Presentations

2024. Statistical Issues in the Design and Analysis of Transplant and Cell Therapy Studies. Invited. 2024 Tandem Meetings —Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR. San Antonio, TX, US.
2016. BOIN: Bayesian Optimal Interval Design for Phase I Clinical Trials. Invited. ENAR 2016 Spring Meeting. Austin, TX, US.
2009. Meta-Analysis of Studies with Missing Data. Conference. International Biometric Society Eastern North American Region 2009 Spring Meeting. San Antonio, TX, US.
2009. Dose finding by Jointly Modeling Toxicity and Efficacy as Time-to-Event Outcomes. Conference. International Biometric Society Eastern North American Region 2009 Spring Meeting. San Antonio, TX, US.
2005. Model-Based Estimates of the Finite Population Mean for Two-Stage Cluster Samples with Unit Non-response. Conference. International Biometric Society Eastern North American Region 2005 Spring Meeting. Austin, TX, US.

National Presentations

2025. Seamless Trial Designs for Rare Cancer Drug Development. Invited. Friends of Cancer Research Annual Meeting 2025. Washington DC, US.
2025. From MTD to OBD: Statistical Innovations in Dose Optimization. Invited. Department of Biostatistics, University of Michigan. Ann Arbor, MI, US.
2025. Bayesian Clinical Trial Designs and Their Implementation. Invited. DahShu Data Science Symposium 2025. Storrs, CT, US.
2025. Developing Novel Trial Designs: Keep it Simple and Smart. Invited. Cancer Center, University of Michigan. Ann Arbor, MI, US.
2025. Second Expert Workshop on Statistical Methods for Hybrid Randomized Controlled Trials and Studies Using RWD. Invited. Washington DC, US.
2025. Backfill and Randomization: Key Strategies for Effective Dose Optimization. Invited. ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop 2025. Rockville, MD, US.
2025. Statistical Considerations and Design Strategies for Dose Optimization in Simple and Complex Settings. Invited. ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop 2025, short course. Rockville, MD, US.
2025. PS-SAM: doubly robust propensity-score-integrated self-adapting mixture prior to dynamically borrow information from historical data. Invited. 2025 Joint Statistical Meetings. Nashville, Tennessee, US.
2025. Innovative Clinical Trial Designs for Dose Optimization: Shaping the Future of Drug Development. Invited. 2025 Joint Statistical Meetings. Nashville, Tennessee, US.
2025. Statistical and Design Considerations for Dose Optimization. Invited. 2025 Joint Statistical Meetings. Nashville, Tennessee, US.
2025. Frontiers of Innovation: Bayesian Adaptive Designs in Clinical Trials. Invited. Department of Biostatistics, Indiana University. Indianapolis, Indiana, US.
2025. Using backfill for flexible and efficient dose optimization. Invited. AACR 2025 Annual Meeting. Chicago, IL, US.
2025. Introduction of the Bayesian Optimal Interval (BOIN) design for early phase clinical trials. Invited. Webinar, Emergent Inc, US.
2025. Digital Controls: An Efficient, Robust, and Privacy-Preserving Bayesian Tool for Adaptive Information Borrowing from External Data. Invited. Workshop on Experimental Designs in the Era of Artificial Intelligence, US.
2024. BOIN: A novel Bayesian platform to innovate phase I clinical trials. Invited. Webinar, Incyte, US.
2024. A Bayesian latent-subgroup phase I/II platform design to co-optimize doses in multiple indications. Invited. Bayesian Biostatistics. Rockville, MD, US.
2024. Frontiers of Innovation: Bayesian Adaptive Designs in Clinical Trials Trial. Invited. University of Florida’s 2024 Data and Artificial Intelligence Symposium (DAISY). Jacksonville Beach, FL, US.
2024. Statistical Designs and Strategies for Dose Optimization. Invited. 2024 ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop. Rockville, MD, US.
2024. BARD: A Two-Stage Seamless Dose Optimization Design with Backfill and Adaptive Randomization. Invited. 2024 ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop. Rockville, MD, US.
2024. Innovative trial designs and novel Bayesian techniques to enhance pediatric drug development. Invited. 2024 Joint Statistical Meeting. Portland, OR, US.
2024. Self-adapting mixture prior to dynamically borrow information from historical data in clinical trials. Invited. 2024 Joint Statistical Meeting. Portland, OR, US.
2024. Model-assisted designs: Make adaptive clinical trials easy and accessible. Invited. short course, ICSA 2024 Applied Statistics Symposium. Nashville, TN, US.
2024. Self-adapting mixture prior to dynamically borrow information from historical data in clinical trials. Invited. ICSA 2024 Applied Statistics Symposium. Nashville, TN, US.
2024. Statistical Designs and Strategies for Dose Optimization. Invited. BeiGene, NJ, US.
2024. BASIC: A Bayesian Adaptive Synthetic-control Design for Phase II Clinical Trials. Invited. Duke Industry Statistics Symposium. Durham, NC, US.
2024. Dose Optimization: Where the Rubber Meets the Road. Invited. Duke Industry Statistics Symposium. Durham, NC, US.
2024. SAM: Self-adapting mixture prior to dynamically borrow information from historical data in clinical trials. Invited. Department of Biostatistics, University of Wisconsin-Madison. Madison, WI, US.
2024. Statistical Designs and Strategies for Dose Optimization. Invited. 16th Annual Conference on Statistical Issues in Clinical Trials, University of Pennsylvania. Philadelphia, PA, US.
2024. BASIC: A Bayesian Adaptive Synthetic Control Design for Phase II Clinical Trials. Invited. 7th International Symposium on Biopharmaceutical Statistics. Baltimore, MD, US.
2024. Backfilling Patients in Phase I Dose-Escalation Trials Using Bayesian Optimal Interval Design (BOIN). Invited. Takeda Pharmaceutical Company Limited, Webinar, US.
2024. Model-Assisted Designs: Make Adaptive Clinical Trials Easy and Accessible. Invited. ENAR 2024 Spring Meeting. Baltimore, MD, US.
2024. Statistical Considerations in Planning and Conduct of Dose Optimization Trials. Invited. ENAR 2024 Spring Meeting. Baltimore, MD, US.
2024. Dose Optimization: Where the Rubber Meets the Road. Invited. 7th International Symposium on Biopharmaceutical Statistics. Baltimore, MD, US.
2024. How to Pivot Beyond Rule-Based and Model-Based Determinations to Support Dosage Selection. Invited. FDA-AACR Workshop on Optimizing Dosages for Oncology Drug Products: Quantitative Approaches to Select Dosages for Clinical Trials. Washington, D.C, US.
2023. Bayesian Adaptive Designs for Early Phase Clinical Trials. Invited. Department of Epidemiology and Population Health, Albert Einstein College of Medicine. Bronx, NY, US.
2023. Statistical Strategies and Practical Considerations for Dose Optimization. Invited. The 79th Annual Deming Conference on Applied Statistics (Deming Conference). Philadelphia, PA, US.
2023. BOIN Design: Journey of FDA FFP (Fit-For-Purpose) Qualification. Invited. The Inaugural Statistical Innovation Members’ Summit: Exploring the Challenges and Opportunities of Statistical Innovation in Pharmaceuticals and Health Agencies. Tarrytown, NY, US.
2023. Elastic Priors to Dynamically Borrow Information from Historical Data in Clinical Trials. Invited. The 41 6th Annual New England Rare Disease Statistics (Nerds) Workshop. East Rutherford, NJ, US.
2023. Bayesian Methods for Clinical Trials. Invited. Short Couse, FDA, US.
2023. Elastic Priors to Dynamically Borrow Information from Historical Data in Clinical Trials. Invited. The ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop. Washington DC,, US.
2023. Design and Sample Size Determination for Multiple-dose Randomized Phase II Trials for Dose Optimization. Invited. The Lifetime Data Science (LiDS) Conference. Raleigh, NC, US.
2023. Elastic Priors to Dynamically Borrow Information from Historical Data in Clinical Trials. Invited. 2023 WNAR/IMS meeting. Anchorage, AK, US.
2023. BOIN: a novel Bayesian phase I trial design to accelerate drug development. Invited. Dose Finding and Other Topics in Drug Development Conference. Storrs, CT, US.
2023. Bayesian Adaptive Designs for Early Phase Clinical Trials. Invited. 36th New England Statistics Symposium (NESS). Boston, MA, US.
2023. Design and Sample Size Determination for Multiple-dose Randomized Phase II Trials for Dose Optimization. Invited. John Hopkins University, US.
2023. Leveraging external data through Bayesian methods in clinical trials. Invited. Short Course, 2023 Society for Clinical Trials Annual Meeting, US.
2023. BOIN Suite: a novel Bayesian design platform to accelerate drug development. Invited. 5th Statistical Practice in Cancer Conference, Moffitt Cancer Center, US.
2023. Elastic Priors to Dynamically Borrow Information from Historical Data in Clinical Trials. Invited. ENAR Spring Meeting. Nashville, TN, US.
2022. Hybrid Randomized Controlled Trial Designs. Invited. Chapel Hill, NC, US.
2022. Statistical Designs for Dose Finding/Optimization. Invited. Amgen, US.
2022. A Bayesian Platform Trial Design to Simultaneously Evaluate Multiple Drugs in Multiple Indications with Mixed Endpoints. Invited. Boston Chapter of American Statistical Association Pharmaceutical Symposium. Boston, MA, US.
2022. Landscape and Emerging Innovations within Clinical Trials: Dose Optimization. Invited. DIA Innovative Trial Designs Conference. Tysons Corner, VA, US.
2022. BOIN: a novel Bayesian phase I trial design to accelerate drug development. Invited. 2seventy bio, US.
2022. Dose-Finding and Optimization for Novel Oncology Agents: The New Challenges and Novel Technologies. Invited. 2022 ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop. Washington DC, US.
2022. DROID: Dose-ranging Approach to Optimizing Dose in Oncology Drug Development. Invited. 2022 ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop. Washington DC, US.
2022. Trial Design for Dose Optimization in Oncology. Invited. Oncology Center of Excellence (OCE), FDA, US.
2022. Recent Development in Bayesian Dynamic Borrowing with Application to Clinical Trials. Invited. 2022 Joint Statistical Meeting (JSM), Washington DC, US.
2022. Complex Innovative Trial Designs to Expedite Drug Development. Invited. Servier Pharmaceuticals, US.
2022. Bayesian Adaptive Designs for Dose Optimization. Invited. ASA NJ Chapter and Princeton-Trenton Chapter Spring Symposium. Rutgers, NJ, US.
2022. Bayesian Adaptive Designs for Dose Optimization. Invited. Annual Meeting of Society of Clinical Trials. San Diego, CA, US.
2022. Adaptive Hybrid Control Design for Comparative Clinical Trials with History Control Data. Invited. New England Statistics Symposium. Storrs, CT, US.
2022. Complex Innovative Trial Designs to Expedite the Development of Drug Combination Therapies. Invited. ASA Connecticut Chapter Mini Conference, US.
2022. Bayesian Designs for Dose Escalation and Optimization Trials. Invited. Sumitomo Dainippon Pharma Oncology Inc, US.
2022. Model-Assisted Designs: A Novel Paradigm to Improve and Accelerate Drug Development. Invited. ASA Annual Florida Chapter Meeting, US.
2022. Elastic Priors to Dynamically Borrow Information from Historical Data. Invited. The University of California Irvine, US.
2021. Biostatistics Research and Innovation Network Scientific Advisory Board Panel Discussion. Invited. Bristol-Myers Squibb, US.
2021. Adaptive Designs with Multiple Endpoints. Invited. Blueprint Medicines, US.
2021. Elastic Priors to Dynamically Borrow Information from Historical Data. Invited. Workshop on Hybrid Designs, University of North Carolina at Chapel Hill. Chapel Hill, NC, US.
2021. Adaptive Designs for Dose Optimization. Invited. ICSA - Midwest Chapter/ASA - NIC Annual Fall Meeting, US.
2021. Challenges and Solutions for Developing Combination Therapies in Cancer. Invited. ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop, US.
2021. A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indications. Invited. ASA Biopharmaceutical Section Webinar, US.
2021. Trial design options in dose-optimization studies in cancer drug development. Invited. ASA Biopharmaceutical Section and FDA Oncology Center of Excellence, US.
2021. Design Clinical Trials with Multiple Endpoints: Methods and Applications. Invited. Workshop for Society of Clinical Trials, US.
2021. Designing dose-optimization studies in cancer drug development. Invited. FDA Oncology COE and LUNGevity Forum, US.
2021. A Bayesian group sequential design for randomized biosimilar clinical trials with adaptive information borrowing from historical data. Invited. Duke-Industry Statistics Symposium (DISS2021), US.
2021. Novel Bayesian Designs for Phase I Clinical Trials. Invited. Pacific Pediatric Neuro-Oncology Consortium (PNOC), US.
2020. BOIN Suite: a novel Bayesian Design Platform for Early Phase Clinical Trials. Invited. City of Hope. Duarte, CA, US.
2020. SNO Clinical Trials Course for Fellows and Junior Faculty. Invited. Society for Neuro-Oncology Annual Scientific Meeting (Virtual), US.
2020. TrialDesign.org: a Platform for Designing and Comparing Various Trials. Invited. Society of Clinical Trials Webinar, US.
2020. Elastic Priors to Dynamically Borrow Information from Historical Data in Clinical Trials. Invited. ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop, US.
2020. Incorporating Historical Information to Improve Phase I Clinical Trials. Invited. West Tennessee ASA chapter Seminar, US.
2020. Bayesian Phase I-II Clinical Trials. Invited. ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop, US.
2020. Bayesian Designs for Early Phase Clinical Trials. Invited. FDA CDER, US.
2020. Drug Approval and Labeling Based on the Bayesian Approach. Invited. 2020 Joint Statistical Meeting (JSM), US.
2020. Bayesian Adaptive Designs to Accelerate the Development of Immunotherapies. Invited. UCSF quantitative cancer immunotherapy symposium, US.
2020. Borrowing Information from Historical Data: A Double-edged Sword. Invited. DIA Advancing Complex Innovative Clinical Trial Designs Conference. Silver Springs, MD, US.
2019. SNO Clinical Trials Course for Fellows and Junior Faculty. Invited. Society for Neuro-Oncology Annual Scientiﬁc Meeting. Phoenix, AZ, US.
2019. Novel Bayesian Adaptive Clinical Trial Designs. Invited. Celgene Pharmaceutical. Summit, NJ, US.
2019. Time-to-event Bayesian Optimal Interval Design to Accelerate Phase I Clinical Trials. Invited. ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop. Washington, DC, US.
2019. Statistical Methods, Challenges and Impacts on Early Phase Trials. Invited. Joint Statistical Meeting. Denver, CO, US.
2019. Time-to-event Bayesian Optimal Interval Design to Accelerate Phase I Clinical Trials. Invited. Webinar for Adaptive Design Scientiﬁc Working Group (ADSWG) KOL lecture, US.
2019. BOP2: Bayesian Optimal Phase II Design for Clinical Trials with Simple and Complex Endpoint. Invited. ASA Boston Chapter Annual Pharmaceutical Symposium. Boston, MA, US.
2019. U-BOIN: A Utility-based Bayesian Optimal Interval Phase I/II Design to Identify the Optimal Biological Dose for Targeted and Immune Therapies. Invited. Society of Clinical Trials 2019 Annual Meeting. New Orleans, LA, US.
2019. A Bayesian Phase I-II Design for Immunotherapy. Invited. St. Jude Children’s Research Hospital. Memphis, TN, US.
2019. Time-to-event Bayesian Optimal Interval Design to Accelerate Phase I Clinical Trials. Invited. 2019 Duke Industry Statistics Symposium. Durham, NC, US.
2019. A Bayesian Clinical Trial Design for Evaluating Biosimilars Using a Calibrated Power Prior. Invited. ENAR. Philadelphia, PA, US.
2019. Integrated Platform for Designing Clinical Trials. Invited. AACR Annual Meeting. Atlanta, GA, US.
2019. BOIN: A Novel Platform for Designing Early Phase Clinical Trials. Invited. Ohio State University. Columbus, OH, US.
2018. BOIN: A Novel Platform for Designing Early Phase Clinical Trials. Invited. DIA Bayesian Scientific Working Group Bayesian KOL Lecture Series Webinar, US.
2018. Novel Bayesian Adaptive Designs for Basket Trials. Invited. Department of Biostatistics. Michigan, MI, US.
2018. BOIN: A Novel Platform for Designing Early Phase Clinical Trials. Invited. 2018 Annual Meeting of Society for NeuroOncology. New Orleans, LA, US.
2018. Bayesian Phase I/II Biomarker-based Dose Finding for Precision Medicine with Molecularly Targeted Agents. Invited. Department of Radiation Oncology. Michigan, MI, US.
2018. Novel Bayesian Adaptive Designs for Basket Trials. Invited. CBI's Basket & Umbrella Trials for Oncology. Philadelphia, PA, US.
2018. Bayesian Phase I/II Biomarker-based Dose Finding for Precision Medicine with Molecularly Targeted Agents. Invited. Indiana University. Indianapolis, IN, US.
2018. Accuracy, Safety and Reliability of Novel Phase I Trial Designs. Invited. 2018 ICSA Applied Statistics Symposium. New Brunswick, NJ, US.
2018. Accuracy, Safety and Reliability of Novel Phase I Trial Designs. Invited. 6th Workshop on Biostatistics and Bioinformatics. Atlanta, GA, US.
2018. Novel Bayesian Adaptive Designs for Basket Trails. Invited. FDA. Silver Springs, MD, US.
2018. Novel Adaptive Designs for Early Phase Clinical Trials. Invited. Society for Clinical Trials 30th Annual Meeting. Portland, OR, US.
2018. MIDAS: A Practical Bayesian Design for Platform Trials with Molecularly Targeted Agents. Invited. International Biometric Society Eastern North American Region 2018 Spring Meeting. Atlanta, GA, US.
2017. Bayesian Adaptive Designs for Clinical Trials. Invited. Juno Therapeutics. Seattle, WA, US.
2017. BOIN: A Novel Platform for Designing Early Phase Clinical Trials. Invited. 2017 ASA Bio-pharmaceutical Section Regulatory-Industry Statistics Workshop. Washington DC, US.
2017. Bayesian Designs for Immunotherapy and Drug Combination Trials. Conference. Washington DC, US.
2017. Bayesian Designs for Immunotherapy and Drug Combination Trials. Invited. 2017 ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop. Washington, DC, US.
2017. BOIN: A Novel Platform for Designing Early Phase Clinical Trials. Invited. 5th Annual Duke-Industry Statistics Symposium (DISS 2017). Durham, NC, US.
2017. Bayesian Designs for Phase I-II Clinical Trials. Invited. 2017 Joint Statistical Meeting. Baltimore, MD, US.
2017. Recent Developments in Early Phase Dose-Finding. Invited. 2017 ICSA Applied Statistics Symposium. Chicago, IL, US.
2017. Designing early phase drug combination trials in practice. Invited. 2017 ICSA Applied Statistics Symposium. Chicago, IL, US.
2017. BOIN: A Novel Platform for Designing Early Phase Clinical Trials. Invited. Georgetown University. Washington, DC, US.
2017. A Bayesian Phase I-II Design for Immunotherapy Clinical Trials. Invited. 2nd Symposium on Early-phase Trial Design Methodology. Charlottesville, VA, US.
2017. MIDAS: A Practical Bayesian Design for Platform Trials with Molecularly Targeted Agents. Invited. ENAR. Washington D.C, DC, US.
2016. Optimal Sequential Enrichment Design for Phase II Clinical Trials. Invited. Mayo Clinic. Rochester, MN, US.
2016. Bayesian Adaptive Clinical Trial Designs. Invited. Vertex Pharmaceuticals. Boston, MA, US.
2016. BOIN: A Simple and Ethical Design for Phase I Clinical Trials. Invited. Joint Statistical Meetings. Chicago, IL, US.
2016. Optimal Marker-Adaptive Designs for Targeted Therapy Based on Imperfectly Measured Biomarkers. Invited. 25th ICSA Applied Statistics Symposium. Atlanta, GA, US.
2016. Bayesian Optimal Interval Design for Phase I Clinical Trials. Invited. Allergan Pharmaceuticals. Irving, CA, US.
2015. Missing Data Approach to Handle Delayed Outcomes in Early Phase Clinical Trials. Invited. University of Michigan. Ann Arbor, MI, US.
2015. Bayesian optimal design fror phase I cancer clinical trials. Invited. Department of Applied Mathematics, University of Notre Dame. Notre Dame, IN, US.
2015. Using Novel Phase I Clinical Trial Designs in Practice. Invited. 2015 Joint Statistical Meeting (JSM). Seattle, WA, US.
2015. Design Drug Combination Clinical Trials. Invited. Joint 24th ICSA Applied Statistics Symposium and 13th Graybill Conference. Fort Collins, CO, US.
2015. Bayesian optimal design for phase I cancer clinical trials. Invited. University of California San Francisco Helen Diller Family Comprehensive Cancer Center. San Francisco, CA, US.
2015. Optimal Marker-Adaptive Designs for Targeted Therapy Based on Imperfectly Measured Biomarkers. Invited. Joint 24th ICSA Applied Statistics Symposium and 13th Graybill Conference. Fort Collins, CO, US.
2014. Bayesian Adaptive Designs for Drug Combination Dose-finding Trials. Conference. Roche Pharmaceuticals. New York, NY, US.
2014. Bayesian Adaptive Designs for Drug Combination Dose-finding Trials. Invited. Onyx Pharmaceuticals. San Francisco, CA, US.
2014. Sequential Continual Reassessment Method for Phase I Dose-combination Trials. Invited. 2014 Joint Statistical Meeting. Boston, MA, US.
2014. Using Bayesian Data Augmentation to Facilitate Phase I/II Trials with Delayed Outcomes. Invited. International Chinese Statistical association Annual Meeting. Portland, OR, US.
2014. A Bayesian dose finding design for oncology clinical trials of combinational biological agents. Conference. Journal Club Webinar, Royal Statistical Society.
2014. Goodness-of-Fit Diagnostics for Bayesian Hierarchical Models. Invited. Columbia University. New York, NY, US.
2013. Optimal Marker Adaptive Designs for Targeted Therapy Based on Imperfectly Measured Biomarkers. Invited. Third Biennial Workshop on Adaptive Early-Phase Clinical Trial Design. Ann Arbor, MI, US.
2013. Optimal Phase I Clinical Trial Designs. Invited. Emory University. Atlanta, GA, US.
2013. Using Data Augmentation to Facilitate Conduct of Phase I-II Clinical Trials with Delayed Outcomes. Invited. 2013 ENAR Annual Meeting. Orlando, FL, US.
2012. Bayesian Optimal Interval Designs for Phase I Clinical Trials. Invited. Nineteenth Annual Biopharmaceutical Statistics Symposium. Savannah, GA, US.
2012. Adaptive Dose-finding Designs for Identifying Optimal Biological Dose for Molecularly Target Agents. Conference. 20th Annual CRI Cancer Immunotherapy Symposium (Poster). New York, NY, US.
2012. Bayesian Data Augmentation Approach to Continual Reassessment Method with Delayed Outcomes. Invited. 2012 Joint Statistical Meetings. San Diego, CA, US.
2012. A Bayesian response-adaptive covariate-balanced randomization design with application to a leukemia clinical trial. Invited. Society for Clinical Trials. Miami, FL, US.
2012. A Bayesian Dose-finding Design for Drug Combination Trials with Delayed Toxicities. Invited. 2012 ENAR Annual Meeting. Washington, DC, US.
2011. Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials. Invited. 18th Annual Biopharmaceutical Statistics Symposium. Savannah, GA, US.
2011. Dose-response curve estimation: A semiparametric mixture approach. Invited. University of Louisville. Louisville, KY, US.
2011. Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials. Invited. WNAR Annual Meeting. San Luis Obispo, CA, US.
2011. Robust EM Continual Reassessment Method in Oncology Dose Finding. Invited. ENAR Annual Meeting. Miami, FL, US.
2010. Bayesian Multilevel Mediation Analysis. Conference. Society of Prevention Research 18th Annual Meeting. Denver, CO, US.
2010. Continual Reassessment Method for Late-Onset Toxicities Using Data Augmentation. Invited. ICSA 2010 Applied Statistics Symposium. Indianapolis, IN, US.
2010. Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials. Conference. International Biometric Society Eastern North American Region 2010 Spring Meeting. New Orleans, LA, US.
2009. Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials. Invited. Memorial Sloan Kettering Cancer Center, US.
2009. Bayesian Phase I/II Drug-combination Trial Design in Oncology. Conference. 2009 Joint Statistical Meeting, US.
2008. Bayesian Dose-Finding in Oncology for Drug Combinations by Copula Regression. Conference. 2008 Joint Statistical Meeting. Denver, CO, US.
2008. Sequential continual reassessment method for two-dimensional dose finding. Invited. 2008 Joint Statistical Meetings. Denver, CO, US.
2008. Bayesian Mediation Analysis. Conference. Society for Prevention Research 16th Annual Meeting. San Francisco, CA, US.
2008. Bayesian dose-findng for drug combinations by copula regression. Invited. Department of Biostatistics and Epidemiology. Pennsylvania, US.
2008. Bayesian Model Assessment for Hierarchical Model. Conference. International Biometric Society Eastern North American Region 2008 Spring Meeting. Arlington, VA, US.
2007. Why there are some any contradicted or exaggerated findings in highly-cited clinical research?. Invited. 2007 Joint Statistical Meetings. Salt Lake City, UT, US.
2006. Bayesian Hypothesis Testing Using Nonparametric Statistics. Conference. 2006 Joint Statistical Meetings. Seattle, WA, US.
2004. Assessment of Proportional Hazard in Cox Regression. Conference. Department of Clinical Biostatistics. La Jolla, CA, US.

International Presentations

2025. A Bayesian latent-subgroup phase I/II platform design to co-optimize doses in multiple indications. Invited. Vancouver, US.
2025. Statistical consideration and strategies for dose optimization. Invited, US.
2024. BOIN Suite: A Bayesian Design Platform to Innovate Phase I Clinical Trials. Invited. 2024 Korean Statistical Society (KSS) Annual Meeting. Seoul, KR.
2024. Bayesian Designs and Methods to Accelerate the Development of Medical Devices. Invited. The Chinese Biopharmaceutical Association (CBA) 2024 conference. Suzhou, CN.
2023. Elastic Priors to Dynamically Borrow Information from Historical Data in Clinical Trials. Invited. IMS International Conference on Statistics and Data Science. Lisbon, PT.
2023. Elastic Priors to Dynamically Borrow Information from Historical Data in Clinical Trials. Invited. DIA Quantitative Science Forum. Nanjing, CN.
2023. BASIC: A Bayesian Adaptive Synthetic Control Design for Phase II Clinical Trials. Invited. Joint Statistical Meeting. Toronto, CA.
2023. Elastic Priors to Dynamically Borrow Information from Historical Data in Clinical Trials. Invited. The 44th Conference of the International Society for Clinical Biostatistics (ISCB44). Milan, IT.
2023. Elastic Priors to Dynamically Borrow Information from Historical Data in Clinical Trials. Invited. The 64th ISI World Statistics Congress. Ottawa, CA.
2023. SAM: Self-adapting Mixture Prior to Dynamically Borrow Information from Historical Data in Clinical Trials. Invited. 2023 ICSA China Conference. Chengdu, CN.
2022. BOIN: a novel Bayesian phase I trial design to accelerate drug development. Invited. Oslo University Hospital, US.
2022. Elastic Priors To Dynamically Borrow Information From Historical Data In Clinical Trials. Invited. Annual meeting of the Statistical Society of Canada, US.
2022. Bayesian Optimal Interval Design for Phase I Clinical Trials. Invited. Drug Information Association (DIA) Statistical Forum, US.
2021. Elastic Priors to Dynamically Borrow Information from Historical Data. Invited. CREATE Clinical Research Forum, Shanghai Jiaotong University. Shanghai, CN.
2021. Bayesian Adaptive Designs for Dose Optimization. Invited. Drug Information Association (DIA) Quantitative Science Forum 2021, US.
2021. BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted Therapies. Invited. Statistics 2021 Canada, US.
2021. Bayesian Adaptive Designs for Dose Finding: Past, Present and Future. Invited. 2021 World Meeting of the International Society for Bayesian Analysis, US.
2021. Bayesian Adaptive Clinical Trial Designs. Invited. 2021 World Meeting of the International Society for Bayesian Analysis, US.
2021. BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for UtilityBased Dose Finding in Immunotherapy and Targeted Therapies. Invited. International Indian Statistical Association 2021 Annual Conference, US.
2021. Bayesian Phase I-II Trial Design for Immunotherapies. Invited. Yonsei University, KR.
2020. Elastic Priors to Dynamically Borrow Information from Historical Data in Clinical Trials. Invited. International Chinese Statistical Association 2020 Applied Statistics Symposium (Virtual), US.
2020. Optimal BHM to Accelerate the Development of Tissue-Agnostic Drugs. Invited. Shanghai Biostatistics Forum, US.
2020. BOIN12: Bayesian Optimal Interval Phase I/II Trial Design to Find the Optimal Biological Dose in Immunotherapy and Targeted Therapies. Invited. International Chinese Statistical Association 2020 Applied Statistics Symposium (Virtual), US.
2020. Elastic Priors to Dynamically Borrow Information from Historical Data in Clinical Trials. Invited. New England Rare Disease Statistics Workshop (NERDS), US.
2020. BOIN12: Bayesian Optimal Interval Phase I/II Trial Design to Find the Optimal Biological Dose in Immunotherapy and Targeted Therapies. Invited. Drug Information Association (DIA) China 2020 Annual Meeting, US.
2019. BOP2: Bayesian Optimal Phase II Design for Clinical Trials with Simple and Complex Endpoints. Conference. 5th International Clinical Trials Methodology Conference. Brington, GB.
2019. Bayesian Adaptive Design for Early Phase Clinical Trials. Invited. 5th Interna-tional Clinical Trials Methodology Conference. Brighton, GB.
2019. Time-to-event Bayesian Optimal Interval Design to Accelerate Phase I Clinical Trials. Conference. AACR Pediatric Conference. Montreal, CA.
2019. BOP2: Bayesian Optimal Phase II Design for Clinical Trials with Simple and Complex Endpoints. Invited. International Society for Biopharmaceutical Statistics. Kyoto, JP.
2019. Bayesian Phase I-II Adaptive Designs for Immunotherapy Trials. Invited. Rajamangala University of Technology. Phra Nakhon, TH.
2019. Novel Adaptive Clinical Trial Designs for Immunotherapy and Modern Drug Development. Invited. International Society for Biopharmaceutical Statistics. Kyoto, JP.
2019. BOP2: Bayesian Optimal Phase II Design for Clinical Trials with Simple and Complex Endpoints. Conference. 40th Annual Conference of the International Society for Clinical Biostatistics. Leuven, BE.
2019. Time-to-event Bayesian Optimal Interval Design to Accelerate Phase I Clinical Trials. Invited. Statistical Society of Canada 2019 Annual Meeting. Calgary, CA.
2018. BOIN: A Novel Platform for Designing Early Phase Clinical Trials. Invited. Montreal Hospital. Montreal, CA.
2018. lncRNA HOTAIRM1 might be a novel tumor suppressor in basal-like subtype of breast cancer. Conference. International Congress on Personalized Health Care. Montreal, CA.
2018. BOIN: A Novel Platform for Designing Early Phase Clinical Trials. Conference. presented at Joint International Society for Clinical Biostatistics and Australian Statistical Conference 2018,. Melbourne, AU.
2018. Bayesian Phase I/II Biomarker-based Dose Finding for Precision Medicine with Molecularly Targeted Agents. Invited. 2018 Joint Statistical Meeting. Vancouver, CA.
2018. Bayesian Phase I/II Biomarker-based Dose Finding for Precision Medicine with Molecularly Targeted Agents. Invited. 7th Workshop of Bayesian Clinical Trial Design and Data Analysis. Kyoto, JP.
2018. Accuracy, Safety and Reliability of Novel Phase I Trial Designs. Invited. Uno Pharmaceuticals. Osaka, JP.
2018. Bayesian Phase I/II Biomarker-based Dose Finding for Precision Medicine with Molecularly Targeted Agents. Invited. 2018 China Pharmaceutical University Clinical Trial Design. Nanjing, CN.
2017. Novel Designs for Phase I Clinical Trials. Invited. 6th Workshop of Bayesian Clinical Trial Design and Data Analysis. Kyoto, JP.
2017. Adaptively Borrowing Information: Mission Possible or Impossible. Invited. Kyoto Prefectural University of Medicine. Kyoto, JP.
2017. BOP2: A Bayesian Optimal Design for Phase 2 Clinical Trials with Simple and Complex Endpoints. Invited. Ono Pharmaceutical. Osaka, JP.
2017. Adaptive Designs for Clinical Trials. Invited. 2017 China Pharmaceutical University Clinical Trial Design. Nanjing, CN.
2017. BOIN: A Novel Platform for Designing Early Phase Clinical Trials. Invited. Third ICSA-Canada Chapter Symposium. Vancouver, CA.
2017. BOIN: A Novel Platform for Designing Early Phase Clinical Trials. Invited. CEN-ISBS 2017 Conference. Vienna, AT.
2017. BOIN: A Novel Platform for Designing Early Phase Clinical Trials. Invited. International Symposium on Biostatistics and Drug Development. Nanjing, CN.
2017. BOIN: A Novel Platform for Designing Early Phase Clinical Trials. Invited. Quantitative Methods for Drug Discovery and Development. Singapore, SG.
2017. Adaptively Borrowing Information: Mission Possible or Impossible. Invited. Society of Clinical Trial 38th Annual Meeting. Liverpool, GB.
2017. Bayesian Phase I/II Biomarker-based Dose Finding for Precision Medicine with Molecularly Targeted Agents. Invited. Kyoto University. Kyoto, JP.
2016. Optimal Sequential Enrichment Design for Phase II Clinical Trials. Invited. 10th International Chinese Statistical Association International Conference. Shanghai, CN.
2016. Bayesian Data Augmentation Continual Reassessment Method for Phase I Cancer Clinical Trials With Delayed Outcome. Invited. Conference on Experimental Design and Analysis 2016. Taipei, TW.
2016. Bayesian Phase I/II Biomarker-based Dose Finding for Precision Medicine with Molecularly Targeted Agents. Invited. China Pharmaceutical University. Nanjing, CN.
2016. Bayesian Optimal Interval Design for Phase I Clinical Trials. Invited. School of Finance and Statistics. Shanghai, CN.
2016. Optimal Sequential Enrichment Design for Phase II Clinical Trials. Invited. 16th International Nutrition & Diagnostic Confrerence. Prague, CZ.
2016. Adaptive Dose Modification for Phase I Clinical Trials. Invited. Ono Pharmaceuticals. Osaka, JP.
2016. Adaptive Dose Modification for Phase I Clinical Trials. Invited. 5th Early Phase Adaptive Trials Workshop. Turnin, IT.
2016. Robust treatment comparison based on utilities of semi-competing risks in non-small-cell lung cancer. Invited. Kyoto University. Kyoto, JP.
2016. Robust treatment comparison based on utilities of semi-competing risks in non-small-cell lung cancer. Invited. Department of Statistics & Actuarial Science. Hong Kong, CN.
2016. Optimal Marker-Adaptive Designs for Targeted Therapy Based on Imprefectly Measured Biomarkers. Invited. 2nd Conference on Data-Driven Medicine. Shanghai, CN.
2016. Optimal Marker-Adaptive Designs for Targeted Therapy Based on Imperfectly Measured Biomarkers. Invited. Fouth Military Medical University. Xi'an, CN.
2016. Big Data and Small Data for Precision Medicine. Invited. Fouth Military Medical University. Xi'an, CN.
2016. Optimal Sequential Enrichment Design for Phase II Clinical Trials. Invited. Chinese Pharmaceutical University. Nanjing, CN.
2016. Optimal Marker-Adaptive Designs for Targeted Therapy Based on Imperfectly Measured Biomakers. Invited. 2016 ICAS China Conference. Qingdao, CN.
2016. Bayesian Optimal Interval Desing for Phase I Clinical Trials. Invited. Society of Clinical Trials 37th Annual Meeting. Montreal, CA.
2015. Optimal Marker-Adaptive Designs for Targeted Therapy Based on Imperfectly Measured Biomarkers. Invited. Kyoto University. Kyoto, JP.
2015. Optimal Marker-Adaptive Designs for Targeted Therapy Based on Imprefectly Measured Biomarkers. Invited. Ono Pharmaceuticals, JP.
2015. Optimal Sequential Enrichment Design for Phase II Clinical Trials. Invited. 9th Conference of the Asian Regional Section of the IASC (IASC-ARS 2015), SG.
2015. Bayesian optimal design for phase I cancer clinical trials. Conference. 36th Annual Conference of the International Society for Clinical Biostatistics. Utrecht, NL.
2015. BOIN: Bayesian optimal design for phase I cancer clinical trials. Invited. Fourth Military Medical University. Xi'an, CN.
2015. Bayesian optimal design for phase I cancer clinical trials. Invited. 2015 ICSA China Statistics Conference. Shanghai, CN.
2015. Bayesian Dynamic Mediation Analysis. Conference. 2015 International Meeting of Psychometric Society. Beijing, CN.
2015. Bayesian data augmentation continual reassessment methods for phase I clinical trials with delayed toxicities. Invited. ISBS-DIA Joint Symposium on Biopharmaceutical Statistics. Beijing, CN.
2015. Optimal Marker-Adaptive Designs for Targeted Therapy Based on Imperfectly Measured Biomarkers. Invited. 3rd Bayesian Clinical Trial Design Workshop, Kyoto University. Kyoto, JP.
2015. Bayesian Adaptive Design for Phase I Immunotherapy Clinical Trial (Poster presentation). Conference. Institute for Research in Immunology and Cancer International Symposium. Montreal, CA.
2015. Bayesian optimal design for phase I cancer clinical trials. Invited. Uno Pharmaceuticals. Osaka, JP.
2015. Bayesian optimal design for phase I cancer clinical trials. Invited. Roche Pharmaceuticals. Basel, CH.
2015. Bayesian optimal design for phase I cancer clinical trials. Invited. Symposium on Early Phase Dose Finding Methodology. Paris, FR.
2015. Bayesian Data Augmentation Continual Reassessment Methods for Delayed Toxicity. Invited. Basel Biometrics Society. Basel, CH.
2014. Goodness-of-Fit Diagnostics for Bayesian Hierarchical Models. Conference. 27th International Biometric Conference. Florence, IT.
2014. Sample size determination for longitudinal mediation analysis. Conference. International Conference for Academic Disciplines. Venice, IT.
2014. Bayesian Data Augmentation Dose Finding with Continual Reassessment Method and Delayed Toxicity. Invited. Ordered Data Analysis Models and Health Research Methods: An International Conference in Honor of H.N. Nagaraja for his 60th Birthday, US.
2013. Statistical Analysis of Longitudinal Data with Nonignorable Dropouts. Invited. School of Public Health, Tongji College of Medicine. Wuhan, CN.
2013. Data Augmentation Continual Reassessment Method for Phase I Trials With Delayed Outcomes. Invited. School of Public Health, Southeastern University. Nanjing, CN.
2013. Bayesian Optimal Interval Designs for Phase I Clinical Trials. Invited. IASC Seoul Conference. Seoul.
2013. Using Data Augmentation to Facilitate Conduct of Phase I-II Clinical Trials with Delayed Outcomes. Conference. IMS-China International Conference on Statistics and Probability. Chengdu, CN.
2011. A Bayesian Phase I/II Design for Oncology Clinical Trials of Combinational Biological Agents. Invited. 2nd Workshop for CRM and Related Issues in Dose Finding. Paris, FR.
2011. Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials. Invited. Statistics 2011 Canada: 5th Canadian Conference in Applied Statistics. Montreal, CA.
2010. Evaluation of Deformable Image Registration Spatial Accuracy Using a Bayesian Hierarchical Model. Conference. 19th International Conference on Computational Statistics. Paris, FR.
2010. Modeling Longitudinal Dyadic Data with Informative Dropout. Conference. 2010 Joint Statistical Meeting. Vancouver, CA.
2010. Estimating Progression-Free Survival When the Progression Status of Some Patients Is Unknown. Conference. 2010 Joint Statistical Meeting. Vancouver, CA.
2008. Bayesian model assessment for hierarchical model. Conference. The 7th Annual Hawaii International Conference on Statistics, Mathematics and Related Fields. Honolulu, US.
2004. Model-Based Estimates of the Finite Population Mean for Two-Stage Cluster Samples with Unit Non-response. Conference. 2004 Joint Statistical Meetings. Toronto, CA.

Less

Grant & Contract Support

Date:	2027 - 2032
Title:	Advancing Agentic AI for Clinical Trials
Funding Source:	other
Role:	Co-I
ID:	#TBA

Date:	2026 - 2031
Title:	Functional connection between pancreatitis and pancreas cancer
Funding Source:	NIH
Role:	Co-I
ID:	1R01CA319805-01

Date:	2026 - 2031
Title:	Phase1-AI
Funding Source:	Subaward via Ohio State University
Role:	Co-I
ID:	#TBA

Date:	2026 - 2031
Title:	MD Anderson Cancer Center SPORE in Gastrointestinal Cancer Core B: Biostatistics and Bioinformatics
Funding Source:	NIH/NCI
Role:	Core-Director
ID:	2P50CA221707-06A1

Date:	2026 - 2030
Title:	OMRD2.0: Converting Detection into Cure
Funding Source:	other
Role:	Co-I
ID:	#TBA

Date:	2025 - 2029
Title:	Adjuvant Drug Development in Circulating Tumor DNA-Defined Minimal Residual Disease for Colorectal Cancer
Funding Source:	Cancer Prevention Research Institute of Texas
Role:	Co-I
ID:	RP260161

Date:	2025 - 2028
Title:	RP260092: Biomarker-based approaches to improve radiation therapy and development of radiosensitization approaches in gastric cancer
Funding Source:	CANCER PREVENTION RESEARCH INST OF TX
Role:	Other Significant Contributor
ID:	RP260092

Date:	2025 - 2028
Title:	42592: Novel and Robust Design and Analysis Methods for Decentralized Clinical Trials
Funding Source:	Patient-Centered Outcomes Res Inst PCORI
Role:	Co-I
ID:	#TBA

Date:	2025 - 2028
Title:	Statistical designs and considerations for dose optimization with drug combination and multiple indications
Funding Source:	Food and Drug Administration (FDA)
Role:	PD/PI
ID:	75F40125C00075

Date:	2025 - 2030
Title:	Delineating the role of TREM2 in chronic pancreatitis
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA307597-01

Date:	2025 - 2027
Title:	Combining TROP2-directed CAR-NK cells with HIF2a inhibition for the immunotherapy of pancreatic Cancer
Funding Source:	Department of Defense (DOD)
Role:	Co-I
ID:	PA240287

Date:	2025 - 2032
Title:	A Phase I Study of the NovoTTF-200M and Novo TTF-200A Systems for the Treatment of Refractory Spinal Metastasis
Funding Source:	Novocure GmbH
Role:	Co-I
ID:	2024-1879

Date:	2025 - 2028
Title:	Targeting pathogenic inflammation to improve therapeutic outcomes in pancreatic cancer
Funding Source:	Department of Defense (DOD)
Role:	Collaborator
ID:	#TBA

Date:	2025 - 2029
Title:	Unlocking the potential of NP-101: A Phase I trial of a novel anti-Cancer agent with immune modulation capabilities
Funding Source:	NIH/NCI
Role:	Co-I
ID:	#TBA

Date:	2025 - 2030
Title:	Statistical methods to delineate the spatial and temporal pattern of cell-cell interactions in Spatial Transcriptomics data
Funding Source:	NIH/NCI
Role:	Other significant contributor
ID:	#TBA

Date:	2025 - 2028
Title:	CA240627: Improving Radiation Sensitivity of Gastric Cancer
Funding Source:	Department of Defense (DOD)
Role:	Other significant contributor
ID:	#TBA

Date:	2025 - 2030
Title:	Enhancing the activity of trastuzumab deruxtecan in HER2-expressing cancers
Funding Source:	NIH/NCI
Role:	Co-I
ID:	#TBA

Date:	2025 - 2029
Title:	ADC-MATCH: Optimizing treatment selection with antibody-drug conjugates
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	#TBA

Date:	2025 - 2029
Title:	Phase 1 Clinical Trial of NP-101: Dose Escalation, Expansion, and Immune Activation in Patients with Solid Tumor
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator
ID:	#TBA

Date:	2024 - 2026
Title:	Novel designs for multi-arm multi-dose multi-stage platform trials
Funding Source:	NIH/NCI
Role:	Co-I
ID:	R21LM014699

Date:	2024 - 2029
Title:	Biomarkers Predicting Response to Radiation Therapy and A Novel Approach Enhancing Radiation Sensitivity in Gastric Cancer
Funding Source:	NIH/NCI
Role:	Other Significant Contributor
ID:	#TBA

Date:	2024 - 2030
Title:	ASCEND-CRC: Adaptive Strategies for Clinical Evolution and Novel Dynamics in Colorectal Cancer
Funding Source:	Advanced Research Projects Agency for Health
Role:	Co-I
ID:	#TBA

Date:	2024 - 2029
Title:	SPORE in Brain Cancer
Funding Source:	NIH/NCI
Role:	Core Director
ID:	P50CA127001

Date:	2024 - 2029
Title:	Center for Clinical Translational Science (CCTS 2024-2031)
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1UM1TR004906

Date:	2024 - 2029
Title:	MD Anderson Cancer Center SPORE in Gastrointestinal Cancer
Funding Source:	NIH/NCI
Role:	Co-Director
ID:	#TBA

Date:	2024 - 2029
Title:	Combination of viroimmunotherapy and off-the-shelf genetically engineered natural killer cells for the treatment of gliomas
Funding Source:	NIH/NCI
Role:	Co-I
ID:	#TBA

Date:	2024 - 2029
Title:	Drug Combo for Phase I Cancer Clinical Trial Design
Funding Source:	Subaward-Subcontract via Ohio State University
Role:	Co-I
ID:	#TBA

Date:	2024 - 2029
Title:	Combination of viroimmunotherapy and off-the-shelf genetically engineered natural killer cells for the treatment of gliomas
Funding Source:	NIH/NCI
Role:	Co-I
ID:	#TBA

Date:	2024 - 2027
Title:	TROP2-Directed CAR-NK Cells for the Immunotherapy of Metastatic Breast Cancer
Funding Source:	Conquer Cancer Foundation
Role:	Co-I
ID:	#TBA

Date:	2024 - 2026
Title:	Novel methods and designs for multi-arm multi-stage platform trials
Funding Source:	NIH/NCI
Role:	Co-I
ID:	#TBA

Date:	2024 - 2027
Title:	An Open-Labeled, Two Arm Phase 2 Efficacy and Safety Study of VAL-083 for Treatment in Adult Diffuse Midline Glioma
Funding Source:	Subaward-Subcontract via Kintara Therapeutics
Role:	Co-I
ID:	#TBA

Date:	2024 - 2029
Title:	TROP2-Directed CAR-NK Cells for the Immunotherapy of Pancreatic Cancer
Funding Source:	NIH/NCI
Role:	Co-I
ID:	R01CA288617

Date:	2024 - 2027
Title:	RA230199: INTERCEPT-AGCT: INTERnational Registry and Clinical Experimental Platform for Therapeutics in Adult-type Granulosa Cell Tumors
Funding Source:	Department of Defense (DOD)
Role:	Supervising Biostatician
ID:	#TBA

Date:	2024 - 2027
Title:	OC230078: Laparoscopic cytoreduction After Neoadjuvant ChEmotherapy (LANCE) Trial
Funding Source:	Department of Defense (DOD)
Role:	Statistician
ID:	OC230078

Date:	2023 - 2028
Title:	Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment: Data Management and Coordinating Unit
Funding Source:	NIH/NCI
Role:	PI
ID:	#TBA

Date:	2023 - 2028
Title:	Novel orally bioavailable imipridone ONC206 in advanced uterine cancer treatment
Funding Source:	NIH/NCI
Role:	Co-I
ID:	#TBA

Date:	2023 - 2028
Title:	Integrating patient-reported outcomes and T-cell receptor sequencing to predict immune-related adverse events
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA279749-01A1

Date:	2023 - 2028
Title:	The University of Texas MD Anderson Cancer Center SPORE in Ovarian Cancer
Funding Source:	NIH/NCI
Role:	Core Co-Director - Biostatistics
ID:	1 P50 CA281701-01

Date:	2023 - 2028
Title:	MD Anderson Endometrial Cancer SPORE
Funding Source:	NIH/NCI
Role:	Co-Director
ID:	1P50CA269916-01

Date:	2023 - 2028
Title:	Mechanisms and Functional Consequence of Tumor Associated TRIM28 in Metastatic Gastric Adenocarcinoma
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	#TBA

Date:	2023 - 2028
Title:	Therapeutic Exploitation of YAP1/CAF Induced Immunosuppression
Funding Source:	NIH/NCI
Role:	Sr. Biostatistician
ID:	#TBA

Date:	2023 - 2025
Title:	An Open-Labeled, Two Arm Phase 2 Efficacy and Safety Study of VAL-083 for Treatment of H3K27M-mutated and Wildtype Adult Diffuse Midline Glioma
Funding Source:	Subaward-Subcontract via Kintara Therapeutics
Role:	Co-I
ID:	#TBA

Date:	2023 - 2030
Title:	Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab (GSK) and LB-100 (Lixte)
Funding Source:	GlaxoSmithKline LLC
Role:	Co-I
ID:	2022-1047

Date:	2023 - 2026
Title:	CA220365 YAP1-Mediated Stromal Activation Leads to Gastric Adenocarcinoma Progression
Funding Source:	Department of Defense (DOD)
Role:	Sr. Biostatistician
ID:	#TBA

Date:	2023 - 2026
Title:	CA220452 Co-Targeting Galectin-3 and CD47 as Novel Therapeutic Strategy in Advanced Gastric Adenocarcinoma
Funding Source:	Department of Defense (DOD)
Role:	Collaborator
ID:	#TBA

Date:	2023 - 2028
Title:	Personalized prediction of response to immune checkpoint inhibitors using circulating biomarkers by machine learning approach
Funding Source:	NIH/NCI
Role:	Co-I
ID:	#TBA

Date:	2023 - 2028
Title:	Coordinating and Data Management Center for Cancer Adoptive Cellular Therapy Network
Funding Source:	NIH/NCI
Role:	PI
ID:	1U24CA283562-01

Date:	2023 - 2027
Title:	Interrogation of KDM6A mutation as a predictive biomarker of immune checkpoint therapy and as a neoantigen vaccine strategy in urothelial cancer
Funding Source:	V Foundation
Role:	Biostatistician
ID:	FP00018996

Date:	2023 - 2028
Title:	YAP1-mediated Stromal Activation Leads to Gastric Adenocarcinoma Progression
Funding Source:	NIH/NCI
Role:	Sr. Biostatistician
ID:	1R01CA278986-01

Date:	2023 - 2028
Title:	Molecular Dissecting and Targeting TRIM28 in Advanced Gastric Adenocarcinoma
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	1R01CA278947-01

Date:	2023 - 2028
Title:	Predicting immune-related adverse events using blood-based biomarkers based on machine learning
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA278875-01

Date:	2023 - 2028
Title:	Integrating patient-reported outcomes and T-cell receptor sequencing to predict immune-related adverse events
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA279749-01

Date:	2023 - 2028
Title:	Targeting DRD2 by novel imipridones in advanced uterine cancer treatment
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA272575-01A1

Date:	2023 - 2028
Title:	Biomarker Development for Immunotherapy/EGFR-Targeted Therapy in Inflammatory Breast Cancer
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA275057-01A1

Date:	2023 - 2028
Title:	MD Anderson Faculty Institutional Recruitment for Sustainable Transformation (FIRST) Program
Funding Source:	NIH/NCI
Role:	Biostatistics SPORE Mentor
ID:	1U54CA280881-01

Date:	2023 - 2026
Title:	Molecular Dissecting and Targeting TRIM28 in Advanced Gastric Adenocarcinoma
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator
ID:	#TBA

Date:	2023 - 2030
Title:	Window -of-Opportunity Trial of Ulixertinib for MAPK-Activated Low-Grade Gliomas in Adults
Funding Source:	BioMed Valley Discoveries
Role:	Co-I
ID:	00014981

Date:	2022 - 2027
Title:	Coordinating and Data Management Center for Translational and Basic Science Research in Early Lesions
Funding Source:	NIH/NCI
Role:	PD/PI
ID:	1U24CA274212-01

Date:	2022 - 2027
Title:	Molecular dissecting and targeting YAP1 mediated cancer stemness and immune suppression in advanced gastric adenocarcinoma
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	1R01CA269685-01A1

Date:	2022 - 2027
Title:	The University of Texas MD Anderson Cancer Center SPORE in Ovarian Cancer
Funding Source:	NIH/NCI
Role:	Core Co-Director - Biostatistics
ID:	2P50CA217685-06

Date:	2022 - 2026
Title:	Biomarker Development for EPA‐Dasatinib Combination Therapy for Metastatic Triple‐Negative Inflammatory Breast Cancer
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA278048-01

Date:	2022 - 2026
Title:	MD Anderson Faculty Institutional Recruitment for Sustainable Transformation (FIRST) Program
Funding Source:	NIH/NCI
Role:	Mentor
ID:	#TBA

Date:	2022 - 2024
Title:	A Precision Oncology Micro-Organosphere-Based Platform to Guide Colorectal Cancer Therapy
Funding Source:	Subaward via Xilis
Role:	Statistician
ID:	#TBA

Date:	2022 - 2027
Title:	STRATEGIC ALLIANCE: Phase 1b Trial Assessing Combinations of TGF-ß Inhibitor (Sar439459) And PD-1 Inhibitor Cemiplimab (TACTIC)
Funding Source:	Pfizer Inc
Role:	PI
ID:	#TBA

Date:	2022 - 2027
Title:	Immunological Determinants of Oncolytic Adenovirus Induced Efficacy for Melanoma Brain Metastases
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator
ID:	#TBA

Date:	2022 - 2024
Title:	Developing a clinical tool to predict the risk of severe immune-related adverse events using patient-reported outcomes in cancer patients treated with immunotherapy
Funding Source:	HESI THRIVE
Role:	Co-I
ID:	#TBA

Date:	2022 - 2024
Title:	A Precision Oncology Micro-Organosphere-Based Platform to Guide Colorectal Cancer Therapy
Funding Source:	Subaward via Xilis
Role:	Statistician
ID:	#TBA

Date:	2022 - 2029
Title:	A Phase 1b study of lurbinectedin in combination with weekly paclitaxel and bevacizumab
Funding Source:	Jazz Pharmaceuticals, Inc
Role:	Co-I
ID:	2022-0231

Date:	2022 - 2027
Title:	Targeting DRD2 by novel imipridones in advanced uterine cancer treatment
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA272575-01

Date:	2022 - 2027
Title:	Biomarker Development for Immunotherapy/EGFR-Targeted Therapy in Inflammatory Breast Cancer
Funding Source:	NIH/NCI
Role:	Co-I
ID:	#TBA

Date:	2022 - 2027
Title:	MD Anderson SPORE in Brain Metastasis
Funding Source:	NIH/NCI
Role:	Core Director
ID:	1P50CA272300-01

Date:	2022 - 2025
Title:	Safety, Tolerability and Dose-Limiting Toxicity of Lacosamide in Patients with Painful Chronic Pancreatitis
Funding Source:	NIH/NIDDK Subaward-Subcontract via INDIANA UNIVERSITY
Role:	Co-I
ID:	1R01DK132709-01

Date:	2022 - 2027
Title:	MD Anderson Endometrial Cancer SPORE
Funding Source:	NIH/NCI
Role:	Co-Director
ID:	P50 CA098258

Date:	2022 - 2027
Title:	Liraglutide in Endometrial Cancer Prevention
Funding Source:	NIH/NCI
Role:	Biostatistician
ID:	1R01CA269616-01

Date:	2022 - 2027
Title:	Optimizing Patient Selection for Antibody-Drug Conjugates through Multiplex Testing
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA262009-01

Date:	2022 - 2025
Title:	Mechanisms of Dysglycemia and Development of Diabetes in Children with Acute Recurrent or Chronic Pancreatitis in INSPPIRE-2
Funding Source:	Subaward-Subcontract via University of IOWA
Role:	PI
ID:	#TBA

Date:	2022 - 2024
Title:	A Precision Oncology Micro-Organosphere-Based Platform to Guide Colorectal Cancer Therapy
Funding Source:	Subaward-Subcontract Xilis
Role:	Biostatistician
ID:	1 R42 CA268563-01

Date:	2022 - 2026
Title:	Targeting Ovarian Cancer Minimal Residual Disease (MRD) Using Immune and DNA Repair Directed Therapies
Funding Source:	Break Through Cancer
Role:	Co-I
ID:	AWD00006544

Date:	2022 - 2026
Title:	MDA-TARGET for Therapeutically Actionable RNA-Guided Treatment
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator
ID:	RP220382

Date:	2022 - 2026
Title:	A Phase I Trial of Personalized Neoantigen Cancer Vaccine Therapy in Combination with Nivolumab and Ipilimumab for Metastatic Clear Cell Renal Cell Carcinoma
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator
ID:	#TBA

Date:	2022 - 2025
Title:	Optimizing Therapy for Glioblastoma by Decoding Bar-Coded Glioma Stem Cells Using High-Throughput Multiplexed Platform
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator
ID:	#TBA

Date:	2022 - 2029
Title:	2021-0400A phase II Study of lenvatinib plus everolimus versus cabozantinib in patients with metastatic renal cell carcinoma that progressed on a PD-1/PDL1 checkpoint inhibitor (LenCabo)
Funding Source:	EISAI INC
Role:	PI
ID:	AWD00006115

Date:	2022 - 2025
Title:	BC210629: The Eicosapentaenoic Acid-Based Combination Therapy for Metastatic Triple-Negative Inflammatory Breast Cancer by Modulating Cholesterol Metabolism
Funding Source:	Department of Defense (DOD)
Role:	Co-I
ID:	#TBA

Date:	2021 - 2026
Title:	Phase II Trial of Alpelisib with iNOS Inhibitor and Nab-paclitaxel in Patients with HER2 negative Metastatic or Locally Advanced Metaplastic Breast Cancer
Funding Source:	NIH/NCI Subaward-Subcontract via Houston Methodist Research Institute
Role:	Co-I
ID:	1U01CA268813-01

Date:	2021 - 2026
Title:	Targeting DRD2 by novel orally bioavailable imipridones in advanced uterine cancer treatment
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA258335-01A1

Date:	2021 - 2026
Title:	Therapeutic Identification of Genomic Signatures Defining Responsiveness to TMZ Combination Therapy by High Throughput Screening using Biological Barcoded Glioma Stem Cell Lines
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01NS121059-01

Date:	2021 - 2026
Title:	EPHARNA: A non-coding RNA therapeutic for gynecologic cancers
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1U01CA268816-01

Date:	2021 - 2024
Title:	Improving anti-tumor responses to immunotherapy using the combination biomarker ARID1A + CXCL 13
Funding Source:	Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation
Role:	Co-I
ID:	AWD00006017

Date:	2021 - 2026
Title:	The MD Anderson Cancer Center-Huntsman Cancer Institute U19 GTN Center
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1U19CA264499-01

Date:	2021 - 2026
Title:	Improving Neoadjuvant Anti-PD-1 Efficacy in Recurrent GBM with Blood Brain Barrier Opening using MRI-Guided Focused Ultrasound (MRgFUS)
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA266997-01

Date:	2021 - 2026
Title:	MD Anderson Endometrial Cancer SPORE
Funding Source:	NIH/NCI
Role:	Co-Director
ID:	P50 CA098258

Date:	2021 - 2025
Title:	EPA-Dasatinib Combination Therapy for Metastatic Triple-Negative Inflammatory Breast Cancer
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA256944-01

Date:	2021 - 2024
Title:	A Phase I Trial of Personalized Frameshift Peptide Neoantigen Cancer Vaccine Therapy in Combination with Nivolumab & Ipilimumab in Patients with Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Funding Source:	Leidos Biomedical Research, Inc
Role:	Biostatistician
ID:	#TBA

Date:	2021 - 2024
Title:	Therapeutic Identification of Genetic Vulnerabilities to TMZ Resistance by Large-Scale Screening using Biological Barcoded Glioma Stem Cell Lines
Funding Source:	Department of Defense (DOD)
Role:	Co-I
ID:	TBA

Date:	2021 - 2023
Title:	A Precision Oncology Micro-Organosphere-Based Platform to Guide Colorectal Cancer Therapy
Funding Source:	Subaward-Subcontract Xilis
Role:	Statistician
ID:	1 R42 CA268563-01

Date:	2021 - 2028
Title:	Immunomodulation of the tumor microenvironment in high-grade serous ovarian cancer patients receiving pembrolizumab and lenvatinib monotherapy and combination therapy
Funding Source:	MERK
Role:	Co-I
ID:	2020-1121

Date:	2021 - 2026
Title:	FOREIGN COLLABORATION
Funding Source:
Role:

Date:	2021 - 2026
Title:	Sequential WEE1 Blockade to Enhance PARP Inhibitor Clinical Efficacy in BRCA1/2 Mutated Cancers (TWINCLE)
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	1R01CA261993-01

Date:	2021 - 2026
Title:	Optimizing Patient Selection for Antibody-Drug Conjugates through Multiplex Testing
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA262009-01

Date:	2021 - 2022
Title:	Using multiple-source data and machine learning methods to predict clinical response for cancer patients
Funding Source:	Boehringer Ingelheim Pharmaceuticals, Inc
Role:	PI
ID:	RCTS: LS2021-00059170-RP

Date:	2021 - 2024
Title:	Leveraging Proteome Instability to Potentiate Immune Checkpoint Blockade in MSI-high Colorectal Cancer
Funding Source:	Department of Defense (DOD)
Role:	Co-I
ID:	TBA

Date:	2021 - 2026
Title:	Enhancing Immunotherapy by Targeting the EGFR Pathway in Inflammatory Breast Cancer
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA258744-01

Date:	2021 - 2026
Title:	Personalized ctDNA NGS Panels Covering Genome-Wide Tumor-Specific Mutations for Blood-based MRD Monitoring
Funding Source:	Subaward-Subcntract via William Marsh Rice University
Role:	Collaborator
ID:	#TBA

Date:	2021 - 2026
Title:	Leveraging proteome instability to potentiate immune checkpoint blockade in MSI-high colorectal cancer
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA258463-01

Date:	2021 - 2026
Title:	Targeting DRD2 by novel orally bioavailable imipridones in advanced uterine cancer treatment
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA258335-01

Date:	2021 - 2026
Title:	Assessing the Immunomodulatory Role of Commensal and Pathogenic Microbiota in HPV-mediated Cancers
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA258979-01

Date:	2021 - 2026
Title:	Therapeutic Identification of Genomic Signatures Defining Responsiveness to TMZ Combination Therapy by High Throughput Screening using Biological Barcoded Glioma Stem Cell Lines
Funding Source:	NIH/NINDS
Role:	Co-I
ID:	1R01NS121059-01

Date:	2021 - 2025
Title:	BC201115 The Encosapentaenoic Acid-Based Combination Therapy for Metastatic Triple-Negative Inflammatory Breast Cancer by Modulating cholesterol Metabolism
Funding Source:	Department of Defense (DOD)
Role:	Co-I
ID:	#TBA

Date:	2021 - 2022
Title:	Expanding Tobacco Use Cessation in Northeast Texas
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Evaluator
ID:	PP190009

Date:	2021 - 2024
Title:	STRATEGIC ALLIANCE: Sanofi - MD Anderson Cancer Center HER2 T-Cell Engager Project Collaboration
Funding Source:	Sanofi Pharmaceuticals
Role:	Biostatistician
ID:	RCTS LS2021-00059219-LG

Date:	2021 - 2022
Title:	ALRN-6924 (MDM2/MDMX inh) and paclitaxel in patients with advanced or metastatic solid tumors with TP53 WT, including ER+ breast cancer
Funding Source:	GATEWAY FOR CANCER RESEARCH
Role:	Statistician
ID:	#TBA

Date:	2021 - 2025
Title:	Tackling use of vaping and combustible tobacco products among youth via a multimedia-interactive program
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA256739-01

Date:	2021 - 2022
Title:	Development and Evaluation of Real-World Data Based Designs with Causally Adaptive Decision Making
Funding Source:	Merck
Role:	Co-PD/PI
ID:	#TBA

Date:	2020 - 2025
Title:	Type 1 Diabetes in Acute Pancreatitis Consortium Data Coordinating Center
Funding Source:	NIH/NIDDK
Role:	PI
ID:	1U01DK127396-01

Date:	2020 - 2025
Title:	Imaging and liquid biopsy-based monitoring of pancreatic cancer to select for local therapies
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA249069-01A1

Date:	2020 - 2027
Title:	Triage of advanced cervical cancer through immunotherapy induction (TRACTION)
Funding Source:	MacroGenics, Inc
Role:	Co-I
ID:	2022-0107

Date:	2020 - 2022
Title:	Modular Phase Ib Hypothesis-testing, Biomarker-driven, Talazoparib Combination Trial (TalaCom)
Funding Source:	MD Anderson Cancer Center
Role:	Co-PI
ID:	#TBA

Date:	2020 - 2023
Title:	Optimizing Anti-EGFR Rechallenge Therapy in Advanced Colorectal Cancer
Funding Source:	The Andrew Sabin Family Foundation Fellowship
Role:	Statistical collaborator
ID:	600656-80-123333-21

Date:	2020 - 2023
Title:	Immunotherapy Targeting Stromal CD5L in Ovarian Cancer
Funding Source:	Department of Defense (DOD)
Role:	Biostatistician
ID:	W81XWH2010335 / OC190224

Date:	2020 - 2025
Title:	EPA-Dasatinib Combination Therapy for Metastatic Triple-Negative Inflammatory Breast Cancer
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA256944-01

Date:	2020 - 2023
Title:	Optimizing Anti-EGFR Rechalleng Therapy in Advanced Colorectal Cancer
Funding Source:	Conquer Cancer Foundation
Role:	Sr. Statistician
ID:	#TBA

Date:	2020 - 2023
Title:	Phase I/Ib Study of Anakinra to Mitigate CAR-T toxicity in subjects with relapsed or refractory large B-cell lymphoma
Funding Source:	Gateway for Cancer Research
Role:	Co-I
ID:	#TBA

Date:	2020 - 2022
Title:	Fecal Microbiota Transplantation and Re-Introduction of Anti-PD-1 Therapy in dMMR Colorectal Adenocarcinoma Anti-PD-1 Non-Responders
Funding Source:	MDACC
Role:	Biostatistician
ID:	#TBA

Date:	2020 - 2026
Title:	Texas EXperimental Cancer Therapeutics Network - TEX CTN
Funding Source:	NIH/NCI
Role:	Co-I
ID:	2UM1CA186688-06

Date:	2020 - 2025
Title:	A Novel Adenoviral-Permissive, Immunocompetent Hamster Model to Evaluate Oncolytic Adenoviral Therapy for Glioblastoma
Funding Source:	NIH/NCI
Role:	Co-I
ID:	5R01CA247970-03

Date:	2020 - 2025
Title:	Imaging and liquid biopsy-based monitoring of pancreatic cancer to select for local therapies
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA249069-01

Date:	2020 - 2023
Title:	Immunotherapy targeting stromal CD5L as an anti-angiogenic therapy
Funding Source:	Ovarian Cancer Research Alliance
Role:	Biostatistician
ID:	20190CRFOOLTSP000185130

Date:	2019 - 2022
Title:	Diffusion-Weighted Imaging-Based Adaptive Replanning for the MR-Linac
Funding Source:	NIH/NCI
Role:	Other Significant Contributor
ID:	1F31DE029093-01A1

Date:	2019 - 2024
Title:	Targeting prolactin/prolactin receptor axis in ovarian cancer
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	1R01CA246145-01

Date:	2019 - 2024
Title:	SPORE in Brain Cancer - BIOSTATISTICS AND BIOINFORMATICS CORE (CORE C)
Funding Source:	NIH/NCI
Role:	Core Director
ID:	5P50CA127001-14

Date:	2019 - 2024
Title:	GOG Foundation Scholar Investigator Award
Funding Source:	Gynecologic Oncology Group (COG)
Role:	Statistical Analyst
ID:	FP00007755

Date:	2019 - 2024
Title:	MD Anderson Cancer Center SPORE in Gastrointestinal Cancer
Funding Source:	NIH/NCI
Role:	Core Leader
ID:	5P50CA221707-04

Date:	2019 - 2026
Title:	Cancer Center Support Grant (CCSG) - Biostatistics Shared Resource (BGR)
Funding Source:	NIH/NCI
Role:	Biostatistician
ID:	P30 CA016672

Date:	2019 - 2024
Title:	Development of functional magnetic resonance imaging-guided adaptive radiotherapy for head and neck cancer patients using novel MR-Linac device
Funding Source:	NIH
Role:	Co-I
ID:	1R01DE028290-01A1

Date:	2019 - 2024
Title:	Image-guided Photothermolysis to Induce Tumor Immunity and Enhance Immune Checkpoint Blockade in Ovarian Cancer
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	1R01CA232444-01A1

Date:	2019 - 2024
Title:	Re-activating Anti-tumor Immunity by Nano-targeting Cancer-associated Fibroblasts in Ovarian Cancer
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	1 R01 CA242988-01

Date:	2019 - 2022
Title:	Bayesian Phase II Trial of Magnetic Resonance Imaging Guided Radiotherapy Dose Adaptation in Human Papilloma Virus Positive Oropharyngeal Cancer
Funding Source:	NIH
Role:	Co-I
ID:	1R01CA234282-01A1

Date:	2019 - 2022
Title:	Blocking adaptive resistance to anti-angiogenesis drugs
Funding Source:	Department of Defense (DOD)
Role:	Collaborator
ID:	W81XWH-19-1-0171

Date:	2019 - 2025
Title:	Phase Ib Clinical Investigation of Intraperitoneal Ipilimumab and Nivolumab in Patients with Peritoneal Carcinomatosis Due to Gynecologic Cancers
Funding Source:	Bristol-Myers Squibb (BMS)
Role:	Statistician
ID:	2017-0264

Date:	2019 - 2024
Title:	Statistical methods and tools for cancer risk prediction in families with germline mutations in TP53
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA239342-01

Date:	2019 - 2022
Title:	Engaging Risk Communication Strategies to Inform Vocational Young Adults about the Risks of Nicotine and Tobacco Products
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA230989-01A1

Date:	2019 - 2023
Title:	An Adaptive Phase I/II Dose Escalation Trial of Stereotactic Body Radiation Therapy with a Radiomodulating Agent GC4419 in Locally Advanced Pancreatic Cancer
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	RP180523

Date:	2019 - 2022
Title:	Bringing Youth-Oriented Nicotine and Tobacco Education up to Modern Standards
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator
ID:	FP00002768_Res1

Date:	2019 - 2022
Title:	Bayesian Phase II Trial of Magnetic Resonance Imaging Guided Radiotherapy Dose Adaptation in Human Papilloma Virus Positive Oropharyngeal Cancer
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	FP00005743

Date:	2019 - 2022
Title:	Expanding Tobacco Use Cessation in Northeast Texas
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Evaluator
ID:	FP00004827_Res1

Date:	2019 - 2021
Title:	Differential targeting of tumor versus wound angiogenesis
Funding Source:	Department of Defense (DOD)
Role:	Collaborator
ID:	FP00006135

Date:	2018 - 2025
Title:	Phase I/II Trial of Ipilimumab or Nivolumab with BMS-986156 and Hypofractionated Stereotactic Radiation Therapy in Patients with Advanced Solid Malignancies
Funding Source:	Bristol-Myers Squibb
Role:	Co-I
ID:	2018-0419

Date:	2018 - 2021
Title:	Bayesian Phase II Trial of Magnetic Resonance Imaging Guided Radiotherapy Dose Adaptation in Human Papilloma Virus Positive Oropharyngeal Cancer
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1 R01 CA207352-01A1

Date:	2018 - 2021
Title:	OC170447: Image-Guided EphB4 Agonist-Based Nanotherapy for Treatment of High-Grade Ovarian Cancer
Funding Source:	Department of Defense (DOD)
Role:	Co-I
ID:	FP00003413

Date:	2018 - 2024
Title:	A Randomized Trial of a Web-based Non-Pharmacological Pain Intervention for Pediatric Chronic Pancreatitis
Funding Source:	NIH/NIDDK Subaward via University of Iowa
Role:	Co-I
ID:	5R01DK118752-03

Date:	2018 - 2023
Title:	Development of functional magnetic resonance imaging-guided adaptive radiotherapy for head and neck cancer patients using novel MR-Linac device
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01DE028290-01

Date:	2018 - 2022
Title:	Targeting Cancer-associated Fibroblasts to Enhance Drug Delivery and Immunotherapy
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Biostatistician – AC
ID:	FP00004657

Date:	2018 - 2020
Title:	Antibody-Amanitin Conjugates Targeting Folate Receptor in TP53-defective Ovarian Cancer
Funding Source:	Department of Defense (DOD)
Role:	Significant Contributor
ID:	FP00003363

Date:	2018 - 2025
Title:	A Phase 2, Open-Label Study to Evaluate Efficacy of Combination Treatment with MEDI0457 (INO-3112) and Durvalumab (MEDI4736) in Patients with Recurrent/Metastatic Human Papilloma Virus Associated Cancers
Funding Source:	AstraZeneca
Role:	Biostatistician
ID:	2017-0302 A Phase 2

Date:	2018 - 2023
Title:	Image-guided Photothermolysis to Induce Tumor Immunity and Enhance Immune Checkpoint Blockade
Funding Source:	National Institutes of Health
Role:	Co-I
ID:	1R01CA232444-01

Date:	2018 - 2020
Title:	Gaining a better understanding of Electronic Nicotine Delivery System use during pregnancy
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R21DA046944-01

Date:	2018 - 2023
Title:	Functional Imaging for Real-time Early Evaluation of Dose-response with On-line Multiparametric MRI-guided RadioTherapy (FREEDOMM-RT)
Funding Source:	NIH/NCI
Role:	Biostatistician
ID:	1R01CA225694-01

Date:	2018 - 2023
Title:	Development and Functional Imaging for Real-time Early Evaluation of Dose-response with On-line Multiparametric MRI-guided RadioTherapy (FREEDOMM-RT)Validation of Neuromedin U and Immune Profiling for Early Detection of Pancreatic Ductal Adenocarcinoma
Funding Source:	NIH/NCI
Role:	Biostatistician
ID:	1R01CA227767-01 (MPI)

Date:	2018 - 2021
Title:	Magnetic resonance imaging biomarker assessment of real-time radiotherapy-induced normal tissue injury
Funding Source:	NIH/NCI
Role:	Biostatistician
ID:	1R01CA227361-01

Date:	2018 - 2021
Title:	Engaging Risk Communication Strategies to Inform Vocational Young Adults about the Risks of Nicotine and Tobacco Products
Funding Source:	NIH
Role:	Co-I
ID:	1R01CA230989-01

Date:	2018 - 2025
Title:	Clinical study to assess efficacy and safety of LN-145 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types
Funding Source:	Iovance Biotherapeutics
Role:	Statistician
ID:	2017-0672

Date:	2018 - 2025
Title:	Clinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) across Multiple Tumor Types
Funding Source:	Iovance Biotherapeutics
Role:	Statistician
ID:	2017-0671

Date:	2018 - 2022
Title:	An Adaptive Phase I/II Dose Escalation Trial of Stereotactic Body Radiation Therapy with a Radiomodulating Agent GC4419 in Locally Advanced Pancreatic Cancer
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	RP180523

Date:	2018 - 2022
Title:	Molecular Analysis for Therapy Choice (MATCH) in Mantle Cell Lymphoma: A Pilot Precision Medicine Trial
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	RP180310

Date:	2018 - 2021
Title:	Identification of exosomal markers of response to a novel drug anti-Dll4/VEGF drug (OMP305B83) in adaptive resistant ovarian cancer
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator
ID:	RP180106

Date:	2018 - 2021
Title:	Targeting Bi-directional EphB4/EFNB2 Signaling as a Novel Anti-Tumor Therapy
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator
ID:	RP180253

Date:	2018 - 2021
Title:	Bringing Youth-Oriented Nicotine and Tobacco Education to the Modern Standards
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	FP00002768

Date:	2018 - 2021
Title:	Prevention of HCV-Associated Second Primary Malignancies
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	FP00003517

Date:	2018 - 2020
Title:	Early Detection of Ovarian Cancer using Plasmonic Chip/Smartphone Microscope to detect precancerous RNA fusions/circular RNA signatures
Funding Source:	The Honorable Tina Brozman Foundation for Ovarian Cancer Research
Role:	Co-I
ID:	FP00003038

Date:	2018 - 2018
Title:	Bioimmune and Cellular Therapeutic Approaches for High-Risk MCL
Funding Source:	Leukemia and Lymphoma Society
Role:	Co-I
ID:	FP00003225

Date:	2017 - 2020
Title:	Fast Track: An Adaptive Phase I/II Dose Escalation Trial of Sterotactic Body Radiation Therapy in Combination with Radiomodulating Agent GC4419 in Locally Advanced Pancreatic AdenoCarcinoma
Funding Source:	Galera Therapeutics, Inc
Role:	Co-I
ID:	CS2017-00054748-LG

Date:	2017 - 2022
Title:	Statistical methods and tools for cancer risk prediction in families with germline mutations in TP53
Funding Source:	NIH
Role:	Co-I
ID:	1R01CA214508-01A1

Date:	2017 - 2020
Title:	CA160823: Induction of Tumor Immunity by Combining Nanoparticle-Based Photothermal Ablation with Checkpoint Inhibition for Treatment of Hepatocellular Carcinoma (HCC)
Funding Source:	Department of Defense (DOD)
Role:	Co-I
ID:	W81XWH-16-PRCRP-TTSA

Date:	2017 - 2023
Title:	The UTMD Anderson Cancer Center SPORE in Ovarian Cancer
Funding Source:	NIH/NCI
Role:	Core Director
ID:	5P50CA217685-05

Date:	2017 - 2024
Title:	Devising early detection/diagnostic and effective therapeutic strategies for brain metastasis
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R35CA209906-01

Date:	2017 - 2022
Title:	Modulating Cancer-Associated Fibroblasts to Potentiate Checkpoint Blockade Immunotherapy
Funding Source:	NIH
Role:	Co-I
ID:	1U01 CA224305-01

Date:	2017 - 2022
Title:	Nano Solutions for Overcoming Stromal Barriers in PDAC
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1U01CA218301-01

Date:	2017 - 2021
Title:	Combating brain metastasis: developing early detection/diagnosis and effective therapeutics
Funding Source:	Department of Defense (DOD)
Role:	Co-I
ID:	BCI60931

Date:	2017 - 2020
Title:	Randomized Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab Administered in Combination Versus Sequential
Funding Source:	Gateway for Cancer Research
Role:	Statistician
ID:	FP00002658

Date:	2017 - 2020
Title:	Linking High Risk Youth and Young Adults to Evidence-Based Tobacco Cessation
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Biostatician
ID:	FP00001783

Date:	2017 - 2020
Title:	Southeast Texas Youth Against Tobacco (SET YAT)
Funding Source:	Julie Rogers "Gift of Life" Program
Role:	Biostatician
ID:	FP00001798

Date:	2017 - 2022
Title:	Ovarian Cancer Survivorship Research Consortium (OCSRC): Determinants of Long-Term Survival
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1P01CA217672-01

Date:	2017 - 2020
Title:	imaging Radiation-Associated Dysphagia (iRAD)
Funding Source:	NIH/NCI
Role:	Co-I
ID:	5R01CA218148-03

Date:	2016 - 2017
Title:	Youth Component Lung Cancer Control and Prevention Moonshot
Funding Source:	Moonshot Program
Role:	Co-I

Date:	2016 - 2021
Title:	Quantitative Characterization and prediction of cancer outcomes in families with Li-Frameni Syndrome
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA201449-01A1

Date:	2016 - 2020
Title:	A Bayesian Adaptive Randomized Phase II trial of combination of vorinostat, isotretinoin and temozolomide in Adults with Recurrent Glioblastoma
Funding Source:	Subaward from Ohio State University
Role:	Collaborator
ID:	Coeus 17159 BTTC09-02

Date:	2016 - 2019
Title:	Magnetic resonance imaging biomarker assessment of real-time radiotherapy-induced normal tissue injury
Funding Source:	NIH/NCI
Role:	Biostatistician
ID:	1R01CA204095-01

Date:	2015 - 2018
Title:	Targeting adaptive changes following anti-angiogenesis therapy in ovarian cancer
Funding Source:	V Foundation
Role:	Co-I
ID:	600389-90-54-100300-3610-1111

Date:	2015 - 2025
Title:	Consortium for the Study of Chronic Pancreatis, Diabetes and Pancreatic Cancer: Coordination and Data Management Center (CSCPDPC-CDMC)
Funding Source:	NIH/NIDDK
Role:	PI
ID:	5U01DK108328-08

Date:	2015 - 2020
Title:	Consortium for the Study of Chronic Pancreatis, Diabetes and Pancreatic Cancer: Coordination and Data Management Center (CSCPDPC-CDMC)
Funding Source:	NIH/NIDDK
Role:	PI
ID:	5U01DK108328 05

Date:	2015 - 2016
Title:	PQC4: Tumor Microenvironmental Phenotyping by Multiparametric MRI
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R21CA194614-01

Date:	2014 - 2019
Title:	Statistical methods for genomic analysis of heterogeneous tumors
Funding Source:	NIH/NCI
Role:	Co-I
ID:	5 R01 CA183793 04

Date:	2014 - 2017
Title:	QuitBuddy: a mobile/social network therapy approach to relapse prevention
Funding Source:	NIH
Role:	Co-I
ID:	1 R01

Date:	2014 - 2015
Title:	Tumor Associated Macrophages Microenvironmental Phenotyping by Multiparametric MRI
Funding Source:	UTMDACC
Role:	Co-I
ID:	Knowledge Gap

Date:	2014 - 2018
Title:	Computational deconvolution of genomic data from heterogeneous tumor samples
Funding Source:	American Cancer Society (ACS)
Role:	Co-I

Date:	2014
Title:	Induction of Reactive Oxygen Species as a Therapeutic Strategy for Glioblastoma
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1R01CA187206-01

Date:	2013 - 2018
Title:	Discovery and translational development of novel immunotherapies
Funding Source:	Leukemia and Lymphoma Society
Role:	Co-I

Date:	2013 - 2018
Title:	Tobacco Center of Regulatory Science of Youth and Young Adults
Funding Source:	NIH/FDA (Subcontract from UT Health Science Center - Houston)
Role:	Co-I
ID:	5 P50 CA180906 05

Date:	2013 - 2015
Title:	Immune-Specific Markers of Oncolytic Adenovirus Efficacy in Gliomas
Funding Source:	NIH
Role:	Co-I
ID:	1R21NS085566-01

Date:	2013 - 2020
Title:	APPSPIRE Expanding The Reach of An Innovative Tobacco Control Program for Youth - Phase II
Funding Source:	Radiant Creative Group, LLC Subaward agreement, NIH/NIDA
Role:	Co-I
ID:	5R42DA035012-04

Date:	2013 - 2018
Title:	Can Exercise Prevent Ovarian Cancer Recurrence: Mechanisms and Biomarkers
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	1 R01 CA178583-01

Date:	2013 - 2018
Title:	Novel Approach Using Coated Catheters for Salvagin Venous Access in CLABSI
Funding Source:	NIH Agency for Health Care Research and Quality (AHRQ)
Role:	Co-I
ID:	1 R01 HS022301-01

Date:	2013 - 2014
Title:	Sensor-based ecological momentary assessment & intervention for tobacco control
Funding Source:	NIH/NIEHS (Subcontract from Radiant Creative Group)
Role:	Co-I
ID:	1 R41 ES022909-01A1

Date:	2013 - 2018
Title:	Toxicity Profiling: Creating Novel Paradigms to Personalize Cancer
Funding Source:	Subaward Agreement from The University of Texas HSC-Houston
Role:	Statistician
ID:	5R01NR013707-05

Date:	2012 - 2017
Title:	Translational development of novel immunotherapy for multiple myeloma (Core A)
Funding Source:	Leukemia and Lymphoma Society
Role:	Co-I

Date:	2012 - 2017
Title:	Targeting Oncogenic Pathways in Lymphoma
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1P01CA163226-01A1

Date:	2012 - 2014
Title:	VIC: A Virtual Interactive Cessation Coach
Funding Source:	NIH/NCI Subcontract from Radiant Creative Group
Role:	Investigator
ID:	N/A

Date:	2011 - 2013
Title:	Second Manhood: A multimedia Intervention for Male Sexual Problems After Cancer
Funding Source:	NIH/NCInologies
Role:	Investigator
ID:	4 R42 CA139822 02

Date:	2011 - 2013
Title:	Exercise-Based Smoking Cessation for an African American Congregation
Funding Source:	NIH/NIDA
Role:	Co-I
ID:	1 R34 DA032722 01

Date:	2011 - 2016
Title:	Optimizing the Delivery of Support for CRC Survivors: Web-Based Vs. Face-to-Face
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1 R01 CA158326 01A1

Date:	2011 - 2013
Title:	A Group Intervention for Women Distressed about Childbearing after Cancer
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1 R21 CA160944 01

Date:	2011 - 2016
Title:	Capitalizing on Vulnerabilities in the P13K/Akt Signaling Pathway in Cancer
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Investigator
ID:	RP110463

Date:	2011 - 2017
Title:	Bayesian Adaptive Designs for Oncology Clinical Trials with Late-onset Outcomes
Funding Source:	NIH/NCI
Role:	PI
ID:	5 R01 CA154591 04

Date:	2011 - 2016
Title:	Organizational Capacity and Program Adaptation in Preschool Sun Protection
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1 R01 CA158049 01

Date:	2011 - 2013
Title:	Increasing attendance, adherence, and weight loss among patients attending the Harris County Hospital District Adult Weight Management Program
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator
ID:	N/A

Date:	2010 - 2013
Title:	Pathways Linking Social Determinants of Smoking Cessation
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Investigator
ID:	RP110025

Date:	2010 - 2015
Title:	Incorporating innovative smoking cessation component in a cancer outreach program
Funding Source:	NIH/NIDA
Role:	Co-I
ID:	1 R01 CA154936 01

Date:	2010 - 2015
Title:	Face-to-face & videophone psychosocial intervention for colorectal patients
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1 R01 CA149110 01A1

Date:	2010 - 2018
Title:	Enhancing cancer outreach for low-income adults with innovative smoking cessation
Funding Source:	NIH/NCI
Role:	Co-I
ID:	5 R01 CA141628 06

Date:	2010 - 2011
Title:	Enhancing cancer outreach for low-income adults with innovative smoking cessation
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1 R01 CA141628 02

Date:	2010 - 2014
Title:	Translation of Evidence-based "Sun Protection is Fun" Program to Texas Early Childhood Education Centers: Evaluation of Adoption, Implementation and Maintenance
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Investigator
ID:	RP100459

Date:	2010 - 2023
Title:	Phase 2 CT Study-Letrozole & RAD001 in Pts w/Endometrial
Funding Source:	Novartis
Role:	Co-I
ID:	CS2009-00027019EB

Date:	2010 - 2011
Title:	Body Image Functioning in Cancer Patients Undergoing Facial Reconstruction
Funding Source:	American Cancer Society (ACS)
Role:	Co-I
ID:	MRSG-10-010-01-CPPB 02

Date:	2009 - 2014
Title:	Healthy Diets, Exercise & Weight Control in Cancer Survivors: Costs and Benefits
Funding Source:	NIH/NCI
Role:	Biostatistician
ID:	1 R01 CA143192 01

Date:	2009 - 2012
Title:	ARRA: Enhanced Smoking Cessation for University Students
Funding Source:	NIH/NCI
Role:	Co-I
ID:	5 R01 CA069425 09

Date:	2009 - 2011
Title:	Adherence to Swallowing Rehabilitation Exercises in Head and Neck Cancer
Funding Source:	NIH/NIDCR
Role:	Co-I
ID:	5 R01 DE019141 02

Date:	2009 - 2011
Title:	Testing a tobacco educational video game among high-risk homeless youth
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1 RC1 CA147250 01

Date:	2009 - 2010
Title:	Second Manhood: A Multimedia Intervention for Male Sexual Problems after Cancer
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1 R41 CA139822 01A1

Date:	2009 - 2012
Title:	Modeling Adherence to Swallowing and Dental Regimens in Head and Neck Cancer
Funding Source:	NIH/NIDCR
Role:	Co-I
ID:	5 R21 DE019954 02

Date:	2009 - 2011
Title:	Adherence to Rehabilitation Swallowing Exercises in Head and Neck Cancer
Funding Source:	American Cancer Society (ACS)
Role:	Co-I
ID:	RSGPB-09-156-01 CPPB 02

Date:	2009 - 2013
Title:	Bayesian Clinical Trial Design in Oncology
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	1 R01 CA140584 01

Date:	2009 - 2010
Title:	Inflammatory Breast Cancer: Exploring Feasibility and Impact of Promoting Weight
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1 R21 CA141206 01

Date:	2009 - 2010
Title:	Suppression of Negative Affect Indexed by the Late Positive Potential in Smokers
Funding Source:	NIH/NIDA
Role:	Mentor
ID:	5 K99 DA025181 02

Date:	2009 - 2014
Title:	Combating Tobacco Use in the United States Army
Funding Source:	Department of Defense (DOD)
Role:	Co-I
ID:	W81XWH-09-2-0033 04

Date:	2009 - 2014
Title:	Effectiveness of Varenicline plus Bupropion for Smoking Cessation
Funding Source:	NIH/NIDA
Role:	Statistician
ID:	5 R01 DA024709 02

Date:	2009 - 2014
Title:	Using Cue Reactivity in Virtual Reality to Assess Adolescent Smoking Risk
Funding Source:	NIH/NCI
Role:	Statistician
ID:	1 R01 CA138652 01

Date:	2009 - 2011
Title:	Winning by losing?: A feasibility trial of weight loss in inflammatory breast cancer
Funding Source:	NIH/NCI
Role:	Co-I

Date:	2009 - 2011
Title:	Self-determination Theory and Lifestyle Behaviors in Barrett's Esophagus Patients
Funding Source:	NIH/NCI
Role:	Significant Contributor
ID:	1 R03 CA136056 01A1

Date:	2009 - 2010
Title:	Ecological Momentary Assessment, Peak-end Rule, and Smoking Relapse
Funding Source:	American Cancer Society (ACS)
Role:	Co-Mentor
ID:	MRSG-09-002-01-CPHPS 02

Date:	2008 - 2009
Title:	Spousal Support, Emotional Disclosure, and Adjustment to Head and Neck Cancer
Funding Source:	NIH/NCI
Role:	Co-Mentor
ID:	1 K07 CA124668 01A2

Date:	2008 - 2014
Title:	The Effects of Smoking and Expectancy on ERP Measures of Attentional Bias
Funding Source:	NIH/NIDA
Role:	Co-Mentor
ID:	5 K23 DA024697 05

Date:	2008 - 2012
Title:	Tendrils: A multimedia intervention for womens sexual dysfunction after cancer
Funding Source:	NIH/NCI
Role:	Co-I
ID:	5 R42 CA123932 04

Date:	2007 - 2010
Title:	The Effects of Atomoxetine on Smoking Cessation and Nicotine Withdrawal
Funding Source:	NIH/NIDA
Role:	Co-I
ID:	1 R01 DA024037 01

Date:	2007 - 2017
Title:	CERN Collaborative Grant Agreement Clinical Research Center (PP-1)
Funding Source:	Collaborative Medical Research, LLC
Role:	Biostatistician
ID:	CS2007 00021388 05

Date:	2007 - 2012
Title:	Effects of Cigarette Availability on Craving and Motivation to Smoke
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1 R01 CA127499 01A1

Date:	2007 - 2018
Title:	SPORE in Brain Cancer - Biostatistics Core C1
Funding Source:	NIH/NCI
Role:	Statistician
ID:	5P50 CA127001-10

Date:	2006 - 2008
Title:	The Psychosocial Impact of a Cancer Diagnosis during Pregnancy
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1 R21 CA124473 01

Date:	2006 - 2009
Title:	A Targeted, Family-Focused Intervention for Melanoma Prevention
Funding Source:	American Cancer Society (ACS)
Role:	Collaborator
ID:	RSGPB 04 010 01 CPPB 04

Date:	2003 - 2023
Title:	MD Anderson Gynecologic SPORE for Uterine Cancers
Funding Source:	NIH/NCI
Role:	Core Director
ID:	5P50CA098258-15 (Under No Cost Extension, 1% effort only, no salary support)

Date:	2002 - 2008
Title:	A Sexual Counseling Intervention for Prostate Cancer Survivors
Funding Source:	American Cancer Society (ACS)
Role:	Co-I
ID:	TURSG 02 189 01 PBP 04

Selected Publications

Peer-Reviewed Articles

Norris, N, Troendle, DM, Wilschanski, M, Wang, F, Cress, GA, Abu-El-Haija, M, Chugh, A, Cohen, RZ, Downs, E, Fishman, D, Gariepy, CE, Giefer, MJ, Gonska, T, Grover, AS, Husain, SZ, Lindblad, D, Liu, QY, Maqbool, A, Mark, J, McFerron, BA, Mehta, M, Morinville, VD, Ng, K, Noel, RA, Ooi, CY, Perito, ER, Sellers, ZM, Trout, AT, Zheng, Y, Yuan, Y, Lowe, ME, Uc, A. Utility and utilization of transabdominal ultrasound in pediatric patients with acute recurrent or chronic pancreatitis. Journal of pediatric gastroenterology and nutrition 82(2):557-565, 2026. e-Pub 2026. PMID: 41318969.
Chi, X, Yuan, Y, Lin, R. BOP2-Comb. Therapeutic Innovation and Regulatory Science 60(1):127-138, 2026. e-Pub 2026. PMID: 40830695.
Chen, K, Zhou, H, Lee, JJ, Yuan, Y. BOP2-TE. Journal of Biopharmaceutical Statistics 36(1):43-58, 2026. e-Pub 2026. PMID: 39582234.
Pan, J, Zhao, L, Zhang, Y, Seery, S, Tan, Y, Deng, B, Shan, L, Ling, Z, Wu, F, Wang, Z, Wang, Q, Yu, X, Zheng, Q, Xu, X, Yuan, Y, Tian, Z, Zhang, Y, Peng, S, Chang, AH, Feng, X. Donor-derived CD7 CAR T cells for pediatric and adult relapsed/refractory T-ALL/LBL. Blood 146(23):2745-2757, 2025. e-Pub 2025. PMID: 40712157.
Zhu, H, Phipps, AN, Yuan, Y, Davidson, BA, Shord, SS, Liu, J, LoRusso, P. FDA–AACR Strategies for Optimizing Dosages for Oncology Drug Products. Clinical Cancer Research 31(23):4872-4881, 2025. e-Pub 2025. PMID: 41036712.
Wang, S, Yuan, Y, Liu, S. Randomized optimal selection design for dose optimization. Biometrics 81(4), 2025. e-Pub 2025. PMID: 41059993.
Msaouel, P, Yu, K, Yuan, Y, Chen, J, Yan, X, Karki, M, Duan, F, Sheth, RA, Rao, P, Sircar, K, Shah, AY, Zurita-Saavedra, A, Genovese, G, Li, M, Yeh, CC, Dang, M, Han, G, Chu, Y, Hallin, M, Olson, P, Yang, R, Slavin, D, Der-Torossian, H, Chin, CD, Tannir, NM, Wang, L, Gao, J. Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma. Nature communications 16(1), 2025. e-Pub 2025. PMID: 39794332.
Fu, J, Zhao, D, Skanji, D, Liu, H, Tang, R, Yuan, Y. Bayesian Prediction of Event Times Using Mixture Model for Blinded Randomized Controlled Trials. Statistics in Medicine 44(28-30), 2025. e-Pub 2025. PMID: 41290204.
Fu, J, Zhao, D, Skanji, D, Liu, H, Tang, R, Yuan, Y. Bayesian Prediction of Event Times Using Mixture Model for Blinded Randomized Controlled Trials. Statistics in Medicine 44(28-30), 2025. e-Pub 2025. PMID: 41290204.
Gouda MA, Janku F, Yuan Y, Drusbosky LM, Chen AP, Zheng X, Patel K, Hamilton SR, Routbort M, Tricoli JV, Williams PM, Iafrate AJ, Sklar J, Coffey B, Little RF, Arteaga CL, O'Dwyer PJ, Flaherty KT, Harris LN, Meric-Bernstam F. Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131). Clin Cancer Res 31(20):4299-4310, 2025. e-Pub 2025. PMID: 40388547.
Ling AL, Gantchev J, Prabhu MC, Basu S, Ahn R, D'Souza A, Masud N, Ball A, Nikas O, Villa GR, Regan MS, Baquer G, Ayoub G, Whittaker CA, Abou-Mrad Z, Santos A, Couturier CP, Elharouni D, Vogelzang J, Yu KKH, Chen H, He Z, Jiang W, Lucas CH, Sax HE, Lang FF, Puduvalli VK, Tabar V, W Brennan C, Boire A, Holdhoff M, Bettegowda C, Cima M, Solomon IH, Yuan Y, Tak PP, Sharma P, White FM, Ligon KL, Agar NYR, Reardon DA, Oliveira G, Chiocca EA. Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analyses. Sci Transl Med 17(819):eadv2881, 2025. e-Pub 2025. PMID: 41061048.
Knisely A, Dai Y, Barlow GL, Lee S, Lawson B, Clark H, Fellman B, Yuan Y, Lu W, Lubo Julio IC, Lazcano RN, Chelvanambi M, Melendez B, Singh B, Singh B, Wani K, Chen J, Yeh CC, Gao J, Barnes S, Shi O, Khan KB, Serrano AG, Gomez-Bolanos LI, Scalise CB, Cheung SK, Dutta P, Velichko S, ElNaggar AC, Liu MC, Wilke RN, How J, Ramondetta LM, Boruta DM, Richardson G, Shafer A, Westin SN, Sims T, Sood AK, Ramirez PT, Lazar AJ, Soliman PT, Lu K, Haymaker CL, Solis Soto LM, Wargo JA, Grisham R, Wucherpfennig KW, Wang L, Jazaeri AA. Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities. Clin Cancer Res 31(19):4122-4135, 2025. e-Pub 2025. PMID: 40748258.
Zhao, S, Thall, PF, Yuan, Y, Lee, J, Msaouel, P, Zang, Y. Precision generalized phase I-II designs. Biometrics 81(3), 2025. e-Pub 2025. PMID: 40705487.
Dai, Y, Knisely, A, Yano, M, Dang, M, Hinchcliff, EM, Lee, S, Welp, A, Chelvanambi, M, Lastrapes, M, Liu, H, Yuan, Z, Wang, C, Nie, H, Jean, S, Montaner, LJ, Hou, J, Patel, A, Patel, S, Fellman, B, Yuan, Y, Sun, B, Pandurengan, RK, Cuentas, EP, Celestino, J, Liu, Y, Liu, J, Hillman, RT, Westin, SN, Sood, AK, Soliman, PT, Shafer, A, Meyer, LA, Gershenson, DM, Vining, D, Ganeshan, DM, Lu, KH, Wargo, J, Peng, W, Zhang, R, Wang, L, Jazaeri, AA. PPP2R1A mutations portend improved survival after cancer immunotherapy. Nature 644(8076):537-546, 2025. e-Pub 2025. PMID: 40604275.
Zhao, Y, Liu, R, Lin, J, Yuan, Y. BARD: A seamless two-stage dose optimization design integrating backfill and adaptive randomization. Clinical Trials 22(4):393-404, 2025. e-Pub 2025. PMID: 40626646.
Chen, K, Chen, TY, Zhang, Y, Lin, R, Yuan, Y. Practical Considerations for Using the TITE-BOIN Design to Handle Late-Onset Toxicity or Fast Accrual in Phase I Trials. Clinical Cancer Research 31(13):2573-2580, 2025. e-Pub 2025. PMID: 40327336.
Xu, X, Yuan, Y, Lee, JJ. Assessing the role of correlation between efficacy and toxicity endpoints in the performance of Bayesian optimal phase II design. Contemporary Clinical Trials 154, 2025. e-Pub 2025. PMID: 40324518.
Shui, L, Maitra, A, Yuan, Y, Lau, KS, Kaur, H, Li, L, Li, Z. PoweREST: Statistical power estimation for spatial transcriptomics experiments to detect differentially expressed genes between two conditions. PLoS computational biology 21(7), 2025. e-Pub 2025. PMID: 40729405.
Li Y, Yuan Y. BPED: A Bayesian basket design for pediatric trials with external data. J Biopharm Stat:1-20, 2025. e-Pub 2025. PMID: 40464201.
Chi, X, Lin, R, Yuan, Y. COCA: A randomized Bayesian design integrating dose optimization and component contribution assessment for combination therapies. Biometrics 81(2), 2025. e-Pub 2025. PMID: 40552493.
Tian, F, Lin, R, Liu, S, Yuan, Y. Sample-size determination for decentralized clinical trials. International journal of epidemiology 54(3), 2025. e-Pub 2025. PMID: 40393699.
Chen, K, Takeda, K, Yuan, Y. COMIC: A Bayesian Dose Optimization Design for Drug Combination in Multiple Indications With Application to CAR-T Therapies. Statistics in Medicine 44(10-12), 2025. e-Pub 2025. PMID: 40386962.
Hahn, AW, Adra, N, Vaishampayan, U, Xiao, L, Dizman, N, Yuan, Y, Mukhida, SS, Campbell, M, Gao, J, Zurita-Saavedra, A, Jonasch, E, Tannir, NM, Shah, AY, Msaouel, P. A phase II trial of sitravatinib + nivolumab after progression on immune checkpoint inhibitor in patients with metastatic clear cell RCC. Oncologist 30(4), 2025. e-Pub 2025. PMID: 40212021.
Strauss, JD, Gilbert, MR, Mehta, MP, Li, A, Zhou, R, Bondy, ML, Sulman, EP, Yuan, Y, Liu, Y, Vera, E, Wendland, MM, Stieber, VW, Puduvalli, VK, Choi, S, Martinez, NL, Robins, HI, Hunter, G, Lin, CF, Guedes, V, Richard, MA, Pugh, S, Armstrong, TS, Scheurer, ME. Clinical and genetic markers of vascular toxicity in glioblastoma patients. Neuro-oncology 27(3):767-778, 2025. e-Pub 2025. PMID: 39549280.
Cress GA, Scudiero KT, Wang F, Patrick VB, Wood PM, Yuan Y, Lowe ME, Uc A. Patient and Family Input to Determine Experiences and Research Interests in Pediatric Pancreatitis: An INSPPIRE-2 Study. Pancreas 54(1):e18-e22, 2025. e-Pub 2025. PMID: 39259842.
Zhang H, Wu J, Miao Y, Yuan Y, Qu Z, Zhang Y, Hua Z. Determination of the Optimal Volume of 0.5% Ropivacaine in Single-injection Retroclavicular Brachial Plexus Block for Arthroscopic Shoulder Surgery: A Phase I/II Trial. Anesthesiology 142(1):155-165, 2025. e-Pub 2025. PMID: 39018520.
D’Angelo, G, Gong, M, Marshall, J, Yuan, Y, Li, X. U-MET: Utility-Based Dose Optimization Approach for Multiple-Dose Randomized Trial Designs. Statistics in Biopharmaceutical Research 17(2):211-221, 2025. e-Pub 2025.
Lu M, Yuan Y, Liu S. A Bayesian pharmacokinetics integrated phase I-II design to optimize dose-schedule regimes. Biostatistics 26(1), 2025. e-Pub 2025. PMID: 39275895.
Sellers ZM, Giefer MJ, Wang F, Cress GA, Abu-El-Haija MA, Chugh A, Cohen RZ, Downs EM, Fishman DS, Freeman AJ, Gariepy CE, Gonska TY, Grover AS, Lindblad D, Liu QY, Maqbool A, Mark JA, McFerron BA, Mehta MS, Morinville VD, Ng K, Noel RA, Ooi CY, Perito ER, Phadke MY, Ruan W, Schwarzenberg SJ, Troendle DM, Wilschanski M, Zheng Y, Yuan Y, Lowe ME, Uc A. Impact of Elevated Serum Triglycerides on Children with Acute Recurrent or Chronic Pancreatitis from INSPPIRE-2. J Pediatr 276:114298, 2025. e-Pub 2025. PMID: 39277078.
Zhu H, Phipps AN, Yuan Y, Davidson BA, Shord SS, Liu J, LoRusso PM. FDA-AACR Strategies for Optimizing Dosages for Oncology Drug Products: Selecting Dosages for First-In-Human Trials. Clinical Cancer Research, 2025. e-Pub 2025.
Chahoud J, Skelton W P IV, Yuan Y, Zurita-Saavedra AJ, Kovitz CA, Alhalabi O, Campbell MT, Jonasch E, Lin JK, Desai M, Moura Nascimento Santos MJ, Hwang H, Corn PG, Msaouel P, Tannir NM, Hahn AW. A multicenter randomized phase II trial of lenvatinib plus everolimus versus cabozantinib in patients with metastatic clear cell RCC that progressed on PD-1 immune checkpoint inhibition (LenCabo). Annals of Oncology S0923- 7534(25):04953-1, 2025. e-Pub 2025.
Pan J, Zhao L, Zhang Y, Seery S, Tan Y, Deng B, Shan L, Ling Z, Wu F, Wang Z, Wang Q, Yu X, Zheng Q, Xu X, Yuan Y, Tian Z, Zhang Y, Peng S, Chang AH, Feng X. Donor-derived CD7 CAR T for pediatric and adult relapsed/refractory T-ALL/LBL: A phase II trial. Blood, 2025. e-Pub 2025.
Yang Y, Wu Y, Yuan Y. Dual-criterion Dose Finding Designs Based on Dose-Limiting Toxicity and Tolerability. Stat Biopharm Res, 2025. e-Pub 2025.
Fu J, Zhao D, Skanji D, Liu H, Tang R, Yuan Y. Bayesian prediction of event times using mixture model for blinded randomized controlled trials. Stat Med. e-Pub 2025.
Xu X, Yuan Y, Lee JJ. Augmenting the Control Arm of Randomized Trials by Incorporating Multiple External Data Sources Using Propensity Score Stratification and Data-Driven Mixture Prior. Stat Biopharm Res:1-15, 2025. e-Pub 2025.
Piha-Paul, SA, Tseng, C, Leung, CH, Yuan, Y, Karp, DD, Subbiah, V, Hong, DS, Fu, S, Naing, A, Rodon Ahnert, J, Javle, M, Ajani, JA, Raghav, KS, Somaiah, N, Mills, GB, Tsimberidou, AM, Zheng, X, Chen, K, Meric-Bernstam, F. Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations. npj Precision Oncology 8(1), 2024. e-Pub 2024. PMID: 39085400.
Rauh-Hain JA, Melamed A, Pareja R, May T, Sinno A, McNally L, Horowitz NS, De Iaco P, Michener CM, Van Lonkhuijzen L, Iniesta MD, Yuan Y, Ramirez PT, Fagotti A. Laparoscopic Cytoreduction After Neoadjuvant Chemotherapy in High-Grade Epithelial Ovarian Cancer: A LANCE Randomized Clinical Trial. JAMA Netw Open 7(11), 2024. e-Pub 2024. PMID: 39570589.
Lin, TA, McCaw, ZR, Koong, A, Lin, C, Abi Jaoude, J, Patel, RR, Kouzy, R, El Alam, MB, Sherry, AD, Noticewala, SS, Fuller, CD, Thomas, CR, Sun, R, Lee, JJ, Lin, R, Yuan, Y, Shyr, Y, Meirson, T, Ludmir, EB. Proportional Hazards Violations in Phase III Cancer Clinical Trials. Clinical Cancer Research 30(20):4791-4799, 2024. e-Pub 2024. PMID: 39133081.
Wang S, Thall PF, Takeda K, Yuan Y. ROMI: a randomized two-stage basket trial design to optimize doses for multiple indications. Biometrics 80(4), 2024. e-Pub 2024. PMID: 39360905.
Freeman AJ, Ng K, Wang F, Abu-El-Haija MA, Chugh A, Cress GA, Fishman DS, Gariepy CE, Giefer MJ, Goday P, Gonska TY, Grover AS, Lindblad D, Liu QY, Maqbool A, Mark JA, McFerron BA, Mehta MS, Morinville VD, Noel RA, Ooi CY, Perito ER, Schwarzenberg SJ, Sellers ZM, Wilschanski M, Zheng Y, Yuan Y, Andersen DK, Lowe ME, Uc A. Pancreatic Enzyme Use Reduces Pancreatitis Frequency in Children With Acute Recurrent or Chronic Pancreatitis: A Report From INSPPIRE. Am J Gastroenterol 119(10):2094-2102, 2024. e-Pub 2024. PMID: 38517077.
Chaftari, AP, Dagher, H, Hachem, RY, Jiang, Y, Lamie, PM, Dib, RW, John, TM, Haddad, AJ, Philip, A, Alii, S, Mulanovich, P, Yuan, Y, Chaftari, P, Raad, II. A randomized non-inferiority study comparing imipenem/cilastatin/relebactam with standard-of-care Gram-negative coverage in cancer patients with febrile neutropenia. Journal of Antimicrobial Chemotherapy 79(10):2543-2553, 2024. e-Pub 2024. PMID: 39092963.
Pan J, Tan Y, Shan L, Seery S, Deng B, Ling Z, Xu J, Duan J, Wang Z, Wang K, Yu X, Zheng Q, Xu X, Hu G, Tan T, Yuan Y, Tian Z, Yan F, Han Y, Zhang J, Feng X. Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 trial. Nat Med 31(1):126-136, 2024. e-Pub 2024. PMID: 39354195.
Zhao L, Li C, Zuo S, Han Y, Deng B, Ling Z, Zhang Y, Peng S, Xu J, Duan J, Wang Z, Yu X, Zheng Q, Xu X, Yuan Y, Tian Z, Tang K, Zhang Y, Niu Q, Zhang J, Chang AH, Luo Y, Feng X, Pan J. Autologous CD7 CAR-T cells generated without T cell pre-selection in pediatric patients with relapsed/refractory T-ALL: A phase I trial. Mol Ther 33(6):2753-2767, 2024. e-Pub 2024. PMID: 39244642.
Yang, P, Hubert, SM, Futreal, PA, Song, X, Zhang, J, Lee, JJ, Wistuba, II, Yuan, Y, Zhang, J, Li, Z. A NOVEL BAYESIAN MODEL FOR ASSESSING INTRATUMOR HETEROGENEITY OF TUMOR INFILTRATING LEUKOCYTES WITH MULTIREGION GENE EXPRESSION SEQUENCING. Annals of Applied Statistics 18(3):1879-1898, 2024. e-Pub 2024.
How JA, Dang M, Lee S, Fellman B, Westin SN, Sood AK, Fleming ND, Shafer A, Yuan Y, Liu J, Zhao L, Celestino J, Hajek R, Morgan MB, Parra ER, Laberiano Fernandez CD, Arrechedera CA, Solis Soto LM, Schmeler KM, Nick A, Lu KH, Coleman R, Wang L, Jazaeri AA. Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial. Med 6(1):100494, 2024. e-Pub 2024. PMID: 39151421.
Jiang, L, Yin, Z, Yan, F, Yuan, Y. MC-Keyboard: A Practical Phase I Trial Design for Targeted Therapies and Immunotherapies Integrating Multiple-Grade Toxicities. Journal of Immunotherapy and Precision Oncology 7(3):159-167, 2024. e-Pub 2024. PMID: 39219992.
Tang, C, Hartley, G, Couillault, CA, Yuan, Y, Lin, Y, Nicholas, C, Srinivasamani, A, Dai, J, Ileana Dumbrava, EE, Fu, S, Karp, DD, Naing, A, Piha-Paul, SA, Rodon Ahnert, J, Pant, S, Subbiah, V, Yap, T, Tsimberidou, AM, Guerrero, PA, Dhebat, S, Proia, T, Curran, M, Hong, DS. Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancer. BMJ Oncology 3(1), 2024. e-Pub 2024. PMID: 39886125.
Son, J, Zhang, Y, Lin, Y, Mirallas, O, Ballesteros, PA, Nardo, M, Clark, N, Hillman, RT, Campbell, E, Holla, V, Johnson, A, Biter, A, Yuan, Y, Cobb, LP, Gershenson, DM, Jazaeri, AA, Lu, KH, Soliman, PT, Westin, SN, Euscher, ED, Lawson, BC, Yang, RK, Meric-Bernstam, F, Hong, DS. Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers. Clinical Cancer Research 30(14):2986-2995, 2024. e-Pub 2024. PMID: 38687597.
Yang, P, Li, D, Lin, R, Huang, B, Yuan, Y. Design and sample size determination for multiple-dose randomized phase II trials for dose optimization. Statistics in Medicine 43(15):2972-2986, 2024. e-Pub 2024. PMID: 38747472.
Mu R, Zhan X, Tang RS, Yuan Y. A Bayesian latent-subgroup platform design for dose optimization. Biometrics 80(3), 2024. e-Pub 2024. PMID: 39253988.
Tian, F, Lin, R, Wang, L, Yuan, Y. A Bayesian quasi-likelihood design for identifying the minimum effective dose and maximum utility dose in dose-ranging studies. Statistical Methods in Medical Research 33(6):931-944, 2024. e-Pub 2024. PMID: 38573788.
Gouda, MA, Shunyakova, J, Naing, A, Ileana Dumbrava, EE, Hong, DS, Yuan, Y, Yang, P, Myers, AL, Liang, Y, Peng, J, Karp, DD, Tsimberidou, AM, Rodon Ahnert, J, Yap, TA, Piha-Paul, SA, Meric-Bernstam, F, Fu, S. A phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumors. ESMO Open 9(6), 2024. e-Pub 2024. PMID: 38914452.
Yuan Y, Zhou H, Liu S. Statistical and practical considerations in planning and conduct of dose-optimization trials. Clin Trials 21(3):17407745231207085, 2024. e-Pub 2024. PMID: 38243399.
Knisely, A, Hinchcliff, EM, Gardiner, E, Rangwala, R, Lito, K, Fellman, B, Yuan, Y, Sood, AK, Westin, SN, Lu, KH, Jazaeri, AA. Phase 1b study of batiraxcept in combination with durvalumab in patients with platinum-resistant ovarian cancer. iScience 27(5), 2024. e-Pub 2024. PMID: 38726365.
Hinchcliff EM, Knisely A, Adjei N, Fellman B, Yuan Y, Patel A, Xu C, Westin SN, Sood AK, Soliman PT, Shafer A, Fleming ND, Gershenson DM, Vikram R, Bathala T, Vining D, Ganeshan DM, Lu KH, Sun CC, Meyer LA, Jazaeri AA. Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer. Cancer 130(7):1061-1071, 2024. e-Pub 2023. PMID: 38009662.
Guo, B, Laird, G, Song, Y, Chen, J, Yuan, Y. Adaptive hybrid control design for comparative clinical trials with historical control data. Journal of the Royal Statistical Society. Series C: Applied Statistics 73(2):444-459, 2024. e-Pub 2024.
Chi, X, Yuan, Y, Yu, Z, Lin, R. A generalized calibrated Bayesian hierarchical modeling approach to basket trials with multiple endpoints. Biometrical Journal 66(2), 2024. e-Pub 2024. PMID: 38368277.
Zang Y, Thall PF, Yuan Y. A generalized phase 1-2-3 design integrating dose optimization with confirmatory treatment comparison. Biometrics 80(1), 2024. e-Pub 2024. PMID: 38364811.
Hui C, Brown E, Wong S, Das M, Wakelee H, Neal J, Ramchandran K, Myall NJ, Pham D, Xing L, Yang Y, Kovalchuk N, Yuan Y, Lu Y, Xiang M, Chin A, Diehn M, Loo BW Jr, Vitzthum LK. Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer: Protocol for a Bayesian Optimal Phase I/II Trial. Clin Lung Cancer 25(2):186-189, 2024. e-Pub 2024. PMID: 38040540.
Lilly MB, Wu C, Ke Y, Chen WP, Soloff AC, Armeson K, Yokoyama NN, Li X, Song L, Yuan Y, McLaren CE, Zi X. A phase I study of docetaxel plus synthetic lycopene in metastatic prostate cancer patients. Clin Transl Med 14(3):e1627, 2024. e-Pub 2024. PMID: 38515274.
Dasgupta P, Ou A, Lin H, Gregory T, Alfaro-Munoz KD, Yuan Y, Afshar-Khargan V, Kamiya-Matsuoka C, Rousseau JF, Majd NK. The risk and burden of thromboembolic and hemorrhagic events in patients with malignant gliomas receiving bevacizumab. J Neurooncol. e-Pub 2024. PMID: 38372903.
Zhao Y, Yuan Y, Korn EL, Freidlin B. Backfilling Patients in Phase I Dose Escalation Trials Using Bayesian Optimal Interval Design (BOIN). Clin Cancer Res 30(4):673-679, 2024. e-Pub 2024. PMID: 38048044.
Subbiah V, Coleman N, Piha-Paul SA, Tsimberidou AM, Janku F, Rodon J, Pant S, Dumbrava EE, Fu S, Hong DS, Zhang S, Sun M, Jiang Y, Roszik J, Song J, Yuan Y, Meric-Bernstam F, Naing A. Phase I study of mTORC1/2 inhibitor sapanisertib in combination with metformin in patients with mTOR/AKT/PI3K pathway alterations and advanced solid malignancies. Cancer Res Commun 4(2):378-387, 2024. e-Pub 2023. PMID: 38126764.
Amaria R, Knisely A, Vining D, Kopetz S, Overman MJ, Javle M, Antonoff MB, Tzeng CD, Wolff RA, Pant S, Lito K, Rangel K, Fellman B, Yuan Y, Lu KH, Sakellariou-Thompson D, Haymaker CL, Forget MA, Hwu P, Bernatchez C, Jazaeri AA. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. J Immunother Cancer 12(2), 2024. e-Pub 2024. PMID: 38309721.
Nowlen CJ, Daniels M, Uzunparmak B, Ileana Dumbrava EE, Yuan Y, Patel KP, Rayes N, Harkenrider J, Wathoo C, Veazie J, Luna KA, Wang W, Horombe C, Javle M, Ahnert JR, Yap TA, Arun B, Lu KH, Meric-Bernstam F. Limited Independent Follow-Up with Germline Testing of Variants Detected in BRCA1 and BRCA2 by Tumor-Only Sequencing. J Immunother Precis Oncol 7(1):7-17, 2024. e-Pub 2024. PMID: 38327755.
Zhang W, Laird G, Chen J, Yuan Y. A Bayesian phase II proof-of-concept design for clinical trials with longitudinal endpoints. Stat Med 43(1):173-183, 2024. e-Pub 2024. PMID: 37937591.
Fogel, EL, Easler, JJ, Yuan, Y, Yadav, D, Conwell, DL, Vege, SS, Han, S, Park, WG, Patrick, V, White, FA. Safety, Tolerability, and Dose-Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis. JMIR Research Protocols 13(1), 2024. e-Pub 2024. PMID: 38451604.
Yang, JY, Li, GC, Yuan, Y. Accelerate vaccine development using seamless phase 2/3 trial designs. Expert Review of Vaccines 23(1):523-534, 2024. e-Pub 2024. PMID: 38682812.
Liu, R, Yuan, Y, Sen, S, Marchenko, O, Jiang, Q, Tian, H, Li, X, Lin, R, Lu, C, Zhou, H. Design Strategy and Consideration for Oncology Dose-Optimization. Statistics in Biopharmaceutical Research 16(3):338-347, 2024. e-Pub 2024.
Chen, K, Wang, L, Yuan, Y. MT-Keyboard: A Bayesian Model-Assisted Interval Design to Account for Toxicity Grades and Types for Phase I Trials. Statistics in Biopharmaceutical Research 16(3):305-314, 2024. e-Pub 2024. PMID: 39877140.
Lu M, Zhang J, Yuan Y, Lin R. Comb-BOIN12: A Utility-Based Bayesian Optimal Interval Design for Dose Optimization in Cancer Drug-Combination Trials. Stat Biopharm Res, 2024. e-Pub 2024.
Chen K, Zhou H, Lee JJ, Yuan Y. BOP2-TE: Bayesian optimal phase 2 design for jointly monitoring efficacy and toxicity with application to dose optimization. Journal of Biopharmaceutical Statistics:1-16, 2024. e-Pub 2024.
Dejardin D, Huang B, Yuan Y, Beyer U, Fridlyand J, Zhu J. Dose Optimization for Novel Oncology Agents: Design Options and Strategies. Stat Biopharm Res 16(3):326–337, 2024. e-Pub 2024.
Ye J, Pan H, Reaman G, Roychoudhury S, Lu C, Renfro LA, Ji Y, Liu R, Yuan Y, Zhang W. Considerations for External Control in Pediatric Oncology. Medical Research Archieves 12(1), 2024. e-Pub 2024.
D'Angelo G, Gong M, Marshall J, Yuan Y, Li X. U-MET: Utility-Based Dose Optimization Approach for Multiple-Dose Randomized Trial Designs. Stat Biopharm Res, 2024. e-Pub 2024.
Guo B, Wang L, Yuan Y. Treatment Comparisons in Adaptive Platform Trials Adjusting for Temporal Drift. Statistics in Biopharmaceutical Research 16(3):361–370, 2024. e-Pub 2024.
Msaouel P, Yu K, Yuan Y, Chen J, Yan X, Karki M, Duan F, Sheth R, Rao P, Sircar K, Shah A, Zurita A, Genovese G, Li M, Yeh C, Dang M, Han G, Chu Y, Hallin M, Olson P, Yang R, Slavin D, Der-Torossian H, Chin C, Tannir N, Wang L, Gao J. Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma: a phase 1 trial. Nature Communications, 2024. e-Pub 2024.
Yang P, Zhao Y, Nie L, Vallejo J, Yuan Y. SAM: Self-adapting mixture prior to dynamically borrow information from historical data in clinical trials. Biometrics 79(4):2857-2868, 2023. e-Pub 2023. PMID: 37721513.
Guo B, Yuan Y. DROID: dose-ranging approach to optimizing dose in oncology drug development. Biometrics 79(4):2907-2919, 2023. e-Pub 2023. PMID: 36807110.
Taniguchi CM, Frakes JM, Aguilera TA, Palta M, Czito B, Bhutani MS, Colbert LE, Abi Jaoude J, Bernard V, Pant S, Tzeng CD, Kim DW, Malafa M, Costello J, Mathew G, Rebueno N, Koay EJ, Das P, Ludmir EB, Katz MHG, Wolff RA, Beddar S, Sawakuchi GO, Moningi S, Slack Tidwell RS, Yuan Y, Thall PF, Beardsley RA, Holmlund J, Herman JM, Hoffe SE. Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial. Lancet Oncol 24(12):1387-1398, 2023. e-Pub 2023. PMID: 38039992.
Abu-El-Haija, M, Hornung, L, Ellery, KM, Fishman, D, Gonska, T, Gariepy, CE, Lowe, ME, Larson Ode, K, Maqbool, A, Mascarenhas, MR, Morinville, VD, Ooi, CY, Perito, ER, Schwarzenberg, SJ, Sellers, ZM, Zemel, BS, Yuan, Y, Wang, F, Uc, A, Kalkwarf, HJ. Bone health in children with recurrent and chronic pancreatitis. Pancreatology 23(7):755-760, 2023. e-Pub 2023. PMID: 37723006.
Uzunparmak B, Haymaker C, Raso G, Masciari S, Wang L, Lin H, Gorur A, Kirby B, Cimo AM, Kennon A, Ding Q, Urschel G, Yuan Y, Feng G, Rizvi Y, Hussain A, Zhu C, Kim P, Abbadessa G, Subbiah V, Yap TA, Rodon J, Piha-Paul SA, Meric-Bernstam F, Dumbrava EE. HER2-low expression in patients with advanced or metastatic solid tumors. Ann Oncol 34(11):1035-1046, 2023. e-Pub 2023. PMID: 37619847.
Yang P, Hubert SM, Futreal PA, Song X, Zhang J, Lee JJ, Wistuba I, Yuan Y, Zhang J, Li Z. A novel Bayesian model for assessing intratumor heterogeneity of tumor infiltrating leukocytes with multi-region gene expression sequencing. bioRxiv, 2023. e-Pub 2023. PMID: 37961165.
Jiang L, Thall PF, Yan F, Kopetz S, Yuan Y. BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials. Clin Trials 20(5):17407745231176445, 2023. e-Pub 2023. PMID: 37313712.
Morinville VD, Husain SZ, Wang F, Cress GA, Abu-El-Haija M, Chugh A, Downs E, Ellery K, Fishman DS, Freeman AJ, Gariepy CE, Giefer M, Gonska T, Liu Q, Maqbool A, Mark J, Mcferron BA, Mehta M, Nathan JD, Ng K, Ooi CY, Perito E, Ruan W, Schwarzenberg SJ, Sellers ZM, Serrano J, Troendle DM, Wilschanski M, Zheng Y, Yuan Y, Lowe M, Uc A, Chronic Pancreatitis CFTSO, Diabetes, Cancer P. Pediatric Drug-Associated Pancreatitis Reveals Concomitant Risk Factors and Poor Reliability of Causality Scoring. J Pediatr Gastroenterol Nutr 77(4):540-546, 2023. e-Pub 2023. PMID: 37496124.
Cao H, Yao C, Yuan Y. Bayesian approach for design and analysis of medical device trials in the era of modern clinical studies. Med Rev (2021) 3(5):408-424, 2023. e-Pub 2023. PMID: 38283256.
Jiang L, Yuan Y. Seamless Phase II/III Design: A Useful Strategy to Reduce the Sample Size for Dose Optimization. J Natl Cancer Inst 115(9):1092-1098, 2023. e-Pub 2023. PMID: 37243720.
Stephen B, Hajjar J, Sarda S, Duose DY, Conroy JM, Morrison C, Alshawa A, Xu M, Zarifa A, Patel SP, Yuan Y, Kwiatkowski E, Wang L, Rodon Ahnert J, Fu S, Meric-Bernstam F, Lowman GM, Looney T, Naing A. T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy. J Immunother Cancer 11(8), 2023. e-Pub 2023. PMID: 37604642.
Thall, PF, Zang, Y, Yuan, Y. Generalized phase I-II designs to increase long term therapeutic success rate. Pharmaceutical statistics 22(4):692-706, 2023. e-Pub 2023. PMID: 37038957.
Zhao Y, Li D, Liu R, Yuan Y. Bayesian optimal phase II designs with dual-criterion decision making. Pharm Stat 22(4):605-618, 2023. e-Pub 2023. PMID: 36871961.
Zhao, Y, Tang, R, Du, Y, Yuan, Y. A Bayesian platform trial design to simultaneously evaluate multiple drugs in multiple indications with mixed endpoints. Biometrics 79(2):1459-1471, 2023. e-Pub 2023. PMID: 35546501.
Zhou Y, Zhao Y, Cicconetti G, Mu Y, Yuan Y, Wang L, Penugonda S, Salman Z. AIDE: Adaptive intrapatient dose escalation designs to accelerate Phase I clinical trials. Pharm Stat 22(2):300-311, 2023. e-Pub 2023. PMID: 36333972.
Jiang L, Nie L, Yuan Y. Elastic priors to dynamically borrow information from historical data in clinical trials. Biometrics 79(1):49-60, 2023. e-Pub 2023. PMID: 34437714.
Raghav K, Kopetz S, Yuan Y. Reply to Y. Yu et al. J Clin Oncol 41(7):JCO2202588, 2023. e-Pub 2023. PMID: 36595731.
Son J, Lin HY, Fu S, Biter AB, Dumbrava EE, Karp DD, Naing A, Pant S, Piha-Paul SA, Rodon J, Subbiah V, Tsimberidou AM, Yap TA, Frumovitz MM, Jazaeri AA, Ramirez PT, Westin SN, Yuan Y, Meric-Bernstam F, Hong DS. Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer. J Immunother Precis Oncol 6(1):10-18, 2023. e-Pub 2023. PMID: 36751659.
Thall PF, Zang Y, Chapple AG, Yuan Y, Lin R, Marin D, Msaouel P. Novel clinical trial designs with dose optimization to improve long-term outcomes. Clin Cancer Res 29(22):4549-4554, 2023. e-Pub 2023. PMID: 37725573.
Qing, Y, Thall, PF, Yuan, Y. A Bayesian piecewise exponential phase II design for monitoring a time-to-event endpoint. Pharmaceutical statistics 22(1):34-44, 2023. e-Pub 2023. PMID: 35851545.
Gregory TA, Mastall M, Lin H, Hess KR, Yuan Y, Martin-Bejarano Garcia M, Fuller GN, Alfaro KD, Gule-Monroe MK, Huse JT, Khatua S, Rao G, Sandberg DI, Wefel JS, Yeboa DN, Paulino AC, McGovern SL, Zaky W, Mahajan A, Suki D, Weathers SP, Harrison RA, de Groot JF, Puduvalli VK, Penas-Prado M, Majd NK. Characterization of recurrence patterns and outcomes of medulloblastoma in adults: The University of Texas MD Anderson Cancer Center experience. Neurooncol Adv 5(1):vdad032, 2023. e-Pub 2023. PMID: 37114244.
Chandra N, Muller P, Yuan Y, De GJ. Bayesian Nonparametric Common Atoms Re gression for Generating Synthetic Controls in Clinical Trials. The Journal of the American Statistical Association 118:2301–2314, 2023. e-Pub 2023.
Marchenko O, Sridhara R, Jiang Q, Barksdale E, Ando Y, Alwis DD, Brown K, Fernandes L, Van Bussel MTJ, Choo Q, Coory M, Garrett-Mayer E, Gwise T, Hess L, Liu R, Mandrekar S, Ouellet D, Pinheiro J, Posch M, Rahman NA, Rantell KR, Raven A, Sarem S, Sen S, Shah M, Shen YL, Simon R, Theoret M, Yuan Y, Pazdur R. Designing Dose-Optimization Studies in Cancer Drug Development: Discussions with Regulators. Statistics in Biopharmaceutical Research 15:697-703, 2023. e-Pub 2023.
Huang B, Yuan Y. Design Strategies for Dose Optimization in Oncology Drug Development. Biopharmaceutical Report 30(2):27-31, 2023. e-Pub 2023.
Lin, R, Shi, H, Yin, G, Thall, PF, Yuan, Y, Flowers, CR. BAYESIAN HIERARCHICAL RANDOM-EFFECTS META-ANALYSIS AND DESIGN OF PHASE I CLINICAL TRIALS. Annals of Applied Statistics 16(4):2481-2504, 2022. e-Pub 2022. PMID: 36329718.
Yuan Y, Zhao Y. Commentary on "Improving the performance of Bayesian logistic regression model with overdose control in oncology dose-finding studies". Stat Med 41(27):5484-5490, 2022. e-Pub 2022. PMID: 36394102.
Uc A, Cress GA, Wang F, Abu-El-Haija M, Ellery KM, Fishman DS, Gariepy CE, Gonska T, Lin TK, Liu QY, Mehta M, Maqbool A, McFerron BA, Morinville VD, Ooi CY, Perito ER, Schwarzenberg SJ, Sellers ZM, Serrano J, Shah U, Troendle DM, Wilschanski M, Zheng Y, Yuan Y, Lowe ME, Chronic Pancreatitis CFTSO, Diabetes, Cancer P. Analysis of INSPPIRE-2 Cohort: Risk Factors and Disease Burden in Children With Acute Recurrent or Chronic Pancreatitis. J Pediatr Gastroenterol Nutr 75(5):643-649, 2022. e-Pub 2022. PMID: 35976273.
Ngoi, NY, Pilie, PG, Piha-Paul, SA, Dumbrava, EE, Fu, S, Hong, DS, Karp, DD, Naing, A, Pant, S, Rodon Ahnert, J, Subbiah, V, Tsimberidou, AM, Salguero, C, Brown, CV, Hoadley, WE, Johnson, A, Yuan, Y, Westin, SN, Meric-Bernstam, F, Yap, TA. DNA Damage Response (DDR) Basket of Baskets (D-BOB) Trial. European Journal of Cancer 174:S10, 2022. e-Pub 2022.
Yap, TA, Ngoi, NY, Dumbrava, EE, Karp, DD, Rodon Ahnert, J, Fu, S, Hong, DS, Naing, A, Pant, S, Piha-Paul, SA, Subbiah, V, Tsimberidou, AM, Dufner, D, Rhudy, J, Gore, SD, Ivy, SP, Yuan, Y, Westin, SN, Mills, GB, Meric-Bernstam, F. NCI10329: Phase Ib Sequential Trial of Agents against DNA Repair (STAR) Study to investigate the sequential combination of the Poly (ADP-Ribose) Polymerase inhibitor (PARPi) olaparib (ola) and WEE1 inhibitor (WEE1i) adavosertib (ada) in patients (pts) with DNA Damage Response (DDR)-aberrant advanced tumors, enriched for BRCA1/2 mutated and CCNE1 amplified cancers. European Journal of Cancer 174:S7, 2022. e-Pub 2022.
Ng, SP, Cardenas, CE, Bahig, H, Elgohari, B, Wang, J, Johnson, JM, Moreno, AC, Shah, SJ, Garden, AS, Phan, J, Gunn, GB, Frank, SJ, Ding, Y, Na, L, Yuan, Y, Urbauer, D, Mohamed, AS, Rosenthal, D, Morrison, WH, MacManus, M, Fuller, C. Changes in Apparent Diffusion Coefficient (ADC) in Serial Weekly MRI during Radiotherapy in Patients with Head and Neck Cancer. Current Oncology 29(9):6303-6313, 2022. e-Pub 2022. PMID: 36135064.
How JA, Jazaeri AA, Fu S, Rodon Ahnert J, Gong J, Stephen B, Ferreira Dalla Pria H, Bhosale P, Johnson A, Yuan Y, Meric-Bernstam F, Naing A. Clinical Outcomes of Patients with Recurrent Microsatellite-Stable Endometrial Cancer in Early-Phase Immunotherapy Clinical Trials. Cancers (Basel) 14(15):3695(15), 2022. e-Pub 2022. PMID: 35954359.
Lu, M, Liu, S, Yuan, Y. Why there are so many contradicted or exaggerated findings in highly-cited clinical research?. Contemporary Clinical Trials 118, 2022. e-Pub 2022. PMID: 35525531.
Chaftari, AP, Hachem, RY, Malek, A, Mulanovich, VE, Szvalb, AD, Jiang, Y, Yuan, Y, Ali, S, Deeba, R, Chaftari, P, Raad, II. A Prospective Randomized Study Comparing Ceftolozane/Tazobactam to Standard of Care in the Management of Neutropenia and Fever in Patients With Hematological Malignancies. Open Forum Infectious Diseases 9(6), 2022. e-Pub 2022. PMID: 35663286.
Zhou Y, Lin R, Lee JJ, Li D, Wang L, Li R, Yuan Y. TITE-BOIN12: A Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy. Stat Med 41(11):1918-1931, 2022. e-Pub 2022. PMID: 35098585.
Tham SW, Wang F, Gariepy CE, Cress GA, Abu-El-Haija MA, Bellin MD, Ellery KM, Fishman DS, Gonska T, Heyman MB, Lin TK, Maqbool A, McFerron BA, Morinville VD, Nathan JD, Ooi CY, Perito ER, Schwarzenberg SJ, Sellers ZM, Shah U, Troendle DM, Wilschanski M, Zheng Y, Yuan Y, Lowe ME, Uc A, Palermo TM, a cuRE ISGOPPISF, Chronic Pancreatitis CFTSO, Diabetes, Cancer P. Health-Related Quality of Life in Pediatric Acute Recurrent or Chronic Pancreatitis: Association with Biopsychosocial Risk Factors. J Pediatr Gastroenterol Nutr 74(5):636-642, 2022. e-Pub 2022. PMID: 35192575.
Msaouel, P, Goswami, S, Thall, PF, Wang, X, Yuan, Y, Jonasch, E, Gao, J, Campbell, M, Shah, AY, Corn, P, Tam, AL, Ahrar, K, Rao, P, Sircar, K, Cohen, L, Basu, S, Duan, F, Jindal, S, Zhang, Y, Chen, H, Yadav, SS, Shazer, R, Der-Torossian, H, Allison, JP, Sharma, P, Tannir, NM. A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Science translational medicine 14(641), 2022. e-Pub 2022. PMID: 35442707.
Park Y, Liu S, Thall P, Yuan Y. Bayesian group sequential enrichment designs based on adaptive regression of response and survival time on baseline biomarkers. Biometrics 78(1):60-71, 2022. e-Pub 2022. PMID: 33438761.
Mu R, Xu J, Tang RS, Kopetz S, Yuan Y. A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indications. Stat Med 41(2):374-389, 2022. e-Pub 2022. PMID: 34730248.
Garmezy B, Gheeya J, Lin HY, Huang Y, Kim T, Jiang X, Thein KZ, Pilié PG, Zeineddine F, Wang W, Shaw KR, Rodon J, Shen JP, Yuan Y, Meric-Bernstam F, Chen K, Yap TA. Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers. JCO Precis Oncol 6:e2100267, 2022. e-Pub 2022. PMID: 35108036.
Scheurer, ME, Zhou, R, Gilbert, MR, Bondy, ML, Sulman, EP, Yuan, Y, Liu, Y, Vera, E, Wendland, MM, Youssef, E, Stieber, VW, Komaki, RR, Flickinger, J, Kenyon, LC, Robins, HI, Hunter, G, Crocker, I, Chao, ST, Pugh, S, Armstrong, TS. Germline polymorphisms in MGMT associated with temozolomide-related myelotoxicity risk in patients with glioblastoma treated on NRG Oncology/RTOG 0825. Neuro-Oncology Advances 4(1), 2022. e-Pub 2022. PMID: 36299794.
van Dijk LV, Frank SJ, Yuan Y, Gunn B, Moreno AC, Mohamed ASR, Preston KE, Qing Y, Spiotto MT, Morrison WH, Lee A, Phan J, Garden AS, Rosenthal DI, Langendijk JA, Fuller CD. Proton Image-guided Radiation Assignment for Therapeutic Escalation via Selection of locally advanced head and neck cancer patients [PIRATES]: A Phase I safety and feasibility trial of MRI-guided adaptive particle radiotherapy. Clin Transl Radiat Oncol 32:35-40, 2022. e-Pub 2022. PMID: 34841093.
Liu, R, Yuan, Y, Sen, S, Yang, X, Jiang, Q, Li, X, Lu, C, Gönen, M, Tian, H, Zhou, H, Lin, R, Marchenko, O. Accuracy and Safety of Novel Designs for Phase I Drug-Combination Oncology Trials. Statistics in Biopharmaceutical Research 14(3):270-282, 2022. e-Pub 2022. PMID: 37275462.
Zhang, W, Pan, Z, Yuan, Y. A Bayesian group sequential design for randomized biosimilar clinical trials with adaptive information borrowing from historical data. Journal of Biopharmaceutical Statistics 32(3):359-372, 2022. e-Pub 2022. PMID: 35679137.
Fu S, Yao S, Yuan Y, Previs RA, Elias AD, Carvajal RD, George TJ, Yuan Y, Yu L, Westin SN, Xing Y, Dumbrava EE, Karp DD, Piha-Paul SA, Tsimberidou AM, Ahnert JR, Takebe N, Lu K, Keyomarsi K, Meric-Bernstam F. Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification. Journal of Clinical Oncology, 2022. e-Pub 2022.
Zhao Y, Yang B, Lee JJ, Yuan Y. Bayesian Optimal Phase II Design for Randomized Clinical Trials. Statistics in Biopharmaceutical Research, 2022. e-Pub 2022.
LinR, LiuR, ZhouH, YangX, YuanY, JiangQ, KeC, LiX, LuC, SenS, ̈onenM G, TianH, and Marchen O. Accuracy, Safety, and Risky Behavior of Novel Phase I Drug-Combination Trial Designs. Statistics in Biopharmaceutical Researc, 2022. e-Pub 2022.
Chaftari AM, Hachem R, Malek AE, Mulanovich VE, Szvalb AD, Jiang Y, Yuan Y, Ali S, Deeba R, Chaftari P, Raad I. A Prospective Randomized Study Comparing Ceftolozane/Tazobactam to Standard of Care in the Management of Neutropenia and Fever in Patients With Hematological Malignancies. Open Forum Infectious Diseases 9(6):ofac079, 2022. e-Pub 2022.
Gross ND, Ferrarotto R, Amit M, Nagarajan P, Yuan Y, Bell D, Johnson JM, Morrison WH, Rosenthal DI, Glisson BS, Johnson FM, Mott F, Esmaeli B, Diaz E, Gidley P, Goepfert R, Lewis CM, Wargo JA, Weber RS, Myers J. Long-term outcomes of a phase II trial of neoadjuvant immunotherapy for advanced, resectable cutaneous squamous cell carcinoma of the head and neck (CSCC-HN). Journal of Clinical Oncology 40:Suppl:9519-9519, 2022. e-Pub 2022.
Yuan Y, Chen K. Novel bayesian adaptive early phase designs to accelerate the development of CAR T-cell therapy. Hematology and Oncology Discovery 1(1):14-23, 2022.
Carmack CL, Parker NH, Demark-Wahnefried W, Shely L, Baum G, Yuan Y, Giordano SH, Rodriguez-Bigas M, Pettaway C, Basen-Engquist K. Healthy Moves to Improve Lifestyle Behaviors of Cancer Survivors and Their Spouses: Feasibility and Preliminary Results of Intervention Efficacy. Nutrients 13(12), 2021. e-Pub 2021. PMID: 34960013.
Westin SN, Labrie M, Litton JK, Blucher A, Fang Y, Vellano CP, Marszalek JR, Feng N, Ma X, Creason A, Fellman B, Yuan Y, Lee S, Kim TB, Liu J, Chelariu-Raicu A, Chen TH, Kabil N, Soliman PT, Frumovitz M, Schmeler KM, Jazaeri A, Lu KH, Murthy R, Meyer LA, Sun CC, Sood AK, Coleman RL, Mills GB. Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. Clin Cancer Res 27(23):6354-6365, 2021. e-Pub 2021. PMID: 34518313.
Yuan Y, Wu J, Gilbert MR. BOIN: a novel Bayesian design platform to accelerate early phase brain tumor clinical trials. Neurooncol Pract 8(6):627-638, 2021. e-Pub 2021. PMID: 34777832.
Prokhorov AV, Calabro KS, Arya A, Russell S, Czerniak KW, Botello GC, Chen M, Yuan Y, Perez A, Vidrine DJ, Perry CL, Khalil GE. Mobile Text Messaging for Tobacco Risk Communication Among Young Adult Community College Students: Randomized Trial of Project Debunk. JMIR Mhealth Uhealth 9(11):e25618, 2021. e-Pub 2021. PMID: 34822339.
Melendez B, Shah S, Jiang Y, Dottino J, Watson E, Pearce H, Borthwick M, Schmandt RE, Zhang Q, Cumpian K, Celestino J, Fellman B, Yuan Y, Lu KH, Mikos AG, Yates MS. Novel polymer-based system for intrauterine delivery of everolimus for anti-cancer applications. J Control Release 339:521-530, 2021. e-Pub 2021. PMID: 34648891.
Phillips LM, Li S, Gumin J, Daou M, Ledbetter D, Yang J, Singh S, Parker Kerrigan BC, Hossain A, Yuan Y, Gomez-Manzano C, Fueyo J, Lang FF. An immune-competent, replication-permissive Syrian Hamster glioma model for evaluating Delta-24-RGD oncolytic adenovirus. Neuro Oncol 23(11):1911-1921, 2021. e-Pub 2021. PMID: 34059921.
Zhang W, Pan Z, Yuan Y. Elastic meta-analytic-predictive prior for dynamically borrowing information from historical data with application to biosimilar clinical trials. Contemp Clin Trials 110:106559, 2021. e-Pub 2021. PMID: 34506959.
Rutherford SC, Abramson JS, Bartlett NL, Barta SK, Khan N, Joyce R, Maddocks K, Ali-Shaw T, Senese S, Yuan Y, Westin J, Leonard JP. Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study. Lancet Haematol 8(11):e818-e827, 2021. e-Pub 2021. PMID: 34634256.
Zhou Y, Lee JJ, Wang S, Bailey S, Yuan Y. Incorporating historical information to improve phase I clinical trials. Pharm Stat 20(6):1017-1034, 2021. e-Pub 2021. PMID: 33793044.
Pan J, Tan Y, Wang G, Deng B, Ling Z, Song W, Seery S, Zhang Y, Peng S, Xu J, Duan J, Wang Z, Yu X, Zheng Q, Xu X, Yuan Y, Yan F, Tian Z, Tang K, Zhang J, Chang AH, Feng X. Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial. J Clin Oncol 39(30):JCO2100389, 2021. e-Pub 2021. PMID: 34324392.
Patel RR, He K, Barsoumian HB, Chang JY, Tang C, Verma V, Comeaux N, Chun SG, Gandhi S, Truong MT, Erasmus JJ, Hong DS, Lee PP, Ning MS, Nguyen QN, Heymach JV, Altan M, Blumenschein G, Fossella FV, Sezen D, Chen D, Carter BW, Davies MA, Glitza IC, Diab A, Ferrarotto R, Cabanillas ME, Yuan Y, Shah SJ, Parra ER, Sun B, Cortez MA, Welsh JW. High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial. Radiother Oncol 162:60-67, 2021. e-Pub 2021. PMID: 34237343.
Ferrarotto R, Amit M, Nagarajan P, Rubin ML, Yuan Y, Bell D, El-Naggar AK, Johnson JM, Morrison WH, Rosenthal DI, Glisson BS, Johnson FM, Lu C, Mott FE, Esmaeli B, Diaz EM, Gidley PW, Goepfert RP, Lewis CM, Weber RS, Wargo JA, Basu S, Duan F, Yadav SS, Sharma P, Allison JP, Myers JN, Gross ND. Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res 27(16):4557-4565, 2021. e-Pub 2021. PMID: 34187851.
Jiang L, Nie L, Yan F, Yuan Y. Optimal Bayesian hierarchical model to accelerate the development of tissue-agnostic drugs and basket trials. Contemp Clin Trials 107:106460, 2021. e-Pub 2021. PMID: 34098036.
Schipper MJ, Yuan Y, Taylor JM, Ten Haken RK, Tsien C, Lawrence TS. A Bayesian dose-finding design for outcomes evaluated with uncertainty. Clin Trials:17407745211001521. e-Pub 2021. PMID: 33884907.
Bahig H, Rosenthal DI, Nguyen-Tan FP, Fuller DC, Yuan Y, Hutcheson KA, Christopoulos A, Nichols AC, Fung K, Ballivy O, Filion E, Ng SP, Lambert L, Dorth J, Hu KS, Palma D. Vocal-cord Only vs. Complete Laryngeal radiation (VOCAL): a randomized multicentric Bayesian phase II trial. BMC Cancer 21(1):446, 2021. e-Pub 2021. PMID: 33888069.
Wu J, Yuan Y, Long Priel DA, Fink D, Peer CJ, Sissung TM, Su YT, Pang Y, Yu G, Butler MK, Mendoza TR, Vera E, Ahmad S, Bryla C, Lindsley M, Grajkowska E, Mentges K, Boris L, Antony R, Garren N, Siegel C, Lollo N, Cordova C, Aboud O, Theeler BJ, Burton EM, Penas-Prado M, Leeper H, Gonzales J, Armstrong TS, Calvo KR, Figg WD, Kuhns DB, Gallin JI, Gilbert MR. Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas. Clin Cancer Res. e-Pub 2021. PMID: 33785481.
Kang D, S Coffey C, J Smith B, Yuan Y, Shi Q, Yin J. Hierarchical Bayesian clustering design of multiple biomarker subgroups (HCOMBS). Stat Med. e-Pub 2021. PMID: 33772843.
Gilbert MR, Yuan Y, Wu J, Mendoza T, Vera E, Omuro A, Lieberman F, Robins HI, Gerstner ER, Wu J, Wen PY, Mikkelsen T, Aldape K, Armstrong TS. A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma. Neuro Oncol 23(3):468-477, 2021. e-Pub 2021. PMID: 33085768.
Jiang L, Li R, Yan F, Yap TA, Yuan Y. Shotgun: A Bayesian seamless phase I-II design to accelerate the development of targeted therapies and immunotherapy. Contemp Clin Trials 104:106338. e-Pub 2021. PMID: 33711459.
Shi H, Cao J, Yuan Y, Lin R. uTPI: A utility-based toxicity probability interval design for phase I/II dose-finding trials. Stat Med. e-Pub 2021. PMID: 33650708.
How JA, Jazaeri AA, Fellman B, Daniels MS, Penn S, Solimeno C, Yuan Y, Schmeler K, Lanchbury JS, Timms K, Lu KH, Yates MS. Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer. Cancers (Basel) 13(5), 2021. e-Pub 2021. PMID: 33668244.
Coleman RL, Hu W, Soliman P, Nick A, Ramirez PT, Westin SN, Garcia ME, Zhu Z, Palancia J, Fellman BM, Yuan Y, Ram P, Bischoff F, Schmeler K, Bodurka D, Meyer LA, Sood AK. Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study. Gynecol Oncol. e-Pub 2021. PMID: 33551196.
Park Y, Yuan Y, Ning J, Liu S, Feng Z. Hybrid design evaluating new biomarkers when there is an existing screening test. Stat Med. e-Pub 2021. PMID: 33540472.
Park M, Liu S, Yap TA, Yuan Y. Evaluation of Deviation From Planned Cohort Size and Operating Characteristics of Phase 1 Trials. JAMA Netw Open 4(2):e2037563, 2021. e-Pub 2021. PMID: 33595664.
Majd NK, Mastall M, Lin H, Dibaj SS, Hess KR, Yuan Y, Garcia MM, Fuller GN, Alfaro KD, Gule-Monroe MK, Huse JT, Khatua S, Rao G, Sandberg DI, Wefel JS, Yeboa DN, Paulino AC, McGovern SL, Zaky W, Mahajan A, Suki D, Weathers SP, Harriso RA, De Groo JF, Puduvalli VK, Penas-Prado M. Clinical characterization of adult medulloblastoma and the effect of first-line therapies on outcome; The MD Anderson Cancer Center experience. Neurooncol Adv 3(1):vdab079, 2021. e-Pub 2021. PMID: 34377987.
Zhou Y, Li R, Yan F, Lee JJ, Yuan Y. A comparative study of Bayesian optimal interval (BOIN) design with interval 3+3 (i3+3) design for phase I oncology dose-finding trials. Statistics in Biopharmaceutical Research 13(2):147-155, 2021. e-Pub 2021.
Lin R, Thall PF, Yuan Y. BAGS: A Bayesian Adaptive Group Sequential Trial Design With Subgroup-Specific Survival Comparisons. J Am Stat Assoc 116(533):322-334, 2021. e-Pub 2021. PMID: 35582047.
Tidwell RSS, Thall PF, Yuan Y. Lessons Learned From Implementing a Novel Bayesian Adaptive Dose-Finding Design in Advanced Pancreatic Cancer. JCO Precis Oncol 5, 2021. e-Pub 2021. PMID: 34805718.
Walker JG, Armstrong TS, O'Brien BJ, Gilbert MR, Casarez RL, Fagundes C, Heijnen CJ, Andersen CR, Yuan Y, Wu J, LoBiondo-Wood G. Associations of meaning of illness with psychosocial, clinical, and immunological characteristics in patients with leptomeningeal metastasis. Comprehensive Psychoneuroendocrinology 8:100099, 2021. e-Pub 2021.
Jin IH, Zhang Z, Yuan Y. Social Network Mediation Analysis: a Latent Space Approach. Psychometrika 86:272–298, 2021. e-Pub 2021.
Lin R, Thall P, Yuan Y. A Phase I-II Basket Trial Design to Optimize Dose-Schedule Regimes Based on Delayed Outcomes. Bayesian Analysis 16:179-202, 2021. e-Pub 2021.
Hoffe S, Frakes JM, Aguilera TA, Czito B, Palta M, Brookes M, Schweizer C, Colbert L, Moningi S, Bhutani MS, Pant S, Tzeng CW, Tidwell RS, Thall P, Yuan Y, Moser EC, Holmlund J, Herman J, Taniguchi CM. Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in Combination with High Dose Stereotactic Body Radiation Therapy (SBRT) in Locally Advanced Pancreatic Cancer (PC). Int J Radiat Oncol Biol Phys 108(5):1399-1400, 2020. e-Pub 2020. PMID: 33427657.
Lin R, Yang Z, Yuan Y, Yin G. Sample size re-estimation in adaptive enrichment design. Contemp Clin Trials:106216. e-Pub 2020. PMID: 33246098.
Yin J, Yuan Y. Checkerboard: a Bayesian efficacy and toxicity interval design for phase I/II dose-finding trials. J Biopharm Stat:1-20. e-Pub 2020. PMID: 32966167.
Atkins JT, George GC, Hess K, Marcelo-Lewis KL, Yuan Y, Borthakur G, Khozin S, LoRusso P, Hong DS. Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trials. Br J Cancer 123(10):1496-1501. e-Pub 2020. PMID: 32868897.
Dottino JA, Zhang Q, Loose DS, Fellman B, Melendez BD, Waters MS, McKenzie LJ, Yuan Y, Yang RK, Broaddus RR, Lu KH, Soliman PT, Yates MS. Endometrial biomarkers in premenopausal obese women: an at-risk cohort. Am J Obstet Gynecol 9378(20):30881-30884. e-Pub 2020. PMID: 32835719.
Westin SN, Fellman B, Sun CC, Broaddus RR, Woodall ML, Pal N, Urbauer DL, Ramondetta LM, Schmeler KM, Soliman PT, Fleming ND, Burzawa JK, Nick AM, Milbourne AM, Yuan Y, Lu KH, Bodurka DC, Coleman RL, Yates MS. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. Am J Obstet Gynecol S0002-9378(20):30861-308619. e-Pub 2020. PMID: 32805208.
Abi Jaoude J, Kouzy R, Minsky BD, Fuller CD, Yuan Y, Do KA, Taniguchi CM, Ludmir EB. Sponsor-involved statistical analyses in Phase III cancer clinical trials. Int J Cancer 147(12):3579-3581. e-Pub 2020. PMID: 32621758.
Zhou H, Chen C, Sun L, Yuan Y. Bayesian optimal phase II clinical trial design with time-to-event endpoint. Pharm Stat(19):776-786. e-Pub 2020. PMID: 32524679.
de Groot J, Penas-Prado M, Alfaro-Munoz K, Hunter K, Pei BL, O'Brien B, Weathers SP, Loghin M, Kamiya Matsouka C, Yung WKA, Mandel J, Wu J, Yuan Y, Zhou S, Fuller GN, Huse J, Rao G, Weinberg JS, Prabhu SS, McCutcheon IE, Lang FF, Ferguson SD, Sawaya R, Colen R, Yadav SS, Blando J, Vence L, Allison J, Sharma P, Heimberger AB. Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro Oncol 22(4):539-549, 2020. e-Pub 2020. PMID: 31755915.
Pan H, Cheng C, Yuan Y. Bayesian adaptive linearization method for phase I drug combination trials with dimension reduction. Pharm Stat. e-Pub 2020. PMID: 32248647.
Puduvalli VK, Wu J, Yuan Y, Armstrong TS, Vera E, Wu J, Xu J, Giglio P, Colman H, Walbert T, Raizer J, Groves MD, Tran D, Iwamoto F, Avgeropoulos N, Paleologos N, Fink K, Peereboom D, Chamberlain M, Merrell R, Penas Prado M, Yung WKA, Gilbert MR. A Bayesian Adaptive Randomized Phase II Multicenter Trial of Bevacizumab with or without Vorinostat in Adults with Recurrent Glioblastoma. Neuro Oncol. e-Pub 2020. PMID: 32166308.
Pan H, Lin R, Zhou Y, Yuan Y. Keyboard design for phase I drug-combination trials. Contemp Clin Trials(92):105972. e-Pub 2020. PMID: 32151751.
Shin SJ, Dodd-Eaton EB, Peng G, Bojadzieva J, Chen J, Amos CI, Frone MN, Khincha PP, Mai PL, Savage SA, Ballinger ML, Thomas DM, Yuan Y, Strong LC, Wang W. Penetrance of Different Cancer Types in Families with Li-Fraumeni Syndrome: A Validation Study Using Multicenter Cohorts. Cancer Res 80(2):354-360, 2020. e-Pub 2020. PMID: 31719101.
Palermo TM, Murray C, Aalfs H, Abu-El-Haija M, Barth B, Bellin MD, Ellery K, Fishman DS, Gariepy CE, Giefer MJ, Goday P, Gonska T, Heyman MB, Husain SZ, Lin TK, Liu QY, Mascarenhas MR, Maqbool A, McFerron B, Morinville VD, Nathan JD, Ooi CY, Perito ER, Pohl JF, Schwarzenberg SJ, Sellers ZM, Serrano J, Shah U, Troendle D, Zheng Y, Yuan Y, Lowe M, Uc A, Chronic Pancreatitis CFTSO, Diabetes, Cancer P. Web-based cognitive-behavioral intervention for pain in pediatric acute recurrent and chronic pancreatitis: Protocol of a multicenter randomized controlled trial from the study of chronic pancreatitis, diabetes and pancreatic cancer (CPDPC). Contemp Clin Trials 88:105898, 2020. e-Pub 2020. PMID: 31756383.
Yan F, Pan H, Zhang L, Liu S, Yuan Y. BOIN: An R Package for Designing Single- Agent and Drug-Combination Dose-Finding Trials Using Bayesian Optimal Interval Designs. Journal of Statistical Software 94(13):1-32, 2020. e-Pub 2020.
Zhou Y, Li R, Kuo Y, Lee JJ, Yuan Y. BOIN Suite: a software platform to design and implement novel early phase clinical trials. JCO Clinical Cancer Informatics, 2020. e-Pub 2020.
Li Y, Yuan Y. PA-CRM: A Continuous Reassessment Method for Pediatric Phase I Oncol-ogy Trials with Concurrent Adult Trials. Biometrics, 2020. e-Pub 2020.
Lin R, Zhou Y, Yan F, Li D, Yuan Y. BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted Therapies. JCO Precis Oncol 4, 2020. e-Pub 2020. PMID: 33283133.
Han Y, Yuan Y, Cao S, Li M, Zang Y. On the Use of Marker Strategy Design to Detect Predictive Marker Eﬀect in Cancer Immunotherapy. Statistics in Biosciences(12):180195, 2020. e-Pub 2020.
Zhou Y, Lee JJ, Yuan Y. A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies. Stat Med 38(28):5299-5316, 2019. e-Pub 2019. PMID: 31621952.
Tidwell RSS, Peng SA, Chen M, Liu DD, Yuan Y, Lee JJ. Bayesian clinical trials at The University of Texas MD Anderson Cancer Center: An update. Clin Trials 16(6):645-656, 2019. e-Pub 2019. PMID: 31450957.
Jiang H, Shin DH, Nguyen TT, Fueyo J, Fan X, Henry V, Carrillo CC, Yi Y, Alonso MM, Collier TL, Yuan Y, Lang FF, Gomez-Manzano C. Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas. Clin Cancer Res 25(22):6801-6814, 2019. e-Pub 2019. PMID: 31455679.
Soliman PT, Westin SN, Iglesias DA, Fellman BM, Yuan Y, Zhang Q, Yates MS, Broaddus RR, Slomovitz BM, Lu KH, Coleman RL. Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study. Clin Cancer Res 26(3):581-587. e-Pub 2019. PMID: 31628143.
Lin R, Thall PF, Yuan Y. An adaptive trial design to optimize dose-schedule regimes with delayed outcomes. Biometrics 76(1):304-315. e-Pub 2019. PMID: 31273750.
Yan F, Thall P, Yuan Y. One-Year Outcomes after PCI Strategies in Cardiogenic Shock. N Engl J Med 380(19):1876-1877, 2019. e-Pub 2019. PMID: 31067386.
Harrison RA, Anderson MD, Cachia D, Kamiya-Matsuoka C, Weathers SS, O'Brien BJ, Penas-Prado M, Yung WKA, Wu J, Yuan Y, de Groot JF. Clinical trial participation of patients with glioblastoma at The University of Texas MD Anderson Cancer Center. Eur J Cancer 112:83-93, 2019. e-Pub 2019. PMID: 30951926.
Lin R, Yuan Y. Time-to-event model-assisted designs for dose-finding trials with delayed toxicity. Biostatistics 21(4):807-824. e-Pub 2019. PMID: 30984972.
Tang R, Shen J, Yuan Y. ComPAS: A Bayesian drug combination platform trial design with adaptive shrinkage. Stat Med 38(7):1120-1134, 2019. e-Pub 2019. PMID: 30419609.
Lin R, Coleman RL, Yuan Y. TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy. J Natl Cancer Inst 112(1):38-45. e-Pub 2019. PMID: 30924863.
Mu R, Yuan Y, Xu J, Mandrekar SJ, Jun Y. gBOIN: A uniﬁed phase I trial design accounting for toxicity grades. Journal of the Royal Statistical Society: Series C 68:289-308, 2019. e-Pub 2019.
Huang J, Yuan Y, Wetter D. Latent Class Dynamic Mediation Model with Application to Smoking Cessation Data. Psychometrika 84(1):1-18. e-Pub 2019. PMID: 30607659.
Zhang C, Martinez-Ledesma E, Gao F, Zhang W, Ding J, Wu S, Li X, Wu J, Yuan Y, Koul D, Alfred Yung WK. Wild-type TP53 defined gamma-secretase inhibitor sensitivity and synergistic activity with doxorubicin in GSCs. Am J Cancer Res 9(8):1734-1745, 2019. e-Pub 2019. PMID: 31497354.
Shin SJ, Yuan Y, Strong LC, Bojadzieva J, Wang W. Bayesian Semiparametric Estimation of Cancer-specific Age-at-onset Penetrance with Application to Li-Fraumeni Syndrome. J Am Stat Assoc 114(526):541-552, 2019. e-Pub 2019. PMID: 31485091.
Ahn, J, Morita, S, Wang W, Yuan, Y. Bayesian Shared Parameter Models for Dyadic Longitudinal Data with Informative Missing Data. Statistical Methods in Medical Research 28(1):70-83, 2019. e-Pub 2019.
Vidrine DJ, Frank-Pearce SG, Vidrine JI, Tahay PD, Marani SK, Chen S, Yuan Y, Cantor SB, Prokhorov AV. Efficacy of Mobile Phone Delivered Smoking Cessation Interventions for Socioeconomically Disadvantaged Individuals: A randomized controlled trial. JAMA Internal Medicine 179(2):167-174, 2019. e-Pub 2019.
Lin R, Yuan Y. On the Relative Efficiency of Model-Assisted Designs: A Conditional Approach. J Biopharm Stat 29(4):648-662, 2019. e-Pub 2019. PMID: 31258039.
Ursino M, Yuan Y, Comets E, Favrais G, Friede T, Lentz F, Stallard N, Zohar S. A dose-finding design for seizure reduction in neonates. Journal of the Royal Statistical Society: Series C 68(2):427-444, 2019. e-Pub 2019.
Vidrine DJ, Frank-Pearce SG, Vidrine JI, Tahay PD, Marani SK, Chen S, Yuan Y, Cantor SB, Prokhorov AV. Efficacy of Mobile Phone-Delivered Smoking Cessation Interventions for Socioeconomically Disadvantaged Individuals: A Randomized Clinical Trial. JAMA Intern Med. e-Pub 2018. PMID: 30556832.
Bahig H, Yuan Y, Mohamed ASR, Brock KK, Ng SP, Wang J, Ding Y, Hutcheson K, McCulloch M, Balter PA, Lai SY, Al-Mamgani A, Sonke JJ, van der Heide UA, Nutting C, Li XA, Robbins J, Awan M, Karam I, Newbold K, Harrington K, Oelfke U, Bhide S, Philippens MEP, Terhaard CHJ, McPartlin AJ, Blanchard P, Garden AS, Rosenthal DI, Gunn GB, Phan J, Cazoulat G, Aristophanous M, McSpadden KK, Garcia JA, van den Berg CAT, Raaijmakers CPJ, Kerkmeijer L, Doornaert P, Blinde S, Frank SJ, Fuller CD. Magnetic Resonance-based Response Assessment and Dose Adaptation in Human Papilloma Virus Positive Tumors of the Oropharynx treated with Radiotherapy (MR-ADAPTOR): An R-IDEAL stage 2a-2b/Bayesian phase II trial. Clin Transl Radiat Oncol 13:19-23, 2018. e-Pub 2018. PMID: 30386824.
Uc A, Perito ER, Pohl JF, Shah U, Abu-El-Haija M, Barth B, Bellin MD, Ellery KM, Fishman DS, Gariepy CE, Giefer MJ, Gonska T, Heyman MB, Himes RW, Husain SZ, Maqbool A, Mascarenhas MR, McFerron BA, Morinville VD, Lin TK, Liu QY, Nathan JD, Rhee SJ, Ooi CY, Sellers ZM, Schwarzenberg SJ, Serrano J, Troendle DM, Werlin SL, Wilschanski M, Zheng Y, Yuan Y, Lowe ME. INternational Study Group of Pediatric Pancreatitis: In Search for a CuRE Cohort Study: Design and Rationale for INSPPIRE 2 From the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer. Pancreas 47(10):1222-1228, 2018. e-Pub 2018. PMID: 30325861.
Hart PA, Andersen DK, Mather KJ, Castonguay AC, Bajaj M, Bellin MD, Bradley D, Contreras N, Habtezion A, Korc M, Kudva Y, Petrov MS, Whitcomb DC, Yadav D, Yuan Y, Rinaudo JAS, Srivastava S, Serrano J, Goodarzi MO. Evaluation of a Mixed Meal Test for Diagnosis and Characterization of PancrEaTogEniC DiabeTes Secondary to Pancreatic Cancer and Chronic Pancreatitis: Rationale and Methodology for the DETECT Study From the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer. Pancreas 47(10):1239-1243, 2018. e-Pub 2018. PMID: 30325863.
Ng SP, Bahig H, Wang J, Cardenas CE, Lucci A, Hall CS, Meas S, Sarli VN, Yuan Y, Urbauer DL, Ding Y, Ikner S, Dinh V, Elgohari BA, Johnson JM, Skinner HD, Gunn GB, Garden AS, Phan J, Rosenthal DI, Morrison WH, Frank SJ, Hutcheson KA, Mohamed ASR, Lai SY, Ferrarotto R, MacManus MP, Fuller CD. Predicting treatment Response based on Dual assessment of magnetic resonance Imaging kinetics and Circulating Tumor cells in patients with Head and Neck cancer (PREDICT-HN): matching 'liquid biopsy' and quantitative tumor modeling. BMC Cancer 18(1):903, 2018. e-Pub 2018. PMID: 30231854.
Guo B, Li D, Yuan Y. SPIRIT: A seamless phase I/II randomized design for immunotherapy trials. Pharm Stat 17(5):527-540, 2018. e-Pub 2018. PMID: 29882388.
Zhou H, Yuan Y, Nie L. Accuracy, Safety, and Reliability of Novel Phase I Trial Designs. Clinical Cancer Research 24(18):4357-4364, 2018. e-Pub 2018. PMID: 29661774.
Yates MS, Coletta AM, Zhang Q, Schmandt RE, Medepalli M, Nebgen D, Soletsky B, Milbourne A, Levy E, Fellman B, Urbauer D, Yuan Y, Broaddus RR, Basen-Engquist K, Lu K. Prospective Randomized Biomarker Study of Metformin and Lifestyle Intervention for Prevention in Obese Women at Increased Risk for Endometrial Cancer. Cancer Prevention Research (Phila) 11(8):477-490, 2018. e-Pub 2018. PMID: 29716897.
Arvold N, Armstrong T, Warren K, Blakeley J, DeAngelis LM, Chamberlain MC, Chang SM, Dunbar E, Loong H, Macdonald D, Reardon DA, Vogelbaum M, Wheeler HR, Yuan Y, Weller M, Van Den Bent M, Wen PY. Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology (RANO) Working Group. Neuro-Oncology 20(7):897-906, 2018. e-Pub 2018. PMID: 29788429.
Zhou H, Murray TA, Pan H, Yuan Y. Comparative review of novel model-assisted designs for phase I clinical trials. Stat Med 37(14):2208-2222, 2018. e-Pub 2018. PMID: 29682777.
Chu Y, Yuan Y. A Bayesian basket trial design using a calibrated Bayesian hierarchical model. Clinical Trials 15(2):149-158, 2018. e-Pub 2018. PMID: 29499621.
Pan H, Liu S, Miao D, Yuan Y. Sample size determination for mediation analysis of longitudinal data. BMC Med Res Methodol 18(1):32, 2018. e-Pub 2018. PMID: 29580203.
Shen W, Ning J, Yuan Y, Lok AS, Feng Z. Model-free scoring system for risk prediction with application to hepatocellular carcinoma study. Biometrics 74(1):239-248, 2018. e-Pub 2018. PMID: 28742219.
Riviere MK, Yuan Y, Jourdan JH, Dubois F, Zohar S. Phase I/II dose-finding design for molecularly targeted agent: Plateau determination using adaptize randomization. Stat Methods Med Res 27(2):466-479, 2018. e-Pub 2018. PMID: 26988926.
Mandel JJ, Yust-Katz S, Patel AJ, Cachia D, Liu D, Park M, Yuan Y, Kent TA, de Groot JF. Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma. Neuro Oncol 20(1):113-122, 2018. e-Pub 2018. PMID: 29016865.
Chu Y, Yuan Y. BLAST: Bayesian Latent Subgroup Design for Basket Trials Accounting for Patient Heterogeneity. Journal of the Royal Statistical Society: Series C 67:723-740, 2018. e-Pub 2018.
Yan F, Thall PF, Lu KH, Gilbert MR, Yuan Y. Phase I-II clinical trial design: A state-of-the-art paradigm for dose finding with novel agents. Annals of Oncology 29:694-699, 2018. e-Pub 2018.
Yuan Y, Lin R, Li D, Nie L, Warren KE. Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials. Clin Cancer Res 24:4921-4930, 2018. e-Pub 2018. PMID: 29769209.
Murray T, Yuan Y, Thall P, Elizondo JH, Hofstetter W. A Bayesian Utility-Based Stratified Medicine Design for the Effectiveness of Nutritional Prehabilitation in Thoracic Surgery. Biometrics 74:1095-1103, 2018. e-Pub 2018.
Liu S, Guo B, Yuan Y. A Bayesian Phase I/II Design for Immunotherapy Trials. Journal of American Statistical Association 113:1016-1027, 2018. e-Pub 2018.
Murray T, Thall P, Yuan Y. A Bayesian Machine Learning Method for Optimizing Dynamic Treatment Regimes. Journal of the American Statistical Association 113:1255-1267, 2018. e-Pub 2018.
Pan H, Yuan Y, Xia J. A Calibrated Power Prior Approach to Borrow Information from Historical Data with Application to Biosimilar Clinical Trials. J R Stat Soc Ser C Appl Stat 66(5):979-996, 2017. e-Pub 2017. PMID: 29249839.
Zhou H, Lee JJ, Yuan Y. BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints. Stat Med 36(21):3302-3314, 2017. e-Pub 2017. PMID: 28589563.
Cai C, Rahbar MH, Hossain MM, Yuan Y, Gonzales NR. A placebo-controlled Bayesian dose finding design based on continuous reassessment method with application to stroke research. Contemp Clin Trials Commun 7:11-17, 2017. e-Pub 2017. PMID: 29062975.
Yan F, Mandrekar SJ, Yuan Y. Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials. Clin Cancer Res 23(15):3994-4003, 2017. e-Pub 2017. PMID: 28546227.
Pakish JB, Zhang Q, Chen Z, Liang H, Chisholm GB, Yuan Y, Mok SC, Broaddus RR, Lu KH, Yates MS. Immune Microenvironment in Microsatellite-Instable Endometrial Cancers: Hereditary or Sporadic Origin Matters. Clin Cancer Res 23(15):4473-4481, 2017. e-Pub 2017. PMID: 28264871.
Harano K, Kogawa T, Wu J, Yuan Y, Cohen EN, Lim B, Reuben JM, Ueno NT. Thrombocytosis as a prognostic factor in inflammatory breast cancer. Breast Cancer Res Treat. e-Pub 2017. PMID: 28831670.
Jiang H, Rivera-Molina Y, Gomez-Manzano C, Clise-Dwyer K, Bover L, Vence LM, Yuan Y, Lang FF, Toniatti C, Hossain MB, Fueyo J. Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination. Cancer Res 77(14):3894-3907, 2017. e-Pub 2017. PMID: 28566332.
Ahn J, Morita S, Wang W, Yuan Y. Bayesian analysis of longitudinal dyadic data with informative missing data using a dyadic shared-parameter model. Stat Methods Med Res:962280217715051. e-Pub 2017. PMID: 28629259.
Pan H, Yuan Y. A Default Method to Specify Skeletons for Bayesian Model Averaging Continual Reassessment Method for Phase I Clinical Trials. Stat Med 36(2):266-279, 2017. e-Pub 2017. PMID: 26991076.
Murray TA, Thall PF, Yuan Y, McAvoy S, Gomez DR. Robust treatment comparison based on utilities of semi-competing risks in non-small-cell lung cancer. J Am Stat Assoc 112:11-23, 2017. e-Pub 2017. PMID: 28943681.
Chen Z, Li Z, Zhuang R, Yuan Y, Kutner M, Owonikoko T, Curran WJ, Kowalski J. Adaptive estimation of personalized maximum tolerated dose in cancer phase I clinical trials based on all toxicities and individual genomic profile,. PLoS One 12(1):e0170187, 2017. e-Pub 2017. PMID: 28125617.
Yuan Y, Qiu H, Hu XY, Luo T, Gao XJ, Zhao XY, Zhang J, Wu Y, Yan HB, Qiao SB, Yang YJ, Gao RL. Risk Factors of Contrast-induced Acute Kidney Injury in Patients Undergoing Emergency Percutaneous Coronary Intervention. Chin Med J (Engl) 130(1):45-50, 2017. e-Pub 2017. PMID: 28051022.
Katz L, Advani S, Burton-Chase AM, Fellman B, Polivka KM, Yuan Y, Lynch PM, Peterson SK. Cancer Screening Behaviors and Risk Perceptions among Family Members of Colorectal Cancer Patients with Lynch-Like Syndrome. Familial Cancer 16:231-237, 2017. e-Pub 2017.
Huang J, Yuan Y. Bayesian Dynamic Mediation Analysis. Psychological Methods 22(4):667-686, 2017. e-Pub 2017.
Zang Y, Yuan Y. Optimal sequential enrichment designs for phase II clinical trials. Stat Med 36:54-66, 2016. e-Pub 2016. PMID: 27640874.
Yuan Y, Hess K, Hilsenbeck S, Gilbert M. Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials. Clinical Cancer Research 22(17):4291-301, 2016. e-Pub 2016. PMID: 27407096.
Iasonos A, Wages NA, Conaway MR, Cheung K, Yuan Y, O'Quigley J. Dimension of model parameter space and operating characteristics in adaptive dose-finding studies. Stat Med 354(21):3760-75, 2016. e-Pub 2016. PMID: 27090197.
Chu Y, Pan H, Yuan Y. Adaptive dose modification for phase I clinical trials Third place winner in Biopharmaceutical Section Student Paper Award of JSM 2016. Statictics in Medicine 35(20):3497-508, 2016. e-Pub 2016. PMID: 27027650.
Guo B, Yuan Y. Bayesian Phase I/II Biomarker-based Dose Finding for Precision Medicine with Molecularly Targeted Agents. Journal of American Statistical Association 112:508-520. e-Pub 2016.
Yuan Y, Guo B, Munsell M, Lu K, Jazzari A. MIDAS: a practical Bayesian design for platform trials with molecularly targeted agents. Statistics in Medicine 35(22):3892-906, 2016. e-Pub 2016. PMID: 27112322.
Zhang, L, Yuan, Y. A practical Bayesian design to identify the maximum tolerated dose contour for drug combination trials. Stat Med 35:4924-4936, 2016. e-Pub 2016. PMID: 27580928.
Zang Y, Liu S, Yuan Y. Optimal Marker-strategy Clinical Trial Design to Detect Predictive Markers for Targeted Therapy. Biostatistics 3:549-60, 2016. e-Pub 2016. PMID: 26951724.
Zhang L, Yuan Y, Lu K, Zhang L. Identification of recurrent focal copy number variations and their putative targeted driver genes in ovarian cancer. BMC Bioinformatics 17(1):222, 2016. e-Pub 2016. PMID: 27230211.
Murray T, Thall P, Yuan Y. Utility-Based Designs for Randomized Comparative Trials with Categorical Outcomes. Statictics in Medicine 35(24):4285-4305, 2016. e-Pub 2016. PMID: 27189672.
Hamza MA, Kamiya-Matsuoka C, Liu D, Yuan Y, Puduvalli VK. Outcome of patients with malignant glioma and synchronous or metachronous non-central nervous system primary neoplasms. J Neurooncol 126(3):527-33, 2016. e-Pub 2016. PMID: 26566652.
Guo B, Li Y, Yuan Y. A dose-schedule-finding design for phase I/II clinical trials. Journal of the Royal Statistical Society, Series C 65:259-272, 2016. e-Pub 2016. PMID: 26877554.
Jin IH, Yuan Y, Bandyopadhyay D. A Bayesian hierarchical spatial model for dental caries assessment using non-gaussian markov random fields. Ann Appl Stat 10(2):884-905, 2016. e-Pub 2016. PMID: 27807470.
Katz LH, Advani S, Burton-Chase AM, Fellman B, Polivka KM, Yuan Y. Cancer Screening Behaviors and Risk Perceptions among Family Members of Colorectal Cancer Patients with Lynch-Like Syndrome. Clinical Genetics 89:392-398, 2016. e-Pub 2016.
Shen W, Ning J, Yuan Y. Rate-adaptive Bayesian indpendent component analysis. Electronic Journal of Statistics 10:3247-3264, 2016. e-Pub 2016.
Zang Y, Lee J, Yuan Y. Two-stage marker-stratified clinical trial design in the presence of biomarker misclassification. Journal of the Royal Statistical Society: Series C 65:585-601, 2016. e-Pub 2016.
Raizer JJ, Giglio P, Hu J, Groves M, Merrell R, Conrad C, Phuphanich S, Puduvalli VK, Loghin M, Paleologos N, Yuan Y, Liu D, Rademaker A, Yung WK, Vaillant B, Rudnick J, Chamberlain M, Vick N, Grimm S, Tremont-Lukats IW, De Groot J, Aldape K, Gilbert MR, Trials Collaborative BT. A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients. J Neurooncol 126:185-192, 2016. e-Pub 2016. PMID: 26476729.
Katz LH, Burton-Chase AM, Advani S, Fellman B, Polivka KM, Yuan Y, Lynch PM, Peterson SK. Screening adherence and cancer risk perceptions in colorectal cancer survivors with Lynch-like syndrome. Clin Genet 89:392-398, 2016. e-Pub 2016. PMID: 26272410.
Yust-Katz S, Mandel JJ, Wu J, Yuan Y, Webre C, Pawar TA, Lhadha HS, Gilbert MR, Armstrong TS. Venous thromboembolism (VTE) and glioblastoma. J Neurooncol 124(1):87-94, 2015. e-Pub 2015. PMID: 25985958.
Zang Y, Liu S, Yuan Y. Optimal Marker-Adaptive Designs for Target Therapy Based on Imperfectly Measured Biomarkers. Journal of the Royal Statistical Society: Series C 64(4):635-650, 2015. e-Pub 2015.
Armstrong TS, Yuan Y, Wu J, Acquaye AA, Vera-Bolanos E, Gilbert MR, Brown PD, Vardy J, Chung C. The relationship between corticosteroids and symptoms in patients with primary brain tumors: utility of the Dexamethasone Symptom Questionnaire-Chronic. Neuro Oncol 17(8):1114-20, 2015. e-Pub 2015. PMID: 25862766.
Gong AH, Wei P, Zhang S, Yao J, Yuan Y, Zhou AD, Lang FF, Heimberger AB, Rao G, Huang S. FoxM1 Drives a Feed-Forward STAT3-Activation Signaling Loop That Promotes the Self-Renewal and Tumorigenicity of Glioblastoma Stem-like Cells. Cancer Res 75(11):2337-48, 2015. e-Pub 2015. PMID: 25832656.
Shen W, Ning J, Yuan Y. A Direct Method to Evaluate the Time-dependent Predictive Accuracy for Biomarkers. Biometrics 71(2):439-49, 2015. e-Pub 2015. PMID: 25758584.
Shen W, Ning J, Yuan Y. Bayesian sequential monitoring design for two-arm randomized clinical trials with noncompliance. Stat Med 34(13):2104-15, 2015. e-Pub 2015. PMID: 25756852.
DeWire M, Fouladi M, Turner DC, Wetmore C, Hawkins C, Jacobs C, Yuan Y, Liu D, Goldman S, Fisher P, Rytting M, Bouffet E, Khakoo Y, Hwang EI, Foreman N, Stewart CF, Gilbert MR, Gilbertson R, Gajjar A. An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN). J Neurooncol 17(8):1114-1120, 2015. e-Pub 2015. PMID: 25859842.
Liu S, Pan H, Xia J, Huang Q, Yuan Y. Bridging continual reassessment method for phase I clinical trials in different ethnic populations. Stat Med 34(10):1681-94, 2015. e-Pub 2015. PMID: 25626429.
Guo B, Yuan Y. A Bayesian dose-finding design for phase I/II clinical trials with nonignorable dropouts. Stat Med 34(10):1721-32, 2015. e-Pub 2015. PMID: 25626676.
Chen Z, Yuan Y, Li Z, Kutner M, Owonikoko T, Curran WJ, Khuri F, Kowalski J. Dose escalation with over-dose and under-dose controls in Phase I/II clinical trials. Contemp Clin Trials 43:133-141. e-Pub 2015. PMID: 26012358.
Olar A, Wani KM, Alfaro-Munoz KD, Heathcock LE, van Thuijl HF, Gilbert MR, Armstrong TS, Sulman EP, Cahill DP, Vera-Bolanos E, Yuan Y, Reijneveld JC, Ylstra B, Wesseling P, Aldape KD. IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. Acta Neuropathol 129(4):585-96, 2015. e-Pub 2015. PMID: 25701198.
Jin IH, Huo L, Yin G, Yuan Y. Phase I trial design for drug combinations with Bayesian model averaging. Pharm Stat 14(2):108-19, 2015. e-Pub 2015. PMID: 25641851.
Vera-Bolanos E, Aldape K, Yuan Y, Wu J, Wani K, Necesito-Reyes MJ, Colman H, Dhall G, Lieberman FS, Metellus P, Mikkelsen T, Omuro A, Partap S, Prados M, Robins HI, Soffietti R, Wu J, Gilbert MR, Armstrong TS, Foundation C. Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. Neuro Oncol 17(3):440-7, 2015. e-Pub 2015. PMID: 25121770.
Jiang Y, Malouf GG, Zhang J, Zheng X, Chen Y, Thompson EJ, Weinstein JN, Yuan Y, Spano JP, Broaddus R, Tannir NM, Khayat D, Lu KH, Su X. Long non-coding RNA profiling links subgroup classification of endometrioid endometrial carcinomas with trithorax and polycomb complex aberrations. Oncotarget 6:39865-39876, 2015. e-Pub 2015. PMID: 26431491.
Zang Y, Liu S, Yuan Y. Optimal marker-adaptive designs for targeted therapy based on imperfectly measured biomarkers. Journal of the Royal Statistical Society: Series C 64:507-523, 2015. e-Pub 2015.
Liu S, Yuan Y. Bayesian Optimal Interval Designs for Phase I Clinical Trials. Journal of the Royal Statistical Society: Series C 64:507-523, 2015. e-Pub 2015.
Fellman B, Yuan Y. Bayesian Optimal Interval Designs for Phase I Clinical Trials. The Stata Journal 15(1):110-120, 2015. e-Pub 2015.
Malouf GG, Zhang J, Yuan Y, Compérat E, Rouprêt M, Cussenot O, Chen Y, Thompson EJ, Tannir NM, Weinstein JN, Valero V, Khayat D, Spano JP, Su X. Characterization of IncRna transcriptome in dlear-cell renal cell carcinoma by next-generation deep sequencing. Mol Oncol 9:32-43, 2015. e-Pub 2015. PMID: 25126716.
Guo B, Zang Y, Yuan, Y. A Bayesian Phase I/II Clinical Trial Design in the Presence of Informative Dropouts. Statistics and Its Interface 8:217-226, 2015. e-Pub 2015.
Riviere MK, Yuan Y, Dubois F, Zohar S. A Bayesian Dose-finding Design for Clinical Trials Combining a Cytotoxic Agent with a Molecularly Targeted Agent. Journal of the Royal Statistical Society, Series C 64:215-229, 2015. e-Pub 2015.
Cai C, Liu S, Yuan Y. A Bayesian Design for Phase II Clinical Trials with Delayed Responses Based on Multiple Imputation. Stat Med 33(23):4017-28, 2014. e-Pub 2014. PMID: 24817556.
Riviere MK, Yuan Y, Dubois F, Zohar S. A Bayesian dose-finding design for drug combination clinical trials based on the logistic model. Pharm Stat 13(4):247-57, 2014. e-Pub 2014. PMID: 24828456.
Liu S, Yuan Y, Castillo R, Guerrero T, Johnson VE. Evaluation of image registration spatial accuracy using a Bayesian hierarchical model. Biometrics 70(2):366-77, 2014. e-Pub 2014. PMID: 24575781.
Zang Y, Lee JJ, Y Y. Adaptive Designs for Identifying Optimal Biological Dose for Molecularly Targeted Agents. Clin Trials 11(3):319-327. e-Pub 2014. PMID: 24844841.
Yuan Y, Mackinnon DP. Robust Mediation Analysis Based on Median Regression. Psychol Methods 19(1):1-20, 2014. e-Pub 2014. PMID: 24079925.
Hong J, Yuan Y, Wang J, Liao Y, Zou R, Zhu C, Li B, Liang Y, Huang P, Wang Z, Lin W, Zeng Y, Dai JL, Chung RT. Expression of variant isoforms of the tyrosine kinase SYK determines the prognosis of hepatocellular carcinoma. Cancer Res 74(6):1845-56, 2014. e-Pub 2014. PMID: 24477596.
Yust-Katz S, Anderson MD, Liu D, Wu J, Yuan Y, Olar A, Fuller GN, Brown PD, de-Groot JF. Clinical and prognostic features of adult patients with gangliogliomas. Neuro Oncol 16(3):409-13, 2014. e-Pub 2014. PMID: 24305706.
Saito N, Fu J, Zheng S, Yao J, Wang S, Liu DD, Yuan Y, Sulman EP, Lang FF, Colman H, Verhaak RG, Yung WK, Koul D. A high Notch pathway activation predicts response to γ secretase inhibitors in proneural subtype of glioma tumor initiating cells. Stem Cells 32(1):301-12, 2014. e-Pub 2014. PMID: 24038660.
Cai C, Yuan Y, Ji Y. A Bayesian Dose-finding Design for Oncology Clinical Trials of Combinational Biological Agents. J R Stat Soc Ser C Appl Stat 63(1):159-173, 2014. e-Pub 2014. PMID: 24511160.
Yust-Katz S, de Groot JF, Liu D, Wu J, Yuan Y, Anderson MD, Conrad CA, Milbourne A, Gilbert MR, Armstrong TS. Pregnancy and Glial brain tumors. Neuro-Oncology 16:1289-1294, 2014. e-Pub 2014.
Castillo SJ, Castillo R, Balter P, Pan T, Ibbott G, Hobbs B, Yuan Y, Guerrero T. Assessment of a quantitative metric for 4D CT artifact evaluation by observer consensus. J Appl Clin Med Phys 15(3):4718, 2014. e-Pub 2014. PMID: 24892346.
Jin IH, Liu S, Thall PF, Yuan Y. Using data augmentation to facilitate conduct of phase I/II clinical trials with delayed outcomes. J Am Stat Assoc 109(506):525-536, 2014. e-Pub 2014. PMID: 25382884.
Cai C, Yuan Y, Ji Y. Bayesian Phase I/II Design for Oncology Clinical Trials of Combining Biological Agents. Journal of the Royal Statistical Society: Series C 63:159-173, 2014. e-Pub 2014.
Pan H, Zhu C, Zhang F, Yuan Y, Zhang S, Zhang W, Li C. The Continual Re- assessment Method for Multiple Toxicity Grades: A Bayesian Model Selection Approach. PLos ONE 9(e98147):1-8, 2014. e-Pub 2014.
Oki Y, Buglio D, Zhang J, Yuan Y, Zhou S, Sureda A, Ben-Yehuda D, Zinzani PL, Prince HM, Harrison SJ, Kirschbaum M, Johnston PB, Shen A, von Tresckow B, Younes A. Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression. Blood Cancer J 4:e236, 2014. e-Pub 2014. PMID: 25105535.
Shinn EH, Basen-Engquist K, Baum G, Steen S, Bauman RF, Morrison W, Garden AS, Sheil C, Kilgore K, Hutcheson KA, Barringer D, Yuan Y, Lewin JS. Adherence to preventive exercises and self-reported swallowing outcomes in post-radiation head and neck cancer patients. Head Neck 35(12):1707-12, 2013. e-Pub 2013. PMID: 24142523.
Liu S, Yin G, Yuan Y. Bayesian Data Augmentation Dose Finding with Continual Reassessment Method and Incomplete Observations. Ann Appl Stat 7(4):1837-2457, 2013. e-Pub 2013. PMID: 24707327.
Ahn J, Liu S, Wang W, Yuan Y. Bayesian Latent-class Mixed-effect Hybrid Models for Dyadic Longitudinal Data with Non-ignorable Dropouts. Biometrics 69(4):914-24, 2013. e-Pub 2013. PMID: 24328715.
Zang Y, Yuan Y. A shrinkage method for testing the hardy-weinberg equilibrium in case-control studies. Genet Epidemiol 37(7):743-50, 2013. e-Pub 2013. PMID: 23934751.
Schover LR, Yuan Y, Fellman BM, Odensky E, Lewis PE, Martinetti P. Efficacy trial of an internet-based intervention for cancer-related female sexual dysfunction. J Natl Compr Canc Netw 11:1389-97, 2013. e-Pub 2013. PMID: 24225972.
Yust-Katz S, Garciarena P, Liu D, Yuan Y, Ibrahim N, Yerushalmi R, Penas-Prado M, Groves MD. Breast cancer and leptomeningeal disease (LMD): hormone receptor status influences time to development of LMD and survival from LMD diagnosis. J Neurooncol 114(2):229-35, 2013. e-Pub 2013. PMID: 23756727.
Ahn J, Yuan Y, Parmigiani G, Suraokar MB, Diao L, Wistuba II, Wang W. DeMix: deconvolution for mixed cancer transcriptomes using raw measured data. Bioinformatics 29(15):1865-71, 2013. e-Pub 2013. PMID: 23712657.
Yust-Katz S, Liu D, Yuan Y, Liu V, Kang S, Groves M, Puduvalli V, Levin V, Conrad C, Colman H, Hsu S, Yung WK, Gilbert MR. Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma. Cancer 119(15):2747-53, 2013. e-Pub 2013. PMID: 23633392.
Fingeret MC, Hutcheson KA, Jensen K, Yuan Y, Urbauer D, Lewin JS. Associations Among Speech, Eating, and Body Image Concerns for Surgical Patients with Head and Neck Cancer. Head Neck 35(3):354-60, 2013. e-Pub 2013. PMID: 22431304.
Jin IH, Yuan Y Liang F. Bayesian analysis for exponential random graph models using the adaptive exchange sampler. Statistics and Is Interface 6:559-576, 2013. e-Pub 2013. PMID: 3956133.
Cai C, Yuan Y, Johnson VE. Bayesian adaptive phase II screening design for combination trials. Clin Trials 10(3):353-62, 2013. e-Pub 2013. PMID: 23359875.
Zhang G, Yuan Y. Bayesian Modeling Longitudinal Dyadic Data with Nonignorable Dropout With Application to a Breast Cancer Study. Ann Appl Stat 6(2):753-771, 2012. e-Pub 2012. PMID: 23814631.
Younes A, Oki Y, McLaughlin P, Copeland AR, Goy A, Pro B, Feng L, Yuan Y, Chuang HH, Macapinlac HA, Hagemeister F, Romaguera J, Samaniego F, Fanale MA, Dabaja BS, Rodriguez MA, Dang N, Kwak LW, Neelapu SS, Fayad LE. Phase II study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood 119(18):4123-8, 2012. e-Pub 2012. PMID: 22371887.
Yuan Y, Johnson VE. Goodness-of-Fit diagnostics for Bayesian Hierarchical Models. Biometrics 68(1):156-64, 2012. e-Pub 2012. PMID: 22050079.
Schover LR, Canada AL, Yuan Y, Sui D, Neese L, Jenkins R, Rhodes MM. A randomized trial of internet-based versus traditional sexual counseling for couples after localized prostate cancer treatment. Cancer 118(2):500-509, 2012. e-Pub 2012. PMID: 21953578.
Yuan Y, Thall PF, Wolff JE. Estimating progression-free survival in paediatric brain tumour patients when some progression statuses are unknown. J R Stat Soc Ser C Appl Stat 61(1):135-149, 2012. e-Pub 2012. PMID: 22408277.
Koul D, Fu J, Shen R, LaFortune TA, Wang S, Tiao N, Kim YW, Liu JL, Ramnarian D, Yuan Y, Garcia-Echevrria C, Maira SM, Yung WK. Antitumor activity of NVP-BKM120--a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells. Clin Cancer Res 18(1):184-95, 2012. e-Pub 2012. PMID: 22065080.
Huo L, Yuan Y, Yin G. Bayesian Dose Finding for Combined Drugs with Discrete and Continuous Doses. Bayesian Anal 7(4):235-252, 2012. e-Pub 2012. PMID: 23956811.
Karuturi M, Arai S, Chen R, Gopal A, Feng L, Yuan, Y, Smith S, Ansell S, Rosenblatt J, Savage K, Ramchandren R, Bartlett N, Cheson B, Forero-Torres A, Moskowitz C, Connors J, Larsen E, Kennedy D, Sievers E, Fanale M, deVos S, Engert A, Illidge T, Borchmann P, Morschhauer F, Horning S, Younes A. Overall survival benefit for patients with relapsed Hodgkin lymphoma treated with Brentuximab Vedotin after autologous stem cell transplant. Blood 120:3701, 2012. e-Pub 2012.
Yin G, Yuan Y. Bayesian model averaging continual reassessment method in phase I clinical trials. Journal of the American Statistical Association 104(487):954-968, 2012. e-Pub 2012.
Karuturi M, Arai S, Chen R, Gopal A, Feng L, Yuan Y, Smith S, Ansell S, Rosenblatt J, Savage K, Ramchandren R, Bartel, N, Cheson B, Forero-Torres A, Moskowitz C, Connors J, Larsen E, Kennedy D, Sievers E, Fanale M, deVos S, Engert A, Illidge T, Borchmann P, Morschhauser F, Horning S, Younes A. Impact of Brentuximab Vedotin on Survival of Patients with classical Hodgkin Lymphoma treated with Prior Autologous Stem Cell Transplant. Journal of Clinical Oncology 120:3701, 2012. e-Pub 2012.
Yao J, Zhao Q, Yuan Y, Zhang L, Liu X, Yung WK, Weinstein JN. Identification of common prognostic gene expression signatures with biological meanings from microarray gene expression datasets. PLoS One 7(9):e45894. 1-11, 2012. e-Pub 2012. PMID: 23029298.
Yuan Y, Yin G. Dose-response curve estimation: A semiparametric mixture approach. Biometrics 67(4):1543-54, 2011. e-Pub 2011. PMID: 21627631.
Yin G, Ma Y, Liang F, Yuan Y. Stochastic generalized method of moments. J Comput Graph Stat 20(3):714-727, 2011. e-Pub 2011. PMID: 22375093.
Yuan Y, Yin G. Robust EM continual reassessment method in oncology dose finding (featured article). J Am Stat Assoc 106(495):818-831, 2011. e-Pub 2011. PMID: 22375092.
Yuan Y, Yin G. Bayesian hybrid design in phase I oncology clinical trials. Statistics in Medicine 30(17):2098-2108, 2011. e-Pub 2011. PMID: 21365672.
Fingeret MC, Yuan Y, Urbauer D, Weston J, Nipomnick S, Weber R. The nature and extent of body image concerns among surgically treated patients with head and neck cancer. Psychooncology 21:836-844. e-Pub 2011. PMID: 21706673.
Yuan Y, Huang X, Liu S. A Bayesian response-adaptive covariate-balanced randomization design with application to a leukemia clinical trial. Stat Med 30(11):1218-29, 2011. e-Pub 2011. PMID: 21432894.
Yuan Y, Yin G. Bayesian Phase I/II Adaptively Randomized Oncology Trials With Combinded Drugs. Ann Appl Stat 5(2A):924-942, 2011. e-Pub 2011. PMID: 22375162.
Lei X, Yuan Y, Yin G. Bayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity. Lifetime Data Analysis 17(1):156-74, 2011. e-Pub 2011. PMID: 20364321.
Song PX, Li M, Yuan Y. Rejoinder to "Joint regression analysis for discrete longitudinal data" by Madsen and Fang. Biometrics 67:1175-1176, 2011. e-Pub 2011.
Yuan Y, Yin G. On adaptive randomization: is it useful?. Journal of Clinical Oncology 29:e390-e392, 2011. e-Pub 2011.
Le-Petross HT, Whitman GJ, Atchely DP, Yuan Y, Gutierrez-Barrera A, Berry D, Hortobagyi GN, and Arun BK. Effectiveness of alternating mammography and magnetic resonance imaging for screening women at high risk of breast cancer. Cancer 117:3900-3907, 2011. e-Pub 2011.
Carmack, CL, Basen-Engquist, K, Yuan, Y, Rodriguez-Bigas, M, Wolff, R, Barker T, Pennebaker J. Feasibility of an expressive-disclosure group intervention for post-treatment colorectal cancer patients: Results of the Healthy Expressions study. Cancer 117:4993-5002, 2011. e-Pub 2011.
Yin G, Yuan, Y. Rejoinder to the correspondence of Gasparini, Bailey and Neuen- schwander on \Bayesian dose finnding in oncology for drug combinations by copula regression.". Journal of the Royal Statistical Society: Series C 59:544-546, 2010. e-Pub 2010.
Yuan Y, Yin G. Quantile regression for longitudinal studies with nonignorable missing data. Biometrics 66:105-114, 2010. e-Pub 2010. PMID: 19459836.
Yuan Y, MacKinnon DP. Bayesian mediation analysis. Psychological Methods 14(4):301-22, 2009. e-Pub 2009. PMID: 19968395.
Kiserud CE, Schover LR, Dahl AA, Fosså A, Bjøro T, Loge JH, Holte H, Yuan Y, Fosså SD. Do male lymphoma survivors have impaired sexual function?. J Clin Oncol 27(35):6019-26, 2009. e-Pub 2009. PMID: 19858388.
Yin G, Yuan Y. A latent contingency table approach to dose finding for combinations of two agents. Biometrics 65(3):866-75, 2009. e-Pub 2009. PMID: 18759848.
Yuan Y, Little RJ. Meta-analysis of studies with missing data. Biometrics 65(2):487-96, 2009. e-Pub 2009. PMID: 18565168.
Yuan Y, Little RJ. Mixed-effect hybrid models for longitudinal data with nonignorable dropout. Biometrics 65(2):478-86, 2009. e-Pub 2009. PMID: 18759842.
Song PX, Li M, Yuan Y. Joint regression analysis of correlated data using Gaussian copulas. Biometrics 65(1):60-68, 2009. e-Pub 2009. PMID: 18510653.
Yin G, Yuan Y. Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials. Journal of the American Statistical Association 104:954-968, 2009. e-Pub 2009.
Yuan Y, Yin G. Bayesian dose-finding by jointly modeling toxicity and efficacy as time-to-event outcomes. Journal of the Royal Statistical Society: Series C 58:719-736, 2009. e-Pub 2009.
Yin G, Yuan Y. Bayesian dose-finding in oncology for drug combinations by copula regression. Journal of the Royal Statistical Society: Series C 58:211-224, 2009. e-Pub 2009.
Yuan Y, Yin G. Sequential continual reassessment method for two-dimensional dose finding. Statistics in Medicine 27(27):5664-78, 2008. e-Pub 2008. PMID: 18618901.
Yuan Y, Little RJA. Model-based inference for two-stage cluster samples subject to nonignorable item nonresponse. Journal of Official Statistics 24(2):193-211, 2008. e-Pub 2008.
Yuan Y, Johnson VE. Bayesian hypothesis tests using nonparametric statistics. Statistica Sinica 18:1185-1200, 2008. e-Pub 2008.
Yuan Y, Little RJ. Parametric and semiparametric model-based estimates of the finite population mean for two-stage cluster samples with item nonresponse. Biometrics 63(4):1172-80, 2007. e-Pub 2007. PMID: 17489967.
Kolker JL, Yuan Y, Burt BA, Sandretto AM, Sohn W, Lang SW, Ismail AI. Dental caries and dietary patterns in low-income African American children. Pediatr Dent 29(6):457-64, 2007. e-Pub 2007. PMID: 18254414.
Yuan Y, Little RJA. Model-based estimates of the finite population mean for two-stage cluster samples with unit non-response. Journal of the Royal Statistical Society:Series C 56(1):79-97, 2007. e-Pub 2007.
Johnson VE, Yuan Y. Comments on 'An Exploratory Test for Excess of Signi. Clinical Trials 4(3):254-255; discussion 256-7, 2006. e-Pub 2006. PMID: 17715250.
Zhou J, Yuan Y, Reynolds R, Raber S, Li Y. Cost-efficient higher-order crossover designs for two-treatment clinical trials. Clinical Pharmacokinetics 45:623-632, 2006. e-Pub 2006. PMID: 16719543.
Burt BA, Kolker JL, Sandretto AM, Yuan Y, Sohn W, Ismail AI. Dietary patterns related to caries in a low-income adult population. Caries Res 40(6):473-80, 2006. e-Pub 2006. PMID: 17063017.
Yuan Y, Zhou J. Cost-Efficient Higher-Order Crossover Designs for Two-Treatment Clinical Trials. Pharmaceutical Statistics 4:245-252, 2005. e-Pub 2005.
Zhou J, He Y, Yuan Y. Comparison of Schuirmann's Two One-Sided Tests with Nonparametric Two One-Sided Tests for Non-normal Data in Clinical Drug-Drug Interaction Studies. Online Journal of Pharmacology and Pharmacokinetics 2:33-43, 2004. e-Pub 2004.
Yuan Y, Wang ZH, Tang JG. Intra-A chain disulphide bond forms first during insulin precursor folding. Biochem J 343 Pt 1:139-44, 1999. e-Pub 1999. PMID: 10493922.
XXXX, Yuan Y, XXXX. Cellular Senescence in Precancer Lesions.
Chen K, Chen TY, Zhang Y, Lin R, Yuan Y. Practical Considerations for Using the TITE-BOIN Design to Handle Late-Onset Toxicity or Fast Accrual in Phase I Trials 31(13):2573-2580.

Review Articles

Son J, Hsieh RC, Lin HY, Krause KJ, Yuan Y, Biter AB, Welsh J, Curran MA, Hong DS. Inhibition of the CD47-SIRPα axis for cancer therapy: A systematic review and meta-analysis of emerging clinical data. Front Immunol 13:1027235, 2022. e-Pub 2022. PMID: 36439116.
Liu Y, Yuan Y, Day AJ, Zhang W, John P, Ng DJ, Banov D. Safety and efficacy of compounded bioidentical hormone therapy (cBHT) in perimenopausal and postmenopausal women: a systematic review and meta-analysis of randomized controlled trials. Menopause 29(4):465-482, 2022. e-Pub 2022. PMID: 35357369.

Abstracts

Zhou J, Yuan Y, Reynolds R, Raber S. Cost-efficient higher-order crossover designs in comparative bioavailability studies. Clinical Pharmacology and Therapeutics 77:90, 2005. e-Pub 2005.

Book Chapters

Guo B, Yuan Y. Precision Medicine Designs for Cancer Clinical Trials. New York: Springer, 2024.
Beibei G, Yuan Y. Precision Medicine Designs for Cancer Clinical Trials Statistics in Precision Health: Theory, Methods and Applications. New York: Springer, 2024.
Guo, B, Yuan, Y. Complex Innovative Design, 17-54, 2022.
Colbert, LE, Yuan, Y, Zindler, JD, Fuller, CD, Thomas CR. Radiotherapy Considerations and Strategic Approaches in Phase I Trials. In: Phase I Oncology Drug Development, 2020.
Yuan Y, Zhou Y, Lee JJ. Early Phase Clinical Trials. In: Principles of Clinical Cancer Research. Springer, 2019.
Yuan Y, Lin R. Novel Designs for Early Phase Drug Combination Trials. In: Bayesian Applications in Pharmaceutical Development. Taylor and Francis, 2019.
Yuan Y, Zhou H, Zhou Y. Phase I Cancer Clinical Trial Design: Single and Combination Agents. In: Biopharmaceutical Applied Statistics Symposium. Springer, 2018.
Yuan, Y, Zhang L. Designing Early-Phase Drug Combination Trials. In: Handbook of Methods for Designing and Monitoring and Analyzing Dose-Finding Trials. Chapman and Hall/CRC Press, 2017.
Zand Y, Yuan Y. Optimal Biomarker-guided Design for Targeted Therapy with Imperfectly Measured Biomarkers. In: Statistical Applications from Clinical Trials and Personalized Medicine to Finance and Business Analytics. Springer International Publishing, 2016.
Yuan Y, Ning J. Covariate-Balanced Bayesian Adaptive Randomization: Achieving Tradeoff Between Inferential and Ethical Goals in Small and Moderate Size Trials. In: Modern Adaptive Randomized Clinical Trials. CRC Press, 2015.
Yin G, Yuan Y. Bayesian approach for adaptive design. In: Handbook of Adaptive Designs in Pharmaceutical and Clinical Development, 2010.

Books (edited and written)

Pan, H, Yuan, Y. Bayesian adaptive design for immunotherapy and targeted therapy, 2023.
Yuan Y, Lin R, Lee JJ. Model-Assisted Bayesian Designs for Dose Finding and Optimization: Methods and Applications. Chapman and Hall/CRC, 2022.
Yuan Y, Nguyen H, Thall P. Bayesian Design for Phase I-II Clinical Trials,. Chapman and Hall/CRC Press, 2016.

Letters to the Editor

Freeman, AJ, Ng, K, Wang, F, Yuan, Y, Lowe, ME, Uc, A. Reply to Yi et al. American Journal of Gastroenterology 119: 1946-1947, 2024.
Zhou H, Yuan, Y, Nie L. Accuracy, Safety, and Reliability of Novel Phase I Designs--Response. Clinical Cancer Research 24: 4357-4364.

Less

CV information above last modified July 22, 2026

Ying Yuan, Ph.D.

About Dr. Ying Yuan

Present Title & Affiliation

Primary Appointment

Research Interests

Education & Training

Degree-Granting Education

Experience & Service

Faculty Academic Appointments

Other Professional Positions

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Review Articles

Other Articles

Abstracts

Book Chapters

Books (edited and written)

Letters to the Editor

Patient Reviews

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Help #EndCancer

Ying Yuan, Ph.D.

About Dr. Ying Yuan

Present Title & Affiliation

Primary Appointment

Research Interests

Education & Training

Degree-Granting Education

Experience & Service

Faculty Academic Appointments

Other Professional Positions

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Review Articles

Other Articles

Abstracts

Book Chapters

Books (edited and written)

Letters to the Editor

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop UT MD Anderson